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Abstract:  
One of the critical challenges in the transmissible spongiform encephalopathy (TSE) 
field is to understand the molecular basis of prion propagation and decipher the 
enigma of prion strains and their role in TSEs. The research approach adopted in this 
dissertation tackled different subjects of keen interest for prion characterisation and 
diagnostics.  
 
A high throughput enzyme-linked immunosorbent assay (ELISA) was developed for 
detection of disease-related prion protein (PrPSc) using the protease thermolysin. 
Thermolysin allowed isolation of protease resistant PrPSc in its full-length form, 
while cellular prion protein (PrPC) was digested.  With further extraction and 
precipitation of PrPSc with sodium phosphotungstic acid (NaPTA) and in conjunction 
with using monoclonal antibodies that recognise distinct epitopes, PrPSc was detected 
and quantified successfully.  
 
Molecular strain typing of ruminant TSEs was investigated using Western blotting 
and depending on the resistance of PrPSc to digestion with proteinase-K (PK) and 
thermolysin. The methods discriminated clearly between classical ovine scrapie and 
experimental ovine BSE. In contrast, experimental CH1641-like isolates showed 
heterogenous molecular profiles. In addition, the findings from this study 
demonstrated the existence of thermolysin-sensitive PrP isoforms which are resistant 
to PK and their presence varied between individual sheep and brain regions. 
 
When studying prion propagation using the serial protein misfolding cyclic 
amplification (sPMCA) technique, different strains/isolates of ruminant prions were 
successfully amplified in vitro from as little as 0.01 ng of brain seed. Furthermore, 
ovine BSE was readily amplified in vitro in brain substrates from sheep with 
homozygous VRQ or AHQ Prnp genotype. In contrast, the CH1641 strain was 
refractory to such amplification. This method allowed for differentiation of 
experimental BSE from CH1641 prion strains within an ovine host, providing hope 
for the potential of sPMCA as a strain typing assay.  
 
The use of bacterially expressed recombinant PrPsen (rPrPsen) as substrate in PMCA 
reactions (rPrP-PMCA) was assessed. The use of the substrate improved the 
sensitivity, specificity, practicality and speed of sPMCA assays for detecting a range 
of ovine prion isolates. Expression and purification of recombinant Syrian hamster 
prion protein (Sha rPrP) and VRQ ovine PrP (VRQ rPrP) provided substrate for 
detecting PrPSc in scrapie affected brain samples. Although both substrates had the 
same level of sensitivity, rSha PrPsen had better specificity than VRQ rPrP. There 
were variations in amplification efficiency between different batches of the same 
rPrP.  
 
This study recommends further investigations looking at the use of a range of 
experimental CH1641 and BSE samples, as well as using panels of CH1641-like 
field isolates for sPMCA reaction to establish (such) strain typing methodology. 
Furthermore, applying the rPrP-PMCA assay to detect PrPSc in secreta and excreta of 
infected sheep in the pre-clinical phase of the disease may provide a non invasive 
ante-mortem test for scrapie.  
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Chapter 1: INTRODUCTION 
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1.1. Prion diseases: 
                                Prion diseases are a group of hereditary, idiopathic and infectious 
diseases of humans and animals. These diseases are generally characterised by 
neurodegeneration and motor dysfunction due to pathological changes to the cellular 
isoform of the prion protein (PrPC) and accumulation of a misfolded disease isoform 
of the prion protein (PrPSc). These diseases present a major threat to human health, as 
well as agricultural and wildlife animals (Tables 1.1 & 1.2).  
Those prion diseases that have not been proven to be transmissible are sometimes 
referred to as prionopathies (Aguzzi et al., 2008). Within inherited human prion 
diseases, greater than 20 different mutations in the human prion protein (PrP) gene 
have been found to coincide with disease. However, such changes in the prion 
protein primary amino acid sequence are not a prerequisite for PrPSc formation, as 
mutations of the PrP gene are not found in sporadic forms of human prion disease 
that include the majority of CJD cases (Pruisner, 1997). 
Transmissible spongiform encephalopathies (TSEs) are mainly a definition for prion 
diseases that result from exposure to infectious prion particles and can transmit 
between different hosts and species (Aguzzi et al., 2008, Pruisner 1997). Doherr, 
2007 described TSEs as a group of human and animal diseases that share the 
following common features:  
(a) Transmissibility between susceptible hosts either orally in nature or through 
other routes experimentally 
(b) Long incubation periods without symptoms and symptoms only appearing in 
the final stage of disease  
(c) Absence of immune response signs as an indication to disease pathology 
(d) Spongiosis and vacuoles in specific brain regions are the main characteristic 
with histopathological lesions in the clinical phase of the disease 
(e) Accumulation of amyloid plaques containing aggregates of the pathological 
isoform (PrPSc) of the physiological prion protein PrPC  
(f)  No preventive vaccination or intervening therapeutic treatment are available 
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Table 1.1: Comparison of the epidemiological parameters of various TSE 
diseases of humans 
 
 
Prion disease Source of prions References (first 
cited) 
Human diseases 
Kuru 
Infectious; exposure to contaminated 
human tissues during cannibalistic rituals 
 
Gajdusek and Zigas 
1957 
Sporadic 
Creutzfeldt-
Jakob disease 
(sCJD) 
 
Spontaneous conversion of PrPC to PrPSc 
Creutzfeldt (1920) 
and Jakob (1921), 
cited by  McKintosh 
et al., 2003 
Familial 
Creutzfeldt-
Jakob disease 
(fCJD) 
 
Genetic; heritable mutations in the PRNP 
JHQH9DOLQH³9´RU0HWKLRQLQH³0´DW
129, and JOXWDPLFDFLG³(´RUl\VLQH³.´
at 200. Another form of mutation where 
9DOLQH³9´DWDQGDVSDUWDWH³'´RU
DVSDUDJLQH³1´DW 
 
Goldfarb et al., 1992 
 
Iatrogenic 
Creutzfeldt-
Jakob disease 
(iCJD) 
 
Infectious; exposure to prion-infected 
surgical equipment, or tissue transplants; 
blood transfusion; human growth 
hormone therapy 
Duffy et al., 1974 
Variant 
Creutzfeldt-
Jakob disease 
(vCJD) 
 
Infectious; exposure to BSE-infected 
food including meat Will et al. 1996 
Gerstmann-
Sträussler-
Scheinker 
disease  
(GSS) 
Genetic; heritable mutations in the PRNP 
gene 
Gerstmann, 1928, 
cited by Mastrianni, 
2004 
Fatal familial 
insomnia (FFI) 
 
Genetic; heritable mutations in the PRNP 
gene (where 0HWKLRQLQH³0´at 129, and 
aspartate ³'´or DVSDUDJLQH³1´ at 178) 
 
Roiter, 1974 cited by 
Cortelli et al., 1999 
Sporadic fatal 
insomnia (sFI) 
 
Unknown; somatic mutations or 
spontaneous conversion of PrPC to the sFI 
confirmation of PrPSc 
 
Mastrianni et al., 
1999 
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Table 1.2: Comparison of the epidemiological parameters of various TSE 
diseases of animals 
Prion diseases  
(host species) Mechanism of transmission References (first cited) 
Scrapie (sheep & 
goat) 
Infectious; ingestion or contact 
with scrapie-infected animals, 
tissues and secretions derived 
from the infected animals, or 
uptake from a prion 
contaminated environment 
1723 cited by Deslys and 
Picot, 2002 
Atypical scrapie/ 
Nor98  (sheep) 
 
Unknown, spontaneous Benestad et al., 2003 
Transmissible mink 
encephalopathy 
(TME) (Mink) 
 
Infectious; ingestion of prion-
contaminated feed Hadlow & Karstad, 1968 
Bovine spongiform 
encephalopathy 
(BSE) (Cattle) 
Infectious; ingestion of prion-
contaminated feed Wells et al., 1987 
Atypical form of 
BSE in cattle (H-
type) & (L-type) 
 
unknown Biacabe et al., 2004& Casalone et al., 2004 
BSE in goat unknown Euro Surveill 2005;10(2):E050203.1 
Feline spongiform 
encephalopathy 
(FSE) (domestic & 
wild cats) 
 
Infectious; ingestion of BSE-
contaminated feed 
Aldhous, 1990, Willoughby 
et al., 1992, Baron et al., 
1997 
Spongiform 
encephalopathy in 
non-human primates  
Ingestion of BSE-contaminated 
feed Bons et al., 1999 
Chronic wasting 
disease (CWD) 
(Deer, Elk, Moose) 
Infectious; ingestion or contact 
with CWD-infected animals, 
tissues and secretions derived 
from the infected animals, or 
uptake from a prion 
contaminated environment 
Williams et al., 1980 (first 
clinical cases had been seen 
in a captive (research) herd as 
early as 1965) 
Exotic ungulate 
encephalopathy 
(Kudu, Oryx, Nyala, 
Eland, Gemsbok) 
 
Infectious; foodborne exposure 
to BSE-infected tissue 
 
Cunningham et al., 1993, 
Jeffrey and Wells, 1988, 
Kirkwood et al., 1990, 1993, 
1994. 
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1.2. The prion protein: structure and function 
The PrP protein is encoded by the prion protein gene (Prnp), and is 256 and 264 
amino acids in length in sheep and cattle respectively. It has an amino-terminal 
signal peptide that directs the protein to the endoplasmic reticulum (ER) and that is 
cleaved shortly after translation. This is followed by an unstructured N-terminal 
domain containing an octapeptide repeat region, and a predominantly alpha-helical 
C-terminal domain with two variably utilised glycosylation sites. The C terminal 
region also contains a hydrophobic carboxy-terminal domain responsible for the 
attachment of the mature PrPC protein to the cell membrane via a 
glycosylphosphatidylinositol (GPI) anchor (Lloyd et al., 2011, Riesner, 2003, 
Pruisner et al., 1998).   
Spectroscopic studies of hamster PrPC have shown that PrPC is rich in Į-helices (42% 
Į-helix content and OLWWOHȕ-sheet content (approximately 3%)), whereas PrPSc has a 
high ȕ-sheet content (43% ȕ-VKHHWDQGDVĮ-helix) (Pan et al., 1993; Figure 1.1).  
 
 
 
Figure 1.1: Schematic drawing to show the secondary structural features of the two 
isoforms of the prion protein, PrPC ZLWKKLJKĮ-helix content (red colour, left model) 
and PrPSc ZLWKDPXFKKLJKHUȕ-sheet content (green colour, right model) (adapted 
from: http://www.cmpharm.ucsf.edu/cohen/) 
 
 
 
PrPC PrPSc
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PrPC is a low abundance protein whose highest expression levels are found in 
nervous tissues within neuronal and glial cells (Aguzzi et al., 2008, Prusiner et al., 
1998). It is also expressed at lower levels by many other cells and various tissues, 
such as blood, digestive tract, lymphocytes, and skin (Bendheim et al., 1992). It is 
known that PrPC is an absolute requirement for the development of a prion disease as 
studies have shown that PrP-gene deficient mice were resistant to scrapie and did not 
develop ataxia or sever pathologies after challenge with infectious inoculum (Bueler 
et al., 1992).  
One of the challenges in prion biology is determining the main physiological 
functions of the cellular prion protein. Research reports have linked its functional 
role to different biological processes such as copper binding (Brown et al., 1997), 
copper internalization and cell haemostasis (Kretzschmar et al., 2000), neuronal 
sensitivity to oxidative stress through regulating superoxide dismutase-1 (SOD-1) 
activity in a copper-dependent manner (Brown et al., 2002). Furthermore, PrPC 
mediates cellular iron uptake and transport not only in cell culture (Singh et al., 
2009), but mice lacking PrPC expression (Prnp0/0) recover slowly from 
experimentally induced haemolytic anaemia (Zivny et al., 2008). Moreover, PrPC is 
involved in the process of intestinal epithelial cell proliferation and in the sub-
cellular distribution of proteins involved in cell architecture and junctions (Morel et 
al., 2008). In addition, other research reports suggested that PrPC has a 
neuroprotective function against internal or environmental stresses and regulating 
apoptosis (Roucou and LeBlanc 2005 and Roucou et al. 2004). Also, due to the 
localisation of PrPC in the lipid raft domains on the plasma membrane, it has been 
suggested that PrPC can activate transmembrane signalling pathways through 
interaction of PrPC with specific protein or peptide ligands and initiating signal 
transduction (Westergard et al., 2007, Kanaani et al., 2005, Santuccione et al., 2005, 
Chen et al., 2003). Recently, a preliminary study using mouse brain cell lines has 
shown that PrPC might be necessary for brain microvascular endothelial cells to 
migrate into damaged regions in the brain (Watanabe et al., 2011). However, to date 
there is no definitive consensus as to the function of this protein.  
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1.3. Aetiology:  
For decades, the molecular structure of the scrapie agent was the most puzzling 
subject for prion scientists. The transmissibility, long incubation period and existence 
of many different strains, have led to the hypothesis that it is a ³VORZYLUXV´(Hadlow, 
1959) RU³YLURLG´ or spherical infectious particle of approximately 25 nm that could 
accommodate a genome of 1-4 kb in length and probably encodes its own protective 
nucleocapsid (Manuelidis et al., 2009, Manuelidis, 2007, Manuelidis et al., 2007). 
Various trials to elucidate its nature, based on the usual known characteristics of 
infectious agents, have failed to isolate any nucleic acid, and the agent retains its 
infectivity during many physical and chemical treatments that would kill 
conventional infectious agents such as bacteria, viruses and fungi. Further research 
provided clear evidence that the scrapie agent is a hydrophobic form of PrPSc and the 
ZRUG³SULRQ´was adopted ZKLFKRULJLQDWHGIURP³SURWHLQDFHRXVLQIHFWLRXVSDUWLFOHV´. 
The prion is thought to be a protein capable of propagation without the need for 
nucleic acid (Prusiner 1997, 1991 & 1982), WKHVRFDOOHG³protein-only´K\SRWKHVLV. 
Recently, the generation of a classic neuropathology of prion disease through 
intracerebral injection of aggregated, protease-resistant bacterially expressed 
recombinant prion protein (rPrP) in wild-type mice has supported the protein-only 
hypothesis (Wang et al., 2011, Wang et al., 2010).  
According to the protein-only hypothesis, the central biochemical event occurring 
during TSE pathology is PrPSc self-replicating by interacting with PrPC and inducing 
its structural conversion to PrPSc (Prusiner 1998 & 1991). The infectious prion 
proteins denoted as PrPSc and/ or PrPres (protease-resistant core of the prion protein), 
have the same amino acid sequence as PrPC but a different three dimensional 
structure. The conversion process is not fully understood. In view of the protein-only 
model proposed by Prusiner, the transition of PrPC to PrPSc, results from the 
interaction between normal (healthy) and an infectious prion molecule to form a 
PrPC±PrPSc heterodimer and subsequently, restructure of the normal PrPC molecule 
into PrPSc. Consequently, after separation of the two molecules, the two new PrPSc 
molecules can again bind healthy PrPC molecules and convert it to PrPSc. This 
autocatalytic conversion process results in crucial changes to the prion protein from 
its predominantly Į-helical structure to a ȕ-sheet rich insoluble misfolded form that 
forms oligomers and is partially resistant to proteases including proteinase-K (PK). 
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This hypothesis was strengthened by the development of a variety of cell-free 
reactions for prion conversion and propagation. These reactions have shown that the 
conversion of PrPC into a protease resistant PrPSc occurres via a seeded or templated 
polymerization mechanism (Castilla et al., 2006, Horiuchi et al., 2000 & 1999, 
Caughey et al., 1995, Jarrett and Lansbury, 1993, Gajdusek, 1988).  
 
1.4. Epidemiology: 
1.4.1. Disease transmission:  
Different routes of transmission were found to exist for different TSE strains and 
host species. Doherr, 2007, has described a general base for TSEs main transmission 
routes (Figure 1.2). The earliest record for TSE diseases was for sheep scrapie in 
Europe in 1732 (Deslys and Picot, 2002). After that, it has been reported in many 
countries with exceptions including Australia and New Zealand. As the prototypic 
prion disease, scrapie in sheep became one of the most studied TSEs and has 
facilitated our understanding of these diseases. Sheep susceptibility to scrapie was at 
first thought to be heritable (Parry, 1962). Further studies looked to the potential of 
breed effect on the susceptibility to infection, but it was revealed unlikely and it 
became clear that there was much variation in the susceptibility between individual 
animals within breeds (Davies and Kimberlin 1985, Nussbaum et al., 1975, Pattison, 
1974, Dickinson et al., 1968). After more extensive experimental challenge of 
different breeds with scrapie, it became obvious that genetics was playing a 
significant role in scrapie susceptibility and in particular a single gene known as Sinc 
(referred to scrapie incubation time), a gene that was defined later as the Prnp gene 
coding for the so-called prion protein, PrPC (Hunter et al., 1996, Hunter et al., 1993, 
Goldmann et al., 1991, Pruisner 1982). Later, it was revealed that polymorphism of 
the Prnp gene of a host has a profound impact on the susceptibility and resistance to 
prion diseases.  
It is now evident that the mode of transmission of TSEs is mainly through (a) 
horizontal transmission: exposure to infectious prion particles via the oral route 
through ingestion of contaminated food or contact with infected materials in the 
environment and gaining entry to the body through the gut-associated lymphoid 
WLVVXHVLQ3H\HU¶VSDWFKHVLQWKHDOLPHQWDU\WUDFW and (b) vertical transmission: when 
9 
 
infection occurs between affected mothers and their offspring in certain animal 
species.  
 
Since the discovery of BSE in UK herds in 1986 (Wells et al., 1987), and 
establishing a possible link between BSE in cattle and other species (Kirkwood et al., 
1994 & 1993, Cunningham et al., 1993, Aldhous, 1990, Kirkwood et al., 1990, 
Jeffrey and Wells, 1988), particularly to humans as the main cause of vCJD (Bruce et 
al., 1997), major research efforts have been intensified to illucidate the nature and 
origin of BSE.  
 
 
 
 
Figure 1.2: Main transmission routes for transmissible spongiform 
encephalopathy (depending on TSE strain and host species). Solid lines: direct 
vertical (intra-uterine, offspring) and horizontal (direct contact) transmission. Dashed 
lines: indirect horizontal transmission via environment (excretion, uptake), which 
may be most relevant for scrapie and CWD.  Dash-dotted lines: indirect horizontal 
transmission via feed (recycling) which may be most relevant for BSE and related 
diseases. Dotted lines: indirect horizontal transmission via food which may be most 
relevant for vCJD (BSE contaminated beef) and Kuru (cannibalistic burial 
ceremonies) (adapted from Doherr, 2007). 
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Different hypotheses were proposed for the origin of the BSE prion that include: (i) 
that one of the sheep or goat scrapie strains was infectious for cattle. This remains 
yet to be proven (ii) that there might be a spontaneous somatic mutation in the Prnp 
gene, or spontaneous conversion of PrPC to PrPSc similar to sporadic CJD in humans, 
that could have produced a TSE strain either in sheep or in cattle that was infectious 
for cattle (Doherr, 2007). 
It is believed that the BSE epidemic resulted from the oral route of transmission with 
meat and bone meal (MBM) containing bovine prion being fed to dairy cows. 
However the origin of the BSE prion has not been determined (Prusiner 1997, 
Wilesmith, 1991).  
The identification of a BSE case associated with the novel mutation E211K  
(glutamic acid 211 lysine) within the prion protein gene (Prnp), similar to the 
pathogenic mutation E200K in humans that has been described as the most common 
cause of genetic CJD has supported this view (Richt and Hall, 2008). Biochemical, 
neuropathological and transgenic animal experimental studies suggest that BSE has 
transmitted to humans causing vCJD (Bruce et al., 1997, Hill et al., 1997), while 
there is no such evidence that classical scrapie is linked to any of the known diseases 
in human.  
Molecular (strain typing) and epidemiological findings showed the ability of BSE to 
cross species barriers. This was demonstrated in the detection of feline spongiform 
encephalopathy (FSE) in domestic & captive wild cats (Baron et al., 1997, 
Willoughby et al., 1992, Aldhous, 1990). In addition, different captive herbivore 
animals (Kudu, Oryx, Nyala, Eland, Gemsbok) were diagnosed with spongiform 
encephalopathy (Kirkwood et al., 1994 & 1993, Cunningham et al., 1993, Jeffrey 
and Wells, 1988, Kirkwood et al., 1990). Furthermore, the susceptibility of small 
ruminants to BSE has caused a great concern that BSE infected small ruminants 
could present a zoonotic risk to human through consumption of food products 
derived from small ruminants. Experimentally, BSE can be transmitted to sheep and 
between sheep in a closed flock (Bellworthy et al., 2005), however so far, no field 
cases of BSE in sheep have been diagnosed. In contrast, a limited number of BSE 
cases in goat have been diagnosed (Spiropoulos et al., 2011, Jeffrey et al., 2006b, 
Eloit et al., 2005), raising concern for a public health risk.  
In CWD of captive and free ranging deer and moose, the mode of transmission is 
mainly through the horizontal route, particularly through contamination of the 
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environment with secreted and excreted biological materials (Gilch et al., 2011). In 
addition, experimental challenge of meadow voles (Microtus pennsylvanicus), red-
backed voles (Myodes gapperi) and deer mice (Peromyscus maniculatus) highlighted 
the potential role of scavenging rodents to act as reservoir for CWD infection 
(Heisey et al., 2010). However, although cross species transmission of CWD to other 
ruminant species was not proved to occur naturally, experimental transmissions to 
sheep, goat and cattle through intracerebral inoculation were successful to transmit 
the infection but appeared to be of low efficiency (Hamir et al., 2006, Hamir et al., 
1993, Williams et al., 1992). Importantly, there is no evidence that CWD has 
transmitted to humans, and epidemiological and experimental studies classified the 
risk as low zoonotic potential (Saunders et al., 2012, Gilch et al., 2011).   
 
1.4.2. Factors contributing to host resistance and susceptibility to 
TSE diseases:  
1.4.2.1. Genotypes and Prnp gene polymorphism: 
Many studies have shown that sheep resistance or susceptibility to scrapie is 
dependent upon the genotype of the host and strongly linked to the single nucleotide 
polymorphic mutations at codons 136, 154 and 171 out of the 256 amino acids of the 
Prnp gene. Mutations linked to disease susceptibility were either arginine (R), 
glutamine (Q) or histidine (H) at codon 171; histidine (H) or arginine at codon 154, 
and valine (V) or alanine (A) at codon 136. These complex polymorphic mutations 
have produced sheep with different genotypes; approximately 15 genotypes with five 
common alleles: A136R154R171, ARQ, ARH, AHQ and VRQ, that differ widely in 
their degree of resistance and susceptibility to scrapie (Baylis and Bilheude et al., 
2007, Goldmann, 2004, Hunter et al., 1996, Belt et al., 1995, Clouscard et al., 1995). 
These genotypes and their related length of incubation period or apparent resistance 
to infection have informed breeding programmes to produce flocks free of scrapie 
and/or minimising disease incidence. Such breeding programmes have been 
employed in the UK and other European countries. In addition, many reports have 
shown polymorphism in other codons that have been associated with sheep resistance 
to infection. Recently, T112ARQ homozygous sheep where a single nucleotide 
polymorphism (SNP) locus at codon 112 resulted in threonine instead of methionine 
(M112T) has been linked to more resistance to the development of classical scrapie 
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(Laegreid et al., 2008). Further SNPs of the sheep Prnp have been reported, such as 
G127V/S, L141F, H143R, M157I, Q171H/R/K, Q189L, Q220H, and R223K, but 
more investigations are needed to understand their relationship to scrapie 
susceptibility or resistance (Wang et al., 2008, Billinis et al., 2004, Thorgeirsdottir et 
al., 1999).  At the same time, the incidence rate of these SNPs is variable within 
flocks, breeds, and countries. Within all ruminant species, the significance of SNP 
and genotypes could not be estimated as there are at least 105 alleles that encode 85 
distinctive mature PrP protein variants. These variable genotypes may reduce the 
potential of TSE incidence and may result in unsuccessful or inefficient transmission 
within and between species (Goldmann, 2008). Therefore, it is difficult to speculate 
on the ability of a particular strain of scrapie to infect different host species 
(Cancellotti et al., 2007).  
 
1.4.2.2. Role of other genes:  
Although, the polymorphism of Prnp gene is mostly influencing prion disease 
susceptibility and pathogenesis, the role of other genes has been suggested to be 
associated with prion disease progression. One homologues gene Sprn (encoding 
shadoo protein, Sho) that is expressed in the central nervous system (CNS), has 
shown a positive expression correlation with PrPC in the cerebral and cerebellar 
cortex of sheep (Lampo et al., 2009). This positive correlation might indicate co-
regulation between these genes and consequently an influence on prion disease 
progression (Gossner et al., 2009, Stewart et al., 2009, Watts et al., 2007); the 
authors suggested that Sho protein may have a PrPC-like neuroprotective activity. 
Further studies are of considerable importance to establish such association and its 
impact on prion diseases in animals. A second homologues gene to Prnp, is Prnd 
(encoding doppel protein, Dpl) but this has little known role in the mechanism of 
prion disease pathology (Gossner et al., 2009).   
The in vivo manipulation of 3 genes: mainly ablation of the amyloid beta (A4) 
precursor protein (APP), or interleukin-1 receptor, type I (IL-1R1), and transgenic 
overexpression of human SOD-1, have all been linked to prolonged prion disease 
incubation period in inbred mice. However these observations have been difficult to 
interpret due to inter-experimental variations (Tamguney et al, 2008).  
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1.4.2.3. Toll-like receptors (TLRs):  
The role of the toll-like receptors (TLRs) family and its agonists in activating the 
host innate immune response against various pathogens including prions has been the 
central point of many immunological research studies (Spinner et al., 2008, Prinz et 
al., 2003). Two research studies have shown that injection of deoxycytidyl- 
deoxyguanosine (CpG) oligodeoxynucleotides (ODN) enhanced the humoral 
immune response to prions via TLR9 and also the production of antibodies to prion 
protein (Spinner et al., 2007). Spinner et al., 2008 also suggested that TLR4 
activation interferes with scrapie pathogenesis in transgenic mice. All of these 
studies aimed to provide an alternative model for developing preventive or 
therapeutic drugs to prion diseases in humans, and whilst identifying TLRs as 
potential therapeutic targets, their role in prion pathogenesis is yet to be fully 
understood. 
 
1.5. Clinical signs:   
In humans, SULRQVFRXOGSHUVLVWVLOHQWO\IRUQHDUO\DWKLUGRIDKRVW¶VOLIHVSDQEHIRUH
being detectable. The clinical symptoms of human prion diseases are variable 
between different forms of the disease; the genetic polymorphism of the PRNP gene, 
the age of onset and duration of disease and the family medical history are greatly 
influencing the clinical phenotype of prion diseases in human (Head and Ironside, 
2012). At terminal stage, ataxia and rapid cognitive decline causing dementia are the 
main symptoms of prion disease, ending in death (Aguzzi et al., 2008). In sheep 
scrapie, clinical signs are variable; these can include unusual social behaviour and 
extreme nervous reactions to stimuli such as human contact, ataxia, change in the 
fleece colour, pruritis due to scratching against fence posts and biting the affected 
area usually around the base of the tail and occasionally the whole of the side of the 
body. Animals lose the ability to feed themselves and muscle wasting may occur at 
the final stage of the disease. In experimentally BSE-infected sheep, the illness is 
more acute with shorter duration (Hunter et al., 2003). However, variations within 
breeds were reported.  
In BSE affected cattle, the signs included: abnormal gait, particularly ataxia of the 
hind limbs; tremors and abnormal behaviour including nervousness or aggressiveness; 
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jumping up suddenly from a lying position and hyper reactivity to stimuli (Konold et 
al., 2004).  
In CWD of cervids, the most common characteristic sign is gradual decrease in 
appetite and weight loss, behavioural alterations gradually arise (such as loss of fear 
of humans, disorientation, and intermittent circling to one side), together with a 
lowered head and drooping ears. In a more clinically progressed stage, affected 
animals show excessive salivation and difficulty in swallowing, regurgitation of food 
and ruminal fluid, ruminal atony, and polyuria. In a later stage of the disease, the 
animal becomes recumbent and might develop aspiration pneumonia (Imran and 
Mahmood, 2011, Hamir et al., 2008, Sigurdson and Miller, 2003).   
 
1.6. Disease pathology:  
In ovine scrapie, CWD and ovine BSE, once an animal has contracted the infectous 
prion by the oral route, accumulation and propagation of PrPSc occur in the gut- 
associated lymph nodes. This is followed by general progression and widespread 
involvement of other lymphatic tissues: palatine tonsils, retropharyngeal and 
PHVHQWHULF O\PSK QRGHV 3H\HU¶V SDWFKHV DQG VSOHHQ (van Keulen et al., 2008, 
Andreoletti et al., 2000, Heggebo et al., 2000, van Keulen et al., 1996). This 
prolonged widespread replication of PrPSc in the lymphatic tissues, and 
hematogenous dissemination in blood, extends to the central and peripheral nervous 
system where it progressively accumulates, causing fatal neurodegenerative changes. 
Also, it is worth noting that a lack of PrPSc in lymphoid tissues from sheep with 
different genotypes and from different breeds (Ligios et al., 2006, Houston et al., 
2002) as well as, in cattle BSE (Beekes et al., 2008, Wells et al., 2005, Terry et al., 
2003) was also recorded, yet PrPSc accumulation within the CNS was still apparent.  
Spongiosis and vacuolation within the brain are the most consistent characteristic 
lesion profiles of TSEs and such changes are visible under the light microscope as 
holes in the tissue sections. In experimentally infected sheep, the severity and 
neuroanatomical distribution of vacuolations and neuronal loss are features indicative 
of the strain of scrapie with which the animal has been infected. The lesion profile 
may also be influenced by route of infection, age at infection, the duration of clinical 
signs, and sheep genotype (Hunter et al., 2003, Begara-McGorum et al., 2002, Ligios 
et al., 2002). At the same time, breed of sheep or age at death (Wood et al., 1997) 
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and the strain agent (Begara-McGorum et al., 2002) were reported to contribute to 
the variation in the pathological lesions in natural sheep scrapie. In experimentally- 
infected mice with BSE, a mild to moderate vacuolation in the grey matter of the 
hypothalamus, medulla oblongata and septum, and a more severe vacuolation of the 
cochlear nucleus was the main characteristic lesion that is similar to vCJD and 
different from sCJD and scrapie strains. This strain-dependent characteristic 
pathological lesion profile was one of the lines of evidence that indicated humans 
had been infected with BSE contaminated meat as the reason for vCJD (Bruce et al., 
1997).  
 
1.7. Atypical prion diseases in animals: 
1.7.1. Atypical scrapie:  
Atypical scrapie is a sheep TSE designated Nor98, having been diagnosed first in 
Norway. It differs from classical scrapie in the neuroanatomical distribution of the 
histopathological lesions and PrPSc deposition in the brain; with predominance of 
pathological lesions in the cerebellar and cerebral cortices and not in the brain stem 
as in classical scrapie (Benestad et al., 2003). When analysed by Western blot, the 
associated PrPSc is less PK-resistant than that found in classical scrapie and also 
characterised by a distinct banding pattern and molecular weight profile for protease-
resistant PrPSc fragments compared to classical scrapie (Buschmann et al., 2004). 
Atypical scrapie is also distinct from classical scrapie in the relationship between 
susceptibility to disease and Prnp polymorphisms; as it occurred in sheep whose 
genotype is associated with resistance to classical scrapie and has also been found in 
closed flocks of sheep (Buschmann et al., 2004). The aetiology, epidemiology, 
source and risk of atypical scrapie are difficult to explain. However, in different 
random surveys, they found that a polymorphism at amino acid 141 
(Phenylalanine/Leucine) (AF141RQ allele or AL141RQ), is linked to susceptibility 
to atypical scrapie where the majority of atypical scrapie cases were ALHQ/ALHQ, 
ALHQ/AFRQ, and AFRQ/AFRQ while ALHQ/ALRQ and AFRQ/ALRQ were less 
susceptible. Furthermore, most cases contained the AHQ allele and also several 
sheep with ARR/ARR genotype were diagnosed with atypical scrapie (Tranulis et al., 
2011, Luhken et al., 2007, Moreno et al., 2007, Saunders et al., 2006). It has been 
speculated that atypical scrapie may be a spontaneous prion disease analogous to 
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sCJD in humans (Benestad et al., 2003). In the UK, the earliest records points to 
sheep dying of atypical scrapie in 1987 (Webb et al., 2009) and 1989 (Hunter, 2007).  
 
1.7.2. Atypical BSE:   
Since 2004, BSE cases with distinct features from classical BSE (³%6(-C´ disease) 
were reported in different countries and were called atypical BSE. (Stack et al., 2009, 
Gavier-Widén et al., 2008, Jacobs et al., 2007, Buschmann et al., 2006, Biacabe et 
al., 2004, Casalone et al., 2004).  Analysis of some cases of these unique infections 
by Western blot showed an unusually high molecular mass of PrPSc compared to 
BSE-C and such cases were called H-type BSE (Stack et al., 2009, Gavier-Widén, et 
al., 2008, Biacabe et al., 2004). In other cases, the PrPSc molecular mass was slightly 
lower than that observed in BSE-C, together with a lower proportion of the 
diglycosylated band and these were termed L-type BSE (Stack et al., 2009, Baron 
and Biacabe, 2006, Casalone et al., 2004). Both H-type and L-type BSE have PrPSc 
with enhanced protease sensitivities at pH 8 (Jacobs et al., 2007). The L-type 
atypical BSE is characterised by the presence of amyloid plaques which are not 
observed in BSE-C. Therefore, the disease was also termed Bovine Amyloidotic 
Spongiform Encephalopathy (BASE). In addition, the neuro-anatomical lesions are 
more abundant in the cortical regions in contrast to the brain stem for cases of BSE-C 
(Casalone et al., 2004).   
 
1.8. Diagnosis of TSEs: 
1.8.1. Post-mortem diagnoses:  
Since the detection of the first case of BSE in cattle in 1986 (Wells et al. 1987) and 
the subsequent discovery of the potential for cattle BSE to be transmitted to humans 
and cause vCJD in 1996 (Brown et al., 2001, Bruce et al., 1997), there was an urgent 
need for the development of rapid tests for post-mortem diagnosis of TSEs in order 
to screen food chain animals to reduce the exposure of the human population to the 
BSE agent. Prior to this, post-mortem histological and immunohistochemical (IHC) 
techniques showing typical TSE characteristic lesions (spongiosis, amyloid plaques) 
in the brain was the main confirmatory tool to diagnose suspected clinical cases 
(Fraser, 1976). With more understanding of the pathogenesis of TSEs and 
lymphatic/haematogenic dissemination of amyloids, the IHC technique was extended 
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to examine VDPSOHV RI WRQVLOV 3H\HU¶V SDWFKHV DQG RWKHU JXW-associated lymphoid 
tissues in scrapie affected sheep (van Keulen et al., 2008, Andreoletti et al., 2000, 
van Keulen et al., 1996). In addition, exploiting the biochemical features of PrPSc 
towards protease digestion formed the basis to differentiate between PrPC and PrPSc 
in more rapid diagnostic tests. PrPC is susceptible to PK digestion and PrPSc is 
partially resistant. Treating prion infected samples with PK results in full digestion of 
PrPC, and the retention of N-terminally truncated PrPSc conformers. Therefore, 
susceptibility and resistance of PrP to PK digestion and identification of a protease 
resistant C-terminal region is a widely-used tool to diagnose prion diseases. 
Furthermore, Owen et al., 2007, found that treating PrPSc infected tissue with a 
distinct protease, thermolysin (TH), reveals a full length PrPSc that is resistant to 
proteolysis, and digests PrPC into small protein fragments. Again, providing the 
diagnostic tools to reveal the presence of PrPSc within biological samples.  
Western blot techniques have been used to detect the PK resistant (PK PrPres) C-
terminal regions, which remain intact after limited protease digestion with PK. 
'HWHFWLRQRIWKLVSURWHDVHUHVLVWDQWµFRUH¶LVGHSHQGHQWRQDQWLERGLHVWKDWELQGWRDQ
epitope situated in the C-terminal region. This technique has been one of the main 
tools in the diagnosis of TSEs and characterisation of prion strains. Strain 
discrimination is based on the molecular weights and glycoform ratios produced by 
the three glycoforms of PrPSc such that Western blot patterns can be found that are 
unique to individual prion strains and are often stable between host species (Stack et 
al., 2006, Stack et al., 2002, Prusiner 1998). Furthermore, different analogous 
immunodetection techniques have been described for the detection of PrPSc 
aggregates in biological samples such as dot blots, and various enzyme-linked 
immunosorbent assays (ELISAs) (Creminon et al., 2004) including time-resolved 
fluorescence (TRF)- DELFIA (dissociation enhanced Lanthanide 
fluoroimmunoassay) enhanced detection assays (Barnard et al., 2000) and 
conformation dependent immunoassay (CDI) (Thackray et al., 2007, McCutcheon et 
al., 2005, Safar et al., 2005, Safar et al., 2002, Bellon et al., 2003, Safar and Prusiner, 
1998, Safar et al., 1998).   
The DELFIA detection system is based on the previously reported ELISA-format but 
with the advantage of using fluorescent chelates. Therefore, the signal is developed 
in a few minutes and is stable up to hours. In addition, Barnard et al., 2000, exploited 
the solubility of PrP isoforms in two concentrations of guanidine hydrochloride 
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without the need for proteolysis to discriminate between PrPC (soluble isoform) and 
PrPSc (less soluble disease associated aggregated isoform). Following quantification 
of the two isoforms, the quantification of disease-associated PrP as a percentage of 
total PrP becomes a measurable parameter that identified healthy from infected 
animals.  
In the CDI, the technique relies on the differential binding of antibodies to native or 
denatured PrPSc rather than resistance or sensitivity to PK. In summary, a specific 
antibody will bind to an exposed epitope in native PrPC while the same epitope is 
buried in non denatured native PrPSc. After denaturation, this epitope will become 
exposed in PrPSc and is then detected by the antibody. The differences in binding 
leads to quantifiable differences between the signal ratio given by denatured and 
native PrPSc compared to the ratio of signals for denatured/native PrPC (Thackray et 
al., 2007, McCutcheon et al., 2005, Safar et al., 2005, 2002 & 1998).  
Experimental animals, particularly rodents, have been thoroughly exploited as the 
most sensitive and specific method of diagnosing and studying the pathogenesis of 
prion diseases.  After experimental infection of an animal with the suspected infected 
biological material, animals are usually monitored for the advent of clinical disease. 
TSE-disease is then confirmed through post-mortem detection of PrPSc and 
characteristic brain lesions through histology, IHC and Western blot analysis (Grassi 
et al., 2008). However, the application of rodent bioassay as a routine screening tool 
for TSE diseases is not feasible due to ethical considerations and because the method 
takes several months to years to complete, as the onset of clinical signs and the 
accumulation of detectable amounts of PrPSc can be very slow during the incubation 
phase (Castilla et al., 2006). Susceptibility to prion disease and the length of 
incubation periods before symptom onset differs between species and can change 
dramatically when infectious prion strains are transmitted between species (Sweeting 
et al  OHDGLQJ WR WKH ³VSHFLHV EDUULHU´ SKHQRPHQRQ ([SHULPHQWDO VWXGLHV
showed that transmission of prion to a new species is less efficient than intra-species 
transmission (Béringue et al., 2008). However, the transmission may result in 
efficient propagation and infection (Konold et al., 2006), probably after a few sub-
passages and adaptation of the infectious prion to the new host (Béringue et al., 2008) 
or it might fail to cause disease (Kimberlin et al., 1978) reflecting an intrinsic 
resistance of the host to the disease. Therefore, transgenic animal models where mice 
carry the PRNP gene of other species can be useful in evaluating the transmissibility 
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and pathogenesis of prion diseases. Taken all together, combination of factors such 
as prion strain, transgenic/wild type animal line, dose and route of challenge dictate 
the incubation time before clinical onset of disease (Béringue et al, 2008). 
Different analytical methods and diagnostic tests have been developed for routine 
TSE diagnosis based upon the immunological detection of PrPSc (Grassi et al., 2008). 
The European Directorate General for Health and Consumer Protection has evaluated 
and approved different commercial, highly sensitive and accurate diagnostic tests 
that analyse tissues sampled post mortem for large-scale epidemiological studies 
identifying animals infected by TSEs. Such widespread surveillance is undertaken to 
minimise human exposure to prion agents through animal products. Such steps 
became of great importance following the BSE-epidemic within the UK and 
subsequent expanding of the BSE geographical range to other European countries. 
The evaluation of these tests within a series of studies proved that the TSE Kit 
(Enfer), Prionics-Check LIA and Prionics-Check Western (Prionics), and CEA 
(Saclay, France) tests have 100% sensitivity and specificity. In addition, TeSeE and 
TeSeE sheep/goat (Bio-Rad), TSE post-mortem test (IDEXX), Prionics-Check 
Western SR and Prionics-Check LIA SR (both from Prionics) had the advantage of 
detecting atypical scrapie in brain stem samples. 
Although all of these tests have contributed significantly to the diagnosis of prion 
diseases and protecting humans from consuming contaminated meat, their 
application is still limited to post-mortem examination of specific nervous tissue 
samples.  
 
1.8.2. Ante-mortem diagnosis of scrapie in sheep:  
Recent studies of prion pathogenesis, dissemination and accumulation of PrPSc in 
infected animals together with IHC detection, CDI-ELISA, cell free conversion 
assays and animal bioassays have shown widespread distribution of PrPSc in a wide 
range of different tissues and excreta/secreta during the clinical and pre-clinical 
phase of scrapie (Table 3.1).   
The understanding of the pathogenesis of scrapie and in particular the early 
lymphatic/haematogenic dissemination and detection of PrPSc from PH\HU¶VSDWFKHV
of the intestine to progressive spread into other lymphoid organs (lymph nodes, 
spleen) has facilitated the development of ante-mortem tests for scrapie. One such 
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ovine scrapie test was based on the IHC examination of biopsies from the third 
eyelid (O'Rourke et al., 2002, 2000 & 1998). Then, the methodology was applied 
further to pharyngeal tonsils and rectal mucosa (Gonzalez et al., 2008b), and allowed 
the preclinical diagnosis of disease. Although this methodology had potential in 
confirming suspected cases, the sensitivity of these tests has varied considerably 
between different studies (Monleon et al., 2011, Gonzalez et al., 2008b, O'Rourke et 
al., 2002). Furthermore, the frequency of positive results was affected by age or 
incubation in both natural and experimental infection. It has been shown that its 
application might be hindered by low numbers of lymphoid follicles and PrPSc 
accumulation in the biopsy materials. Moreover, the degree of involvement of 
lymphoid tissue in scrapie pathogenesis is influenced by the host genetic code and in 
turn, the availability and level of detectable PrPSc in the biopsied lymphoid tissue 
particularly in ARQ/ARQ sheep (Monleon et al., 2011).   
Taking into account the routes of prion transmission (Mathiason et al., 2009, Doherr, 
2007, Safar et al., 2008) particularly with CWD and scrapie, there might be potential 
for environmental contamination and lateral or indirect horizontal transmission of the 
disease between flock- or herd-mates as well as exposure of other species to prions. 
Such environmental dissemination of infectivity through biological secretion and 
excreta is likely to be from both clinical and subclinical carrier animals. Further 
animal studies have demonstrated that oral exposure to prion infected blood, urine, 
saliva, faeces in the animal environment; exposure to infected environmental fomites 
or excreta from subclinical infected animals can be enough for prion transmission in 
CWD or scrapie (Maddison et al., 2010, Mathiason et al., 2009, Safar et al., 2008, 
Mathiason et al., 2006). Based on these findings, a considerable research effort is 
still in progress to develop further ante-mortem, pre-clinical diagnostic tests for prion 
diseases using readily accessible biological samples. Such tests would contribute to 
the eradication of pre-clinically infected animal and therefore control of the unseen 
transmission pathways of prion diseases.  
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Table 1.3: Detection of prion infectivity or PrPSc within excreta / secreta or 
within tissues.  
Biological 
material 
Prion strain/ 
host species 
Prion detection 
method Disease status Reference 
     
Mammary 
gland 
 
scrapie/sheep Western blots, IHC clinical Ligios et al., 2005 
Milk scrapie/sheep Ovine bioassay clinical Konold  et al., 2008 
 scrapie/sheep rodent bioassay preclinical/clinical Lacroux et al., 2008 
 scrapie/sheep sPMCA(a) preclinical/clinical Maddison et al., 2009 
     
Faeces scrapie/hamster CDI preclinical/clinical Safar et al., 2008 
 scrapie/hamster sPMCA clinical Krüger et al., 2009 
 scrapie/sheep sPMCA preclinical/clinical Terry et al., 2011 
 CWD/deer Cervid bioassay preclinical/clinical Tamgüney et al., 2009 
     
Urine scrapie/mouse rodent bioassay preclinical/clinical Seeger et al., 2005 
 scrapie/hamster sPMCA clinical Murayama et al., 2007 
 scrapie/hamster rodent bioassay clinical Gregori et al., 2008 
 scrapie/hamster sPMCA clinical Gonzales-Romero 
et al., 2008 
 CWD/deer murine bioassay and 
sPMCA clinical Haley et al., 2009 
     
Saliva scrapie/sheep sPMCA preclinical Maddison et al., 2010 
 
CWD/deer cervid bioassay clinical Mathiason et al., 2006 
 
CWD/deer cervid bioassay preclinical Mathiason et al., 2009 
 
CWD/deer murine bioassay clinical Haley et al., 2009 
 
    
Blood CWD/deer cervid bioassay preclinical Mathiason et al., 2009 
 
CWD/deer ELISA and PMCA preclinical/clinical Chang et al., 2007 
 
scrapie/sheep immunocapillary 
electrophoresis preclinical/clinical 
Jackman et al., 
2003 
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Scrapie/ 
hamsters 
immunoprecipitation 
and QUiC(b) preclinical/clinical Orru et al., 2011 
 
scrapie/sheep sPMCA clinical Thorne and Terry (2008) 
 
scrapie/sheep 
CWD/deer PMCA and SOFIA
(c)
 preclinical/clinical Rubenstein et al., 2010 
 
scrapie/sheep 
BSE/sheep 
rapid ligand-based 
immunoassay preclinical/clinical Terry et al., 2009 
 
scrapie/sheep 
 
Surface-FIDA(d) clinical Bannach et al., 2012 
 
    
Nasal 
secretion TME/hamster 
rodent bioassay and 
QUiC clinical 
Bessen et al., 
2010 
 
    
Skin scrapie/hamster Western blot preclinical/clinical Thomzig et al., 2007 
 scrapie/sheep Western blot clinical Thomzig et al., 2007 
 BSE/kudu rodent bioassay clinical Cunningham et 
al., 2004 
 BSE/hamster Western blot clinical Thomzig et al., 2007 
 CWD/elk rodent bioassay and 
sPMCA clinical 
Angers et al., 
2009 
     
Placenta scrapie/sheep sheep/goat bioassay clinical Pattison et al., 1972 
 scrapie/sheep Western blot preclinical Tuo et al., 2001 
 scrapie/sheep Western blot, IHC preclinical/clinical Tuo et al., 2002 
 scrapie/sheep ELISA preclinical Andréoletti et al., 2002 
     
Rectal 
mucosa 
scrapie/sheep IHC, Western blot, HerdChek CWD EIA(e) preclinical/clinical 
Gonzalez-Romero 
et al. 2008a 
 
    
lymph 
nodes(f) scrapie/sheep IHC preclinical 
Andreoletti et al., 
2000 
 
    
(a) Protein Misfolding Cyclic Amplification (PMCA).  
(b) QUiC (Quake-induced Conversion). 
(c) SOFIA (Novel surround optical fibre immunoassay). 
(d) Surface-FIDA Fluorescence intensity distribution analysis. 
(e) HerdChek CWD EIA: HerdChek CWD (chronic wasting disease) antigen EIA 
(enzyme immunoassay) test.  
(f) Gut-Associated Lymphoid Tissues 
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Almost all existing tests detect PrPSc within biological samples either directly or after 
concentration of the PrPSc through precipitation (e.g. NaPTA) (Cronier et al., 2008, 
Wadsworth et al., 2006, 2001). Alternative approaches for the detection of the 
disease marker PrPSc were introduced into prion research studies through the in vitro 
conversion assays. Various in vitro conversion assays were developed to understand 
the mechanism of PrPSc propagation and a method to improve early non- invasive 
diagnosis of prion diseases particularly in pre-clinical cases (Table 1.4) (Ryou and 
Mays, 2008). Each assay has a different methodology and degree of sensitivity; and 
the so called quaking-induced conversion (QUIC) method and protein misfolding 
cyclic amplification (PMCA) are the most widely used techniques. In the QUIC 
technique, the method depends on incubating prion-infected crude brain homogenate 
with rPrP at 45ºC along with periodic vigorous agitation of the sample. In PMCA, 
prion-infected crude brain homogenate is incubated with normal, TSE-free crude 
brain homogenate or rPrP at 37ºC and subjected to repeated pulses of sonication. For 
both methods, prion amplification is typically carried out over multiple days. These 
assays have shown great potential for the development of an ultra-sensitive 
diagnostic test through amplification of prion in vitro. 
 
1.8.3. Protein misfolding cyclic amplification (PMCA):  
The principal idea of PMCA is to mimic pathological processes and is analogous in 
principle to the polymerase chain reaction (PCR) used to amplify DNA (but without 
addition of an enzyme). The first development of this technique by Saborio et al., 
2001, allowed rapid conversion of part of a large excess of PrPC substrate (a brain 
extract from the same species)  into a protease-resistant, PrPSc- like form in the 
presence of minute quantities of PrPSc template. This conversion occurred as a result 
of repeat cycles of sonication and incubation at 37ºC. It is hypothesised that with 
each sonication, the PrPSc aggregates are disrupted to form multiple smaller units that 
act as a template capable of initiating further recruitment of PrPC for conversion into 
PrPSc (Soto et al., 2002) (Figure 1.3).  
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Table 1.4: Summary of in vitro assays for PrPC conversion and PrPSc formation (adapted from Ryou and Mays, 2008)  
Conversion 
Method Conversion Buffer 
Incuba-
tion 
Sonication/ 
Agitation PrP
C
 Source PrPSc Source 
Percent 
Converted/ 
Amplified 
Infec- 
tivity Reference 
Mixing PBS with protease inhibitors 
37°C 
KU  
Lysate of N2a cells 
expressing MHM2 PrPC 
PrP27-30 purified 
from prion-infected 
mouse brains 
0%  
Raeber et al., 
1992 
Metabolic 
Radiolabeling 
PBS with protease 
inhibitors 
37°C 
KU  
Lysate of ScN2a cells 
expressing [35S]- PrPC 
Endogenous PrPSc 
of ScN2a cells 0%  
Raeber et al., 
1992 
Microsomal 
Membranes 
20 mM Tris buffer, pH 
7.5 
25°C 
1 hr 
 
[35S]-PrPC synthesized 
by cell-free 
translation systems 
Microsomal 
membranes from 
scrapie-infected 
hamster brain cells. 
0%  
Raeber et al., 
1992 
Cell-Free 
Conversion 
0.75 M GdnHCl, 130 
mM NaCl, 10 mM Tris-
HCl, pH 7.0 
20°C 
22 hr 
 
[35S]-PrPC expressed 
in mouse fibroblast 
cells 
Brain-derived PrPSc 
treated with  2-3 M 
GdnHCl for 5 h at 
37°C 
10 - 20% of PrPC 
converted No 
Kocisko et al., 
1994 
Cell-Lysate 
Conversion 
50 mM Tris, pH 7.4, 150 
mM NaCl, 0.5% Triton 
X-100, 0.5% SDS 
37°C 
48 hr 
 Lysate of CHO cells 
expressing MHM2 
PrP 
Brain-derived 
mouse PrPSc 
Successful, not 
quantified 
 Saborio et al., 
1999 
PMCA PBS with 0.05% Triton 
X-100, 0.05% SDS, 
protease inhibitors 
 
37°C 
16-48 hr 
40 sec 
sonication 
Normal, uninfected 
crude brain homogenate 
Prion-infected 
crude brain 
homogenate 
~ 20 -100 fold 
increase of PrPSc 
Yes Saborio et al., 
2001, Castilla et 
al., 2005, 2006 
PMCA under 
non-denaturing 
conditions 
PBS with 1% Triton-X 
100, 0.5 mM EDTA 
37°C 
16-48 hr 
Continuous 
agitation, 
800 rpm 
Purified brain -derived 
PrPC 
PrP27-30 ~10-fold increase 
of  PrPSc 
Yes Lucassen et al., 
2003, Deleault 
et al., 2005 
rPrP-PMCA 
PBS with 0.05-0.1% 
SDS, 0.05-0.1% Triton 
X-100 
37°C 
24 hr 
40 sec 
sonication 
rPrP expressed in 
E.coli 
Purified PrPSc or 
crude homogenate 
of prion-infected 
brains 
~10% of rPrP 
converted; fold 
increase of PrPSc 
not quantified 
 
Geoghegan et 
al., 2007 
QUIC 
PBS with 0.05% SDS, 
0.05% Triton X-100 
45°C 
46 hr 
10 sec 
agitation, 
every 2 min. 
rPrP expressed in 
E.coli 
Prion-infected crude 
brain  homogenate 
Variable, sensitive 
to environmental 
conditions 
 
Atarashi et al., 
2008 
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Further technique development was achieved by high numbers of rounds of 
sonication through a programmable sonicator and periodic dilution of amplified 
PrPSc with fresh substrate materials after each round (a technique termed serial 
PMCA or sPMCA). This modified technique maximised the rate of PrPSc 
amplification in an autocatalytic manner and allowed the detection of minute 
amounts of PrPSc: as little as 20 fg/ml, or as few as 4 x 105 equivalent molecules of 
PrPSc per millilitre (Castilla et al., 2005a). These modifications enabled high level 
amplification and sensitive detection of PrPSc in different biological materials from 
scrapie infected rodents in the clinical and preclinical stages of disease, including 
detection of PrPSc in brain tissue, blood, urine and faeces (Gonzalez-Romero et al., 
2008, Maluquer de Motes et al., 2008, Murayama et al., 2007, Saa et al., 2006, 
Castilla et al., 2005b, Soto et al., 2005). 
 
 
 
Figure 1.3: Diagram for the mechanism of amplifying PrPSc by PMCA through 
subjecting a sample containing minute quantities of PrPSc and a large excess of PrPC 
to cycles of incubation and sonication (adapted from Soto et al., 2002).  
 
 
PrPC
Incubation
Growing 
of units
Incubation
Growing 
of units
+
PrPSc
Soto et al. (2002) Trends Neurosci. 25:390-394
Sonication
Multiplication 
of units
Sonication
Multiplication 
of units
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Moreover, in rodent scrapie amplification by PMCA, the addition of polyA or host-
encoded RNA molecules has increased the efficiency of amplification. This 
phenomenon has raised the attention to the cellular factors other than PrPC, 
particularly specific RNA molecules that might be needed for efficient PrPSc 
production (Deleault et al., 2007 & 2005). However, the addition of polyA to 
enhance amplification of sheep scrapie resulted in spontaneous (de novo) synthesis 
of PK-resistant forms of PrP from partially purified PrPC, adding a limitation to the 
wide application of PolyA (Thorne and Terry, 2008).   
The technique also demonstrated successful amplification of PrPSc from a range of 
mammalian species including scrapie in sheep (Thorne and Terry, 2008), CWD in 
deer (Angers et al., 2009, Haley et al., 2009, Kurt et al., 2007), BSE in cattle (Soto et 
al., 2005) and vCJD in humans (Jones et al., 2009 & 2007). Recently, it has been 
applied to detect PrPSc in different DQLPDOV¶tissues, secretion and excretion including: 
blood (Thorne and Terry, 2008, Chang et al., 2007), milk (Maddison et al., 2009), 
saliva from clinically normal scrapie-exposed sheep (Gough et al., 2012, Maddison 
et al., 2010) and faeces (Terry et al., 2011). Furthermore, it has allowed the detection 
of PrPSc within environmental samples (Maddison et al., 2010, Gough and Maddison 
2010). Moreover, further modification to sPMCA have successfully demonstrated the 
use of bacterially-expressed rPrP as a substrate (Orrú et al., 2011, Wang et al., 2011, 
Kim et al., 2010, Wang et al., 2010, Wilham et al., 2010, Orru et al., 2009, Atarashi 
et al., 2008, Atarashi et al., 2007). Within these studies, experimental animal 
infections together with the PMCA technique have enhanced the understanding of 
PrPSc dissemination as well as providing a technique for the potential ante-mortem 
diagnosis of preclinical prion disease. 
 
1.8.4. Quaking-induced conversion (QUIC):  
Similarly to PMCA, the standard QUIC (S-QUIC) assay depends on propagation of 
PrPSc using a rPrPsen as the substrate and replaces sonication with automated 
intermittent tube shaking to induce the conversion of rPrPsen to rPrPres (Atarashi et al., 
2008). Initially, the assay was tested to detect PrPSc in brain homogenate and 
cerebrospinal fluid (CSF) of scrapie-affected hamsters. It showed similar sensitivity 
to rPrP-PMCA to detect sub-femtogram levels of PrPres, with clear discrimination 
between uninfected and scrapie-affected hamster CSF samples, in addition to the 
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advantage of simplicity and more speed than conventional PMCA (Atarashi et al., 
2008). Further adaptation of the QUIC reaction was carried out for the detection of 
prions in CSF of human CJD and sheep scrapie (Orru et al., 2009), and nasal lavages 
from HY (hyperaethesia strain; a short-incubation-period strain) TME-infected 
hamsters (Bessen et al., 2010). Further development of the S-QUIC assay for 
estimating the relative amount of prions resulted in the advent of a real-time quaking 
induced conversion assay (RT-QuIC) (Wilham et al., 2010). RT-QuIC has the 
advantage of a lack of the use of chaotropic salts like SDS (virtually detergent-free; 
<0.002% SDS) that is responsible of stabilizing rPrPres polymers which might affect 
efficiency of conversion, and GdnHCL (which reduces the potential for false positive 
reactions) (Atarashi et al., 2011 a & b, Wilham et al., 2010). It also depends on ThT 
(thioflavin T) based fluorescence detection of prion seeded rPrPsen amyloid fibrils. 
The assay has been used to detect prions of sheep, deer and hamster with a high 
sensitivity similar to animal bioassays (Wilham et al., 2010).  Furthermore, RT-QuIC 
showed promising enhanced diagnostic capacity for the detection of PrPSc in CSF 
from patients with CJD (McGuire et al., 2012, Atarashi et al., 2011), and in human 
and sheep plasma when coupled with a immunoprecipitation step (Orru et al., 2011). 
However, although the QuIC assay is of high sensitivity and specificity, further 
investigations of the variation in sensitivity in detection of different forms of CJD in 
humans, particularly vCJD, are required (Peden et al., 2012, Orru et al., 2011) 
 
In summary, the exhibited diverse heterogeneous prion strains in ruminants, 
particularly scrapie in sheep, has initiated a substantial amount of research aimed at 
producing diagnostic tests with higher sensitivity and specificity, after concentrating 
or amplifying the PrPSc. Within these areas, Western blot protocols, ELISA tests, and 
IHC protocols were initially validated by examination of samples for PrPSc detection 
through its protease resistance and identification by use of PrP-antibodies. 
Furthermore, the reliability of these tests for detection of prion in non neural tissues, 
clinical samples at an earlier stage in the incubation period and environmental 
samples have opened more avenues for a better understanding and accurate diagnosis 
of prion diseases in sheep. The limited knowledge of diverse scrapie strains and the 
need for early diagnostics methods in the field made scrapie in sheep an interesting 
host to study.  
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1.9. Aims of the study: 
Based on the latest published research reports regarding diagnosis of TSEs in 
animals, this study will research the characterisation of prion diseases in sheep 
through:  
1. The development of an ELISA for the detection of PrPSc:  
Digesting PrPSc by the protease TH resulted in full length PrPSc and digested PrPC 
(Owen et al., 2007). In order to detect full length PrPSc by ELISA, I looked at 
digesting scrapie infected brain homogenate samples with the protease TH. To 
separate the two isoforms; full length PrPres and fragmented PrPC, PrPres would be 
precipitated with NaPTA, isolated from PrPC fragments and then detected within the 
sandwich ELISA using capture antibody directed towards an epitope in the N-
terminal part of PrPSc and a detection antibody directed against the PrPSc core. The 
success of developing this ELISA to detect PrPres in brain homogenate will further 
extend to detect amplified products of seeded PMCA reaction.  
 
2. Defining molecular differences of experimental and natural 
strains/isolates of ovine prion diseases through differential protease 
resistance and Western blotting:  
Using PK and TH proteases for digesting PrPSc and analysing the products by 
Western blotting using a range of antibodies targeted to the N-terminal and core 
regions of PrP have enabled to differentiate between classical scrapie and ovine BSE 
(Owen et al., 2007, Thuring et al., 2004). But, the molecular profile of PrPres in 
Western blots showed that PK PrPres from sheep inoculated with CH1641 scrapie 
gave a molecular profile similar to that of sheep inoculated with BSE (Hope et al., 
1999, Stack et al., 2002, Lezmi et al., 2004). Since each protease has different 
proteolytic activity against PrPSc, resulting in truncated PrPres fragments with PK and 
full length PrPres with TH, I hypothesised that digesting CH1641 and ovine BSE 
samples with TH will generate unique PrPres molecular profiles for each strain.  This 
approach will help in developing a strain typing assay capable of distinguishing 
between CH1641 from ovine BSE and ovine scrapie. 
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3. Characterising experimental and natural strains/isolates of ovine prion 
diseases by amplification within PMCA and using natural PrPC 
substrates:  
PMCA has achieved a considerable success in the in vitro replication of rodent 
adapted scrapie and detecting low level of prion in biological materials. Previous 
research reports have showed that different factors have been implicated in the 
success of PrPSc replication. This includes: prion strains and PrPC substrate genotype 
(Thorne and Terry, 2008) and cross species compatibility between the PrPSc seed and 
PrPC substrate (Soto et al., 2005). In ruminant TSE diseases, it has not been used in a 
large scale to assure the efficient replication of varieties of TSE strains in ruminants. 
Therefore, different strains of ruminant prions will be used to seed PMCA reactions 
to elucidate the potential amplification of these strains and detection of low levels of 
PrPSc. I will also investigate:  
1) The effect of prion strain, host species and Prnp genotype on prion 
replication.  
2) The differentiation between ovine BSE and CH1641 through 
amplification within natural PrPC substrates of different Prnp genotypes.  
 
4. The potential of amplification of experimental and natural 
strains/isolates of ovine prion diseases by PMCA within rPrP substrates:  
Due to the difficulty of obtaining a continuous supply of crude brain homogenate as 
a substrate, there are different trials that showed successful use of rPrP expressed in 
bacteria as a substrate in cell free conversion assays (Atarashi et al., 2007, Atarashi 
et al., 2008, Kim et al., 2010, Orrú et al., 2011, Orru et al., 2009, Peden et al., 2012, 
Wang et al., 2010, Wang et al., 2011, Wilham et al., 2010). Therefore, I will test the 
use of bacterially expressed rPrP as a substrate through expression and purification 
of rSha PrP and ovine VRQ rPrP. These rPrP proteins will be used as substrates in 
PrPSc seeded sPMCA reactions with a range of sheep prion seeds to generate PK 
rPrPres fragments. 
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Chapter 2: MATERIALS AND METHODS 
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2.1. Source of CNS materials:  
TSE-infected ruminants were sourced from the Veterinary Laboratories Agency 
(VLA) transmissible spongiform encephalopathy (TSE) archive or collected 
prospectively from confirmed TSE-infected ruminants submitted to the VLA for 
diagnosis. All samples were confirmed negative or positive by routine diagnosis 
using Bio-Rad TeSeE ELISA, immunohistochemistry and VLA hybrid Western blot 
(Stack et al., 2002). Experimentally infected animals were euthanized following 
onset of symptoms, sampled within 60 minutes of euthanasia and samples snap 
frozen at -80°C. All animal procedures were performed under Home Office (UK) and 
local ethical review committee approval and compliance with the Animal (Scientific 
Procedures) Act 1986.   
 
2.2. Brain tissue homogenate preparation:  
Brain tissues from healthy or prion-infected sheep were homogenised to 10% (w/v) 
in lysis buffer (0.5% Nonidet P-40 (v/v) (Igepal CA-630, Cat No. I8896, Sigma) and 
0.5% (w/v) sodium deoxycholate (Cat No. 5670, Sigma) in PBS, pH 7.4) in a 
microbiological safety cabinet. The resulting suspension was passed through needles 
of decreasing diameters (19-, 21-, and then 23-gauge needles), and the samples were 
centrifuged for 5 minutes at 270 g to remove cellular debris. The supernatants were 
removed carefully and stored in 1 ml aliquots at -Û& 
 
2.3. PMCA brain substrate preparation:  
Healthy sheep brains were prepared from a New Zealand-derived scrapie-free flock. 
Whole brain was cleared of attached membranes and all superficial blood vessels and 
then washed with cold PBS. The brain was placed into ice cold conversion buffer (50 
mM NaCl, 4 mM Ethylene diamine tetraacetic acid (EDTA), pH 8.0, 1.0% (v/v) 
Triton X-100 and miniprotease inhibitor, Roche in PBS pH 7.4) and immediately 
homogenized at 10% (w/v) using a liquidiser. For further homogenisation, the 
liquidised brain was placed into a bead beater in batches and each batch was 
homogenised for 30 seconds. After ensuring full tissue homogenisation, any cellular 
debris was removed by a low speed centrifugation at 600 g for 10 minutes at 4°C. 
The supernatant was removed into a clean 1 Litre bottle placed into an ice bath, and 
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mixed thoroughly. Prepared homogenates were placed into 2 ml eppendorf tubes and 
stored immediately at -80ºC.   
 
2.4. Automated serial PMCA (sPMCA): 
Different volumes/dilution series of 10% (w/v) infected brain tissues from sheep with 
distinct PrP genotypes were spiked into brain homogenate substrate (10% (w/v) brain 
homogenate from sheep with different PrP genotypes or bovine samples in PMCA 
conversion buffer (50 mM NaCl, 4 mM EDTA, pH 8.0, 1.0% (v/v) Triton X-100 and 
miniprotease inhibitor, Roche in PBS pH 7.4) or rPrP substrate [0.1 or 0.2 mg/ml 
rPrP in conversion buffer (PBS (pH 7.4) with 0.05% (w/v) Sodium dodecyl sulfate 
(SDS) and 0.05% (v/v) Triton X-100 and sucrose up to 6% (w/v)]. Each spiked 
sample together with non-spiked control substrate samples were loaded into 200 µl 
PCR tubes (Dutscher Scientific, West Thurrock, UK). All samples were placed in an 
ultrasonicating water bath (model 3000; Misonix) at 37ºC and sonicated for 40s at 
200W. Sonications were repeated once every 30 minutes for 24 hours (one PMCA 
round). After each round the sonicated samples were gently pulsed in a microfuge. 
Samples were divided into two parts; one part was frozen at -Û&DQGWKHRWKHUSDUW
was diluted 1: 3 with 10% (w/v) brain homogenate substrate or rPrP substrate (0.1 or 
0.2 mg/ml) to a final volume of the original spiked substrate samples. Samples were 
then subjected to further rounds of PMCA. The number of PMCA rounds was 
typically 3 to 10. Further samples were prepared in exactly the same way as for the 
PMCA samples, but were to act as controls to show the efficiency of PMCA 
amplification. These samples were not subjected to amplification. All amplified 
samples were stored at -20ºC. All samples were digested with PK, and PrPres was 
detected by immunological methods; Western blot or ELISA.  
 
2.5. Optimising proteinase-K (PK) and thermolysin (TH) 
protease for the complete clearance of ovine PrPC or rPrP:  
Aliquots of brain homogenates (20 µl of 10% w/v) from healthy sheep or rPrP (10 µl 
of 0.1 mg/ml) were treated with dilution series of PK and/or TH separately to assess 
for the complete clearance of PrPC. PK digestions were carried out at final 
concentrations between 1 and 100 µg/ml protease for 1 h at 37ºC and digestion 
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stopped by boiling the samples at 100ºC for 5 minutes. When assessing the digestion 
of rPrP, digestions were carried out +/- 0.01% (w/v) SDS. TH (Sigma, Poole, United 
Kingdom) digestions were carried out at final concentrations between 10 and 150 
µg/ml protease for 1 h at 70°C, and digestion was stopped by adding EDTA to a final 
concentration of 10 mM.  
Each digested sample was diluted with two volumes of NuPAGE 2x LDS sample 
buffer containing 5% (v/v) ȕ-mercaptoethanol (Invitrogen, Paisley, United Kingdom), 
and the samples heated to 100°C for 10 minutes. Typically, 3.3 µl of each digested 
10% (w/v) brain homogenate sample or 5 µl of digested rPrP sample were analyzed 
by Western blotting.  
2.6. Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting: 
SDS-PAGE was carried out through a running gel containing 12% (w/v) total 
acrylamide using NuPAGE precast Bis-Tris gels (Invitrogen, Paisley, United 
Kingdom). Separated proteins were transferred to a polyvinylidene difluoride 
membrane (Roche, Lewes, United Kingdom) by using a NuPAGE blot module 
(Invitrogen, Paisley, United Kingdom) at 30 V for 1 h. All membranes were blocked 
with 15 ml of 5 % (w/v) powdered milk baby formula  (SMA) (in Tris-base buffer (8 
g NaCl, 0.2 g KCl, 3 g Tris base, dissolved in distilled water up to 1 Litre and pH 
was adjusted to 8.0 ) containing 0.05% (v/v) Tween 20 (TBST) RYHUQLJKW DW Û& 
Each blot was probed with a primary monoclonal antibody (mAb) diluted in 0.5 % 
(w/v) SMA-TBST , that is specific for epitope in the ovine PrP. Membranes were 
incubated with one of the primary mAbs (Table 2.1 and Figure 2.1) for two hours 
with shaking. After 3 times washing with 0.5 % (w/v) SMA-TBST, membranes were 
incubated with goat anti-mouse horseradish peroxidase (HRP) conjugate 
(DakoCytomation, Glostrup, Denmark) diluted in 0.5 % (w/v) SMA-TBST, for 75 
minutes with gentle shaking. After three washes with 0.5 % (w/v) SMA-TBST, 
membrane was treated with 5 ml EZ- chemiluminescence for HRP substrate (Gene 
flow, Staffordshire, UK) for 5 minutes. Bound anti-PrP antibodies were visualised 
after exposure of the membranes on Fuji X- ray films (Fisher Scientific, 
Leicestershire, UK) or using an ICCD225 camera system from Photek Ltd., (Photek 
Ltd., East Sussex, UK).  
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MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQGSPGGNRYPPQGGGGW 60 
                                 WNTGGSRYPGQGSPGGNRYPP (AG4-1) 
 
 
                                    GSHSQWNKPSK (8G8) 
GQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGGWGQGGSHSQWNKPSKPKTNMKHVAGAAA 120 
               WGQPHGGGWGQPHGGGGW (SAF32) 
                         QPHGGGGWG (SAF34) 
                                WGQGGSHSQWN (P4) 
 
                 (8H4) GNDYEDRYYRENMYRYPNQVYYRPVDRYSNQNNFVH                                   
AGAVVGGLGGYMLGSAMSRPLIHFGNDYEDRYYRENMYRYPNQVYYRPVDRYSNQNNFVH 180 
                                            YYRPVD (SAF84) 
                           YEDRYYRENMYRYPNQVYY (L42) 
                        GNDYEDRYYRENMYRYPNQ (SAF70) 
                              RYYRENMYRYPNQVYYR (AG4-2) 
                           YEDRYYRE (SHA31) 
 
DCVNITVKQHTVTTTTKGENFTETDIKIMERVVEQMCITQYQRESQAYYQRGASVILFSS 240 
                                    CITQYQRESQAYY(RPC) 
 
 
 
PPVILLISFLIFLIVG 256 
 
 
Figure 2.1: Epitope recognition sequences map for Anti-prion antibodies: AG4 
(AG4-1: N- terminal epitope and AG4-2: C- terminal epitope), SAF32, SAF34, P4, 
8G8, 8H4, SAF84, L42, SAF70, SHA31 and Rabbit polyclonal antibody (RPC)  in 
relation to the primary amino acid sequence of ovine prion protein (EMBL accession 
number P23907). 
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Table 2.1: Characteristics of monoclonal antibodies (mAbs) used for Western blotting: 
 
 * Recognise solid-phase immobilized peptide 126-164, but failed to bind peptide 142- 160 of hamster PrP (Feraudet et al., 2005).  
** Assessed by solid phase peptide mapping (Pepscan analysis) and binding is highly dependent on 171Q containing allelotypes (Jacobs et al., 
2011).  
*** Ov = ovine, Bov = bovine, Mo = mouse, Ha = hamster, Hu = human, Mi = mink and SAF = scrapie associated fibrils. 
Antibody Linear epitope on PrP Immunogen Species tested and recognised
*** 
Antibody 
concentration 
(working 
dilution) 
Reference (s) 
SAF32 59 - 89 Ha SAF Ov, Bov, Mo, Ha and Hu 1: 40,000 Feraudet et al., 2005 
SAF34 59 - 89 Ha SAF Ov, Bov, Mo, Ha and Hu 1: 40,000 Feraudet et al., 2005 
P4 93 - 99 Ov PrP Peptide Ov and Bov  1: 5,000 Harmeyer et al., 1998, Thuring et al., 2004 
AG4 31 - 51 along with 147 - 163 Ov full length rPrP Mo and Hu  1: 2,000 
TSE Resource 
Center, UK. 
Maddison et al., 2007 
SHA31 145 - 152 Ha SAF Mo, Ha and Ov  1: 40,000 Feraudet et al., 2005 
SAF70 145 - 162 Ha SAF Mo, Ha and Ov  1: 40,000 Feraudet et al., 2005 
SAF84 126  - 164* or 166 - 172** Ha SAF Mo, Ha and Ov  1: 40,000 
Feraudet et al., 2005, 
Jacobs et al., 2011 
8G8 97 - 102 or        100 - 107 rec Hu PrP Ov, Bov, Mo, Ha and Hu  1: 10,000 
Feraudet et al., 2005 and 
Gretzschel et al., 2006 
8H4 145 - 180  Hu 1: 10,000  
L42 148 - 153 Ov PrP peptide Ov, Bov, Mi and Hu 1: 1,000 Harmeyer et al., 1998 , Gretzschel et al., 2006 
Rabbit 
polyclonal 
antibody 
(RPC) 
217 - 229 Bov PrP Ov, Bov 1 µg/ml Fisher Scientific 
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2.7. Expression and purification of VRQ full length rPrP: 
2.7.1. Bacterial culture:  
A glycerol stock of Novablue DE3 containing plasmid pET22b-VRQ1-3 was 
provised by ADAS biotechnology group. The VRQ1-3 clone (expressing PrP 23-231) 
was cloned into the Nde1/BamH1 sites in pET22b. The expression is driven by a T7 
polymerase promoter on the pET22b, and IPTG induces expression of T7 
polymerase, which then drives high level expression of the gene under T7 control. 
This expression vector clone contains the ovine Prnp gene coding for the protein 
with the VRQ polymorphisms (expressing amino acids 23-231 and lacking the N- 
and C-terminal signal sequences). The expression vector clone was streaked out onto 
a Luria-Bertani- agar (LB) plate containing 50ug/ml ampicillin (Melford, Suffolk, 
UK), the plate was incubated at 37ºC overnight. On the following day, the plate was 
stored at 4ºC until use. 
 
 2.7.2. Induction of protein expression:  
A single colony of E. coli was picked and inoculated into 5 ml 2x YT-A-G medium 
[2xYT medium (16 g Bacto tryptone (Oxoid), 10 g Bacto yeast extract (Oxoid), 5 g 
NaCl, up to 1 litre distilled water, pH 7.0, then autoclaved) containing ampicillin 
(Melford, Suffolk, UK) (up to 100 µg/ml; 5 µl 100 mg/ml) and glucose (up to 3% 
glucose). Four Falcon tubes were prepared, incubated at 37ºC overnight with shaking 
in the incubator at 200 rpm. In addition, 10 ml of the 2x YT-A-G medium without 
bacteria was kept as an absorbance reference for cell growth monitoring.   
1 ml of the overnight culture was inoculated into each of 4 x 250 ml 2YT-A-G (250 
ml 2 YT + 25 ml glucose + 125 µl ampicillin) in 4 flasks (1L unbaffled flask).  
In addition, 0.3 ml of the overnight culture was inoculated into each of 4 x 250 ml 2 
YT-A-G in 4 flasks (1 L non baffled flasks). All flasks were incubated at 37ºC with 
shaking in the incubator for 2 to 4 hours or until absorbance at 595nm reaches ~ 0.4. 
Absorbance reference was measured against 2x YT-A-G medium without bacterial 
growth.  
After an absorbance of ~0.4 was reached, the cultures were transferred into sterilized 
bottles and centrifuged at 1810 g for 30 minutes to pellet cells.  
The cell pellets were re-suspended in 2YT-A-IPTG [250 ml 2YT + 125 µl ampicillin 
+ IPTG (Isopropyl-B-D-thiogalactopyranoside) (Melford, Suffolk, UK) for a final 
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concentration of 1.0 mM]. Each bottle received 50 ml 2YT-A-IPTG media to re-
suspend the cell pellets and transferred to a flask containing 200 ml of 2YT-A-IPTG 
media. The inductions were incubated at 37ºC overnight with shaking at 250 rpm in 
the incubator.  
 
2.7.3. Cell lysis and isolation of inclusion bodies:  
2.7.3.1. Cell harvesting:  
 The media were transferred into sterilized 500 ml centrifuge bottles and centrifuged 
at 1810 g for 30 minutes to pellet cells.  
2.7.3.2. Enzymatic digestion of the cell membrane:  
After centrifugation, the supernatant was discarded. The culture pellets were 
thoroughly re-suspended in 1 ml lysis buffer (50 mM Na2H2PO4, 300 mM NaCl, 0.1% 
Nonidet P-40, (10 mg/ml) 1 Lysozyme (Sigma), Roche Complete Mini tab, (EDTA-
Free; Sigma)) per 50 ml culture volume (i.e. 20 ml per 1 litre). The pellets were re-
suspended with the lysis buffer at room temperature by pipetting up and down with a 
25 ml pipette. Cell lysates were poured into a beaker and frozen at -Û& IRU 
minutes and thawed at least one time.  
DNase I (Deoxyribonuclease) (Boehringer Mannheim, Germany) was added up to 20 
µg/ml (i.e. 800 µg/ 40 ml of the cell lysate) with MgCl2 to 10 mM and the mixture 
was stirred at room temperature until the liquid became viscous. The lysates were 
divided between 50 ml centrifuge tubes (8 tubes) and the viscous liquid was 
centrifuged to pellet inclusion bodies at 12000 g for 20 minutes.  
After centrifugation, the supernatant was discarded. Each pellet was washed by 
thorough re-suspension (vortex) in 25 ml washing buffer (0.1% Nonidet P-40, 10 
mM Tris pH 8 up to 2 litres and incubated on ice for 20 minutes before use ) per 
pellet, and re-centrifuged again at 12000 g for 20 minutes.   
The washing process was repeated up to 5 times until pellets became white. The 
supernatants were removed and the pellets were well drained, resulting in pellets 
containin rPrP precipitated in the form of inclusion bodies which were stored 
ovHUQLJKWDWÛ& 
2.7.3.3. Solubilising the PrP-containing inclusion body pellets:  
Pellets were solubilised in 20 ml of urea buffer (9 M urea, 20 mM Tris HCl pH 8 and 
100 mM DTT). Using a Pasteur pipette, the urea solubilising buffer was gently 
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pipetted across the pellet surface until covering the pellet volume (5 ml urea 
solubilising buffer per pellet) and this step was repeated until all was re-suspended, 
avoiding bubbles. To complete the solubilisation step the samples were mixed 
RYHUQLJKWE\URWDWLRQDWÛ& 
5 ml of the solubilised pellet solution was centrifuged to pellet insoluble debris at 
12000 g for one hour. The supernatant was removed and added to 15 ml 8M urea 
solubilising buffer in preparation for purification through a Fast Protein Liquid 
Chromatography (FPLC) system (AKTA prime, GE Healthcare).  
 
2.7.4. Purification of rPrP protein: 
The purification method is based on the affinity of the conserved octapeptide repeats 
in the N-terminus of the prion protein for transition-metal cations (Viles et al., 1999). 
This metal affinity was exploited to purify full length rPrP through binding of a 
tandem repeat sequence (PHGGGWGQ) to copper ions by immobilised metal 
affinity chromatography (IMAC).  A 5 ml chelating sepharose column was used 
(IMAC HP, GE Health care, Buckinghamshire, UK) to immobilise copper ions. The 
column was assembled on the FPLC machine, and was loaded with copper by 
passing through a solution of copper sulphate (50 mM CuSO4), the column was 
washed and then primed with denaturing buffer (8 M urea, 50 mM NaH2PO4, 300 
mM NaCl, pH 7.5). The sample (20 ml) was loaded as a denatured protein in the urea 
solution at flow rate 0.2 ml per minute. After loading the sample, the protein was 
refolded using a gradient wash step using a urea gradient from 8 M to 0 M over 2.5 
hours [The gradient washing steps were done initially at a rate of 0.5 ml per minutes 
denaturing buffer passing through the column for 10 minutes, followed by 1 ml per 
minute from denaturing buffer to non-denaturing buffer (i.e. refolding step) for 140 
minutes]. Refolded rPrP was eluted in an imidazole elution gradient from 0 - 0.5 M 
imidazole elution buffer  (50 mM NaH2PO4, 300 mM NaCl, 0.5 M imidazole, pH 
7.5), at a flow rate of 0.2 ml per minute for 100 minutes and fractions (1 ml each) 
were collected using an automated fraction collector. Samples were stored at 4ºC. 
Protein fractions corresponding to a protein peak elution on the A280 chart recorder 
were taken and pooled. The concentration of this purified protein was measured by 
Bradford assay (Cat. No. B6916, Sigma) against a BSA standard. The purity of the 
final product was determined by SDS - PAGE. i.e. 30 µl of NuPAGE 2x LDS sample 
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buffer containing 5% (v/v) ȕ-mercaptoethanol (Invitrogen, Paisley, UK) was added 
to 10 µl of selected samples. Samples were heated to 100°C for 5 minutes. All 
samples were stored at 4°C for further analysis. Typically, 5 µl of each sample was 
loaded into SDS-PAGE and electrophoresis was carried out through a running gel 
containing 12% (w/v) total acrylamide using NuPAGE precast Bis-Tris gels 
(Invitrogen, Paisley, UK) at 200 V for 1 hour. Separated proteins were stained with 
Coomassie blue stain. Samples containing pure rPrP were mixed with sucrose (up to 
60%) and then aliquoted and stored at -80ºC.  
This production and purification of VRQ rPrP procedure was carried out during this 
study. Other preparations of VRQ rPrP as well as rPrP of distinct ovine genotypes 
and hamster rPrP were carried out by other members of the research group and the 
pure proteins used in this study.  
 
2.8. Development of a quantitative ELISA to measure PrP:  
The following represents the typical ELISA protocol developed in the current study. 
ELISA plates (Nunc, Fisher Scientific) were coated with 100 µl/well of anti-PrP 
antibody GLOXWHG LQ 3%6 DV D FDSWXUH DQWLERG\ 3ODWHV ZHUH LQFXEDWHG DW Û&
overnight. Plates were blocked with 400 µl of blocking agent diluted in PBS 
containing 0.05% (v/v) Tween 20 (Cat No. P7949- Sigma) (PBST) for 1 h at room 
temperature. Test samples containing PrPSc were treated with the protease TH and 
then precipitated with sodium phosphotungstic acid (NaPTA) (as described by 
Cronier et al. 2008), before re-suspension in the original buffer volume. All samples 
were denatured and spun at 11393 g for 5 minutes to precipitate any non-soluble 
aggregates. For all samples, 60 ȝORIHDFKGHQDWXUHGVDPSOHVXSHUQDWDQWZDVIXUWKHU
diluted to 600 µl in PBST (dilution buffer) and 200 ȝORIWKLVW\SLFDOO\FRQWDLQLQJ 
µl of biological material) was added to ELISA wells in triplicate and incubated at 
room temperature for 1 h.  Bound PrP was detected with 100 µl of antibody SHA31 
(recognising ovine PrP residues 145 - 152) diluted in blocking buffer and incubated 
for one hour at room temperature. Bound SHA31 was detected with rabbit anti-
mouse IgG1-alkaline phosphatase conjugate (anti IgG1 isotope specific antibody, 
Invitrogen, Carlsbad, CA92008, USA) diluted in blocking buffer (1: 2,000). All wash 
steps consisted of five washes with PBST. Bound conjugate was visualised with p-
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Nitrophenyl phosphate (pNPP) substrate (Cat. no. N-2770, Sigma) and optical 
density (OD) was measured at an emission of 405 nm on a microplate reader.  
This general ELISA procedure was conducted with each step optimised to develop 
the final ELISA format. The steps which were empirically optimised included the 
following:  
2.8.1. Antibody concentrations, specificity and compatibility: 
Typically 100 µl of each coating antibody that recognize ovine PrP were diluted into 
PBS (pH 7.4) and were assessed at different concentrations ranging from 1: 2,000 to 
1: 12,000. The antibodies used were SAF15 (recognising PrP residues  79 - 92, 
isotype IgG3), SAF32 (recognising PrP residues 79 - 92, isotype IgG2b), SAF70 
(recognising PrP residues 142 - 160, isotype IgG2b), SAF84 (recognizing solid-
phase immobilized peptide 126 - 164, isotype IgG2b), SAF33 (recognising PrP 
residues 79 - 92, isotype IgG2b) and SAF34 (recognising PrP residues 79 - 92, 
isotype IgG2a)  (all kindly provided by J. Grassi, CEA Saclay, Gif/Yvette, France) 
and detection antibody SHA31 (isotype IgG1).  
  
2.8.2. Blocking agent:  
With optimised antibody concentrations (see result sections 3.2.1) the blocker of 
choice was determined; blocking agents were powdered milk baby formula (SMA 
nutrition, UK), Bovine Serum Albumin (Cat No. A-2153, Sigma) and Chicken Egg 
Ovalbumin (Cat No. A-5253, Sigma), assessed at different concentrations in different 
dilution buffers. 
 
2.8.3. Denaturation conditions: 
With optimised antibodies and blocking agent concentrations (see result section, 
3.2.2.), all healthy brain samples were denatured in different denaturation conditions; 
these were denaturation through boiling for 5 minutes, denaturation with SDS (Cat 
No. S1030, Melford, Ipswich, UK) up to a final concentration of 4% (w/v) and 
incubation at 100°C for 10 minutes, and denaturation with Guanidine hydrochloride 
(Gdn-Hcl) (Cat No. 4505, Sigma) up to 4% (w/v) and incubation at 80°C for 5 
minutes.  
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2.8.4. Precipitation of PrPSc: 
Digested diseased brain homogenates were precipitated by adding N-lauryl-sarcosyl 
to 0.1% or 4% and incubation for 30 minutes at 37ºC, and then incubation with 
NaPTA for 30 minutes at 37ºC. This assessed the recovery and precipitation of 
aggregated PrPSc.   
 
2.8.5. Detection of a dilution series of scrapie-affected brain 
homogenate (standard curve):  
This was performed using increasing amounts of diseased brain homogenates diluted 
into either 10% (w/v) brain homogenate from a TSE-free animal or PBS. Following 
NaPTA precipitation, all samples were treated with the protease TH (Cat No. P1512, 
Sigma) at a final concentration of 100 µg/ml for one hour at 70°C, centrifuged at 43 
g for 45 seconds, and then the digestion was stopped by the addition of EDTA (to 10 
mM).  
 
2.8.6. Detection of ovine VRQ rPrP: 
An aliquot of ovine rPrP (VRQ) (0.8 mg/ml) was diluted into PBS to obtain different 
dilution series ranging from 40 ng to 0 ng per well. Then, all serially diluted samples 
were denatured and the optimised ELISA procedures applied.  
 
2.8.7. Comparison of PrP detection limits using Western blot and the 
developed ELISA protocol:  
Based on previous optimisation steps, a further experiment was conducted to 
compare the sensitivity and quantitative detection limit between the developed 
ELISA assay and a high sensitivity Western blot technique. 
Two dilution series of PrPSc  using 0.031 µl, 0.062 µl, 0.125 µl, 0.25 µl, 0.5 µl, 1 µl, 
2 µl, and 3 µl volumes of 10% (w/v) scrapie positive brain homogenates were spiked 
into healthy brain homogenates to a total volume of 5 µl of brain homogenates per 
well. One dilution series was digested with TH and a second dilution series was 
digested with PK (50 ug/ml) at 37ºC for one hour. All TH digested samples were 
processed based on the optimised procedures for precipitating PrPSc with NaPTA and 
re-suspension to the original volume of the sample. These were then analysed using 
the optimised ELISA protocol.   
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In addition, 30 µl of NuPAGE 2x LDS sample buffer containing 5% (v/v) B-
mercaptoethanol (Invitrogen, Paisley, UK) was added to 10 µl of all TH and PK 
digested homogenates, and samples were heated to 100°C for 5 minutes. All samples 
were stored at 4 °C for further analysis. Typically, 5 µl of digested 10% (w/v) brain 
homogenate within the dilution series was analysed by Western blot. For PK digested 
samples, membrane was probed with primary mAb SHA31 (1: 40,000). For TH 
digested samples, one membrane was probed with primary mAb SHA31 (1: 40,000) 
and a second membrane was probed with anti N-terminal mAb SAF34 (1: 40,000). 
Blots were visualized by using an ICCD225 camera (Photek Ltd., East Sussex, UK). 
 
2.8.8. Comparison between high sensitivity Western blotting and the 
developed ELISA protocol for detecting PMCA- PrPSc: 
To estimate total PrPSc-PMCA levels, 20 µl of each sample subjected to PMCA 
reaction was treated with CaCl2 and ZnSO4 (up to a final concentration of 10 mM 
each), and then digested with TH (100 µg/ml) for one hour at 70ºC, and digestion 
stopped with EDTA (final concentration 20 mM). A further 20 µl of each sample 
was treated with SDS (up to final concentration of 0.04%) and digested with PK (50 
ug/ml) at 37ºC for one hour. Digestion was stopped with PMSF up to 5 mM.  
To remove fragments of PrPC, each digested sample was then precipitated with 
sodium phosphotungstic acid (NaPTA) as described by Cronier et al., 2008, and 
pellets were re-suspended to their original volume in PBS.  
5 µl of each TH digested sample was analysed by the developed ELISA and OD 
values (absorbences read at 405 nm) were used to record qualititative data; positive 
or negative for PMCA-PrPSc.  In addition, 5 µl of each PK and TH digested sample 
were analysed by Western blot. Comparison of the detection result (detected or not 
detected) of each sample analysed by ELISA to the signal intensity of each sample 
digested with PK and TH and analysed by Western blot were conducted to compare 
the sensitivity of detecting PMCA-PrPSc by each method.  
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3.1. Introduction:  
                              The biochemical features of PrP digestion by proteases form the 
basis for differentiating between PrPC and PrPSc where PrPC is susceptible to protease 
digestion and PrPSc is partially resistant. Treating prion infected samples with PK 
results in full digestion of PrPC, and N-terminally truncated PrPSc conformers.  
In a sandwich ELISA technique, PrPSc is captured with an anti-PrP 
antibody through incubation with immobilised anti-PrP mAb on an ELISA plate. The 
PrPSc sample would first be digested with PK followed by denaturation to reveal 
PrPSc epitopes. The captured PrPSc is then recognised by a second anti-PrP antibody 
and this detection antibody is then labelled with a secondary conjugated antibody. 
Bound secondary antibody conjugate is then detected using chemiluminescence 
(Creminon et al., 2004) or colorimetric enzyme substrates.  
With a conformation dependent immunoassay (CDI) (Safar et al., 
2005, 2002 & 1998), the technique relies on the differential binding of antibodies to 
native or denatured PrPSc rather than resistance or sensitivity to PK. In this assay, a 
specific antibody will bind to an epitope exposed in native PrPC while the same 
epitope is buried in native PrPSc. After denaturation of PrPSc, this epitope will 
become exposed and will be recognised by the antibody. These distinct binding 
patterns lead to quantifiable differences between the ratio of the signals given by 
denatured PrPSc and native PrPSc, compared to those with denatured and native PrPC 
(Thackray et al., 2007, McCutcheon et al., 2005, Safar et al., 2005, 2002 & 1998). 
Further modifications of the CDI assay have been developed by incorporating an 
extraction and concentration step using NaPTA allowing the detection of low 
concentrations of PrPSc (Wadsworth et al., 2006, 2001).  
Within the present study, I have adopted the principle of a 
sandwich ELISA to detect full length PrPSc but through treating samples with the 
protease TH. Owen et al., 2007, found that treating PrPSc infected tissue with TH 
reveals a full length PrPSc that is resistant to proteolysis, and digests PrPC into small 
protein fragments. In addition, extraction of PrPSc with NaPTA (Cronier et al., 2008) 
removed any PrPC fragments. I was able to develop an ELISA protocol for PrPSc 
quantification within prion infected samples.  
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3.2. Results:  
3.2.1. Determining antibody concentrations, specificity and 
compatibility: 
To assess antibody specificity and compatibility, the ELISA plate was incubated with 
either: (1) no capture or detection antibodies, (2) capture antibody alone, (3) 
detection antibody alone or (4) both capture and detection antibodies. The pairing of 
different capture antibodies against the detection antibody SHA31 was assessed as 
well as the use of different PrPSc denaturing methods. Dilution series of the detection 
antibody SHA31 was used to detect 1 µl 10% healthy brain homogenate per well 
captured by dilution series of capture antibody SAF32 (Graph 3.1). When assessing a 
panel of IgG mouse monoclonal antibodies for the capture of PrP, SAF15, SAF32 
and SAF34, at different concentrations ranging from 1: 2,000 to 1: 12,000, all had 
successful binding to the N-terminal region of the PrP residue 79 - 92 and captured 
PrP onto the ELISA plate (Table 3.1).  
The optimal dilutions of capture antibody were 1:5,000 - 1:8,000 for SAF15, 1:5,000 
± 1:12,000 for SAF34 and 1:8,000 ± 1:12,000 for SAF32 (Table 3.2). However, the 
signals produced were consistently higher for SAF34 compared to the other capture 
antibodies and this was selected for further method development and used at a 
dilution of 1:8,000. The bound SHA31 antibody was detected with conjugated 
Alkaline Phosphatase (AP)-Rabbit Anti-Mouse IgG1 (diluted 1: 2,000 in blocking 
buffer) which recognised SHA31 but did not cross react with SAF34 or the other                 
capture antibody (data not shown).   
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Graph 3.1: Determining detection antibody optimum dilutions within a 
sandwich ELISA format: Dilutions series from 1: 1,000 to 1: 8,000 for detection 
antibody SHA31 against capture antibody SAF32 1:2,000. Signals generated with 1 
µl 10% (w/v) healthy brain homogenate in PBS per well were compared to 
background signals (no brain homogenate). All samples were added to ELISA wells 
in triplicate. Further controls (0) included omitting capture and detection antibodies. 
Through comparing absorbance densities at 405 nm, there was little difference 
between different detection antibody concentrations, so the optimised dilution for 
SHA31 detection was determined to be 1: 8,000 (This experiment was done once 
only).  
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Table 3.1: Determining capture antibody concentration, specificity and 
compatibility: Dilution series from 1:2,000 to 1:12,000 for a panel of IgG mouse 
monoclonal capture antibodies SAF15 (A) SAF32 (B), SAF34 (C), and detection 
antibody SHA31 at a dilution of 1: 8,000. Signals (OD values at 405 nm) generated 
with 1 µl 10% healthy brain homogenate per well and denatured with SDS were 
compared. Further controls included omitting capture antibody (no coating) or 
detection antibody (no SHA31) or no PrP containing sample (-- BH). All samples 
were added to ELISA wells in triplicate. The average signals obtained for a PrP 
sample (+ BH) and control background (-- BH) were calculated to obtain the highest 
signal to background ratio for each antibody at different concentrations (shown in 
bold). The highest signal to background ratio were obtained with SAF34 (1: 8,000) 
as a capture antibody together with SHA31 as a detection antibody (B). (This 
experiment was done once only).  
         
    
                   (A) SAF15: 
Coating SAF15 
in different 
dilutions 
OD value after 60 minutes incubation with the 
substrate 
Signal to 
background 
ratio + BH  -- BH no SHA31 no coating 
1: 2,000 0.4559 0.2189 0.1036 0.0929 2.08 
1: 3,000 0.4202 0.1945 0.0948 0.087 2.1 
1: 5,000 0.4175 0.1513 0.0856 0.092 2.7 
1: 8,000 0.3424 0.1102 0.0759 0.0947 3.1 
1:12,000 0.1825 0.0669 0.0518 0.0892 0.27 
No coating 0.0885 0.0469 0.0436 0.0794 1.8 
 
                 
(B) SAF34:                           
Coating SAF34 
in different 
dilutions 
OD value after 60 minutes incubation with the 
substrate 
Signal to 
background 
ratio + BH -- BH no SHA31 no coating 
1: 2,000 1.124 0.3292 0.0778 0.072 3.4 
1: 3,000 1.1302 0.293 0.074 0.0736 3.8 
1: 5,000 1.1057 0.2652 0.0697 0.0717 4.1 
1: 8,000 0.9478 0.2206 0.0596 0.0702 4.2 
1:12,000 0.5283 0.1218 0.0507 0.07 4.3 
No coating 0.0742 0.0444 0.0398 0.0666 1.6 
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 (C) SAF32:  
Coating SAF32 
in different 
dilutions 
OD value after 60 minutes incubation with the 
substrate 
Signal to 
background 
ratio 
+ BH -- BH no SHA31 no coating 
1: 2,000 0.7628 0.4261 0.1172 0.0866 1.7 
1: 3,000 0.6635 0.2962 0.1136 0.0846 2.2 
1: 5,000 0.5057 0.2272 0.094 0.0861 2.2 
1: 8,000 0.4272 0.1771 0.0758 0.0801 2.4 
1:12,000 0.3827 0.1269 0.0675 0.0824 3.01 
No coating 0.0802 0.0459 0.039 0.0865 1.7 
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3.2.2. Optimising blocking agent:  
The comparison of different blocking agents demonstrated that incubating the 96 
well plate with Ovalbumin for one hour at 20ºC yielded the lowest background 
values and non-specific binding while SMA had higher background and potential 
binding of its component to conjugated Alkaline Phosphatase (AP)-Rabbit Anti-
Mouse IgG1. There was no difference between using PBS or Tris-buffer on the 
background of the ELISA (Table 3.2). Further experiments confirmed that using a 
concentration of 0.5 - 1 % (w/v) Ovalbumin diluted in PBST was the optimum for 
the lowest background values. Although, bovine serum albumin showed similar 
advantage to the Ovalbumin (data not shown), the latter blocker was selected for 
routine use in order to avoid potential cross-reactivity of the selected antibodies with 
any PrPC protein fragments that may be present in the BSA.  
 
3.2.3. Optimising the denaturation of PrP:  
All healthy brain samples were denatured in different denaturation conditions: 1) 
boiling for 5 minutes, 2) treatment with SDS (Cat No. S1030, Melford, Ipswich, UK) 
up to a final concentration of 4% (v/v) at 100ºC for 10 minutes, 3) treatment with 
Guanidine hydrochloride (Gdn-HCl) (Cat No. 4505, Sigma) up to 4% at 80ºC for 5 
minutes. The equivalent of 1 µl 10% healthy brain homogenate in PBS (pH 7.4) 
(w/v), within a final volume of 200 µl PBST was analysed in each ELISA well. The 
result of different denaturation conditions showed that heating samples at 100ºC for 
10 minutes with 4% (w/v) SDS had the optimum epitope exposing effect for the 
detection antibody SHA31 and capture antibody SAF34 (Graph 3.1).  
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Table 3.2: Comparing the effect of different blocking reagents and dilution 
buffers on background signals: an ELISA plate was coated with SAF34 (1: 8,000) 
as a capture antibody. The plate was divided into different parts and each part was 
loaded with one blocking solution for one hour. The plate was then loaded with 1 µl 
10% healthy brain homogenate per well after denaturation with 4% SDS, and 
incubated at room temperature for one hour. The bound PrP was detected with 
SHA31 (1: 8,000) and conjugated Alkaline Phosphates (AP)-Rabbit Anti-Mouse 
IgG1 (diluted 1: 2,000 in blocking buffer). Signals (OD value) generated from using 
each blocking agent were compared. Optical density (OD value at 405 nm) for the 
lowest background was obtained primarily through blocking with Ovalbumin.  
 
Blocking Solutions 
Absorbance at 405 nm for ELISAs 
employing different buffer systems  
PBSc  Tris bufferd 
 
PrP No PrP PrP No PrP 
3% SMAa 2.58065 0.4029 2.5492 0.36085 
1% SMA 2.09795 0.1472 1.54365 0.13575 
3% Ovalbuminb 1.8432 0.14605 2.1881 0.15665 
1% Ovalbumin 1.4867 0.12395 1.68035 0.13205 
 
 
a
 SMA: Powdered milk baby formula   
bOvalbumin: Albumin, Chicken Egg  
cPBS: 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, in distilled water to 1 
Litre, pH 7 
dTris buffer: 8 g NaCl, 0.2 g KCl, 3 g Tris base in distilled water to 1 Litre, pH 8  
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Graph 3.2: Optimising denaturation conditions for PrP: each of four ELISA 
plates, each was coated with dilution series of SAF34 as capture antibody from 1: 
2,000 to 1: 12,000. Each ELISA plate was loaded with 1 µl 10% healthy brain 
homogenate per well subjected to different denaturation conditions; (A) no 
denaturation, (B) denaturation through boiling, (C) denaturation with 4% SDS and 
(D) denaturation with 4% GndHCl. Bound PrP containing brain homogenate was 
detected with detection antibody SHA31 at a dilution 1: 8,000. Further controls 
included omitting capture antibody (no coating) or detection antibody (no SHA31) or 
no PrP containing sample (-- BH). Signals (OD value) generated from each 
denaturation condition were compared. Optical density (OD value at 405 nm) for the 
highest detection of 1 µl PrP containing brain homogenate were obtained through 
denaturing PrP containing samples with 4% SDS.  
 
 
 
(A) The plate was loaded with 1 µl 10% (w/v) healthy brain homogenate per well 
without denaturation 
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(B) The plate was loaded with 1 µl 10% (w/v) healthy brain homogenate per well, 
denatured through boiling. 
 
 
(C) The plate was loaded with 1 µl 10% (w/v) healthy brain homogenate per well, 
denaturation with 4% SDS. 
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(D) The plate was loaded with 1 µl 10% (w/v) healthy brain homogenate per 
well, denaturation with 4% GndHCl. 
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3.2.4. Precipitation of disease-associated PrP:  
Two series of 0.031 µl, 0.062 µl, 0.125 µl, 0.25 µl, 0.5 µl, 1 µl, 2 µl, 3 µl positive 
brain homogenates spiked into healthy brain homogenates up to a total of 5 µl of 
brain homogenates per well were analysed. One dilution series was incubated with an 
equal amount of PBS containing 0.1% N-lauryl-sarcosyl and the second dilution 
series with PBS containing 4% N-lauryl-sarcosyl to evaluate the influence of the 
concentration of N-lauryl-sarcosyl on PrPSc precipitation. The comparison of these 
two sets of samples was undertaken to determine the optimum conditions for the 
precipitation of aggregated PrPSc. All samples were incubated for 30 minutes at 37ºC 
and then precipitated with NaPTA. All samples were denatured and detected using 
the optimised ELISA procedure. The use of 4% Na-lauryl-Sarcosyl, compared to 
0.1%, increased PrPSc recovery by more than 10% (Graph 3.3).   
  
3.2.5. Generation of standard curves for PrPSc: determination and 
validation of assay parameters:    
Production of PrPSc standard curves was performed using three dilution series of 
diseased brain homogenates as follow: Dilution series of 0.1 µl, 0.2 µl, 0.4 µl, 0.6 µl, 
0.8 µl 10% positive scrapie brain homogenates (w/v) into healthy brain homogenates 
making a total of 1 µl brain homogenate per well. Two dilution series of 0.031 µl, 
0.062 µl, 0.125 µl, 0.25 µl, 0.5 µl, 1 µl, 2 µl, 3 µl, 4 µl, 5 µl positive brain 
homogenates; one spiked into healthy brain homogenates up to a total of 5 µl of 
brain homogenates per well, and the second one spiked into PBS up to a total of 5 µl 
of per well.  
The negative control samples were either healthy brain homogenate or PBS only. All 
samples were treated with the protease TH, and then PrPSc precipitated with 4% N-
lauryl-sarcosyl and NaPTA. All samples were denatured and detected using the 
optimised ELISA procedure as detailed in the previous sections. These ELISAs were 
performed to determine the limit of detection (LOD) for PrPSc within the context of 
buffer and when present within brain, representing the LOD for detecting a volume 
of diseased-brain and for detecting decreasing levels PrPSc within the brain material 
respectively.   
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Graph 3.3: Comparison of two different concentrations of Na-lauryl-sarcosyl (4% 
and 0.1% respectively) for the precipitation of PrPSc: Two spiked concentration 
series of 0.031 µl, 0.062 µl, 0.125 µl, 0.25 µl, 0.5 µl, 1 µl, 2 µl, and 3 µl positive 
brain homogenates were spiked into healthy brain homogenates to a total volume of 
5 µl of brain homogenates per well. The first concentration series was treated with an 
equal amount of PBS containing 0.1% N-lauryl-sarcosyl and the second one with 
PBS containing 4% N-lauryl-sarcosyl for 30 minutes at 37ºC to determine the 
optimum conditions for precipitation of aggregated PrPSc. The comparison of signals 
(OD values at 405 nm) for these two sets of samples showed increased PrPSc 
recovery by more than 10% when samples were incubated with 4% Na-lauryl-
sarcosyl, compared to 0.1%.  
LOD= 3* standard deviation of the mean of OD value for negative samples + mean 
of OD values for healthy brain homogenate (6 replicates) 
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LOD is usually described as the lowest volume of diseased brain material that 
produces a signal above the background of the assay. This was calculated as the 
mean OD values produced with PBS or healthy brain homogenate + 3 x standard 
deviation (stdev) of the mean of OD values of negative samples. R2 value (The 
coefficient of determination; the square of the sample correlation coefficient between 
the outcomes and their predicted values) was calculated computationally.  
All spiked concentration series into healthy brain homogenates or PBS making a 
total of 1 µl and 5 µl brain homogenate per well were analysed by the developed 
ELISA. The result of these experiments showed that both antibodies; SAF34 (1: 
8,000) and SHA31 (1: 8,000) have had high compatible detection of VRQ ovine 
PrPSc in brain samples. When analysing positive scrapie brain homogenate spiked 
into healthy brain homogenate at 1 µl in total per well (Graph 3.4: A), as well as 5 µl 
in total per well (Graph 3.3 and Graph 3.4: B) or into PBS (5 µl total per well, Graph 
3.4: C), over 3 experiments, the lowest volume of PrPSc containing brain homogenate 
to be detected within the ELISA was 0.125 µl 10% positive brain homogenate (12.5 
µg of positive brain material). Linear detection of PrPSc was up to 3 µl (300 µg of 
positive brain material) (Graph 3.4: B and C). The R2 was equal to 0.97 for 
decreasing amount of PrPSc within a background of healthy brain homogenate (Graph 
3.4: B). Similar result was obtained for decreasing amounts of PrPSc within a 
background of PBS (R2 = 0.95) (Graph 3.4: C). The inter-assay variation coefficient 
(CV; coefficient of variation) was equal to 0.02 (i.e. 2%). These optimised conditions 
were used in all subsequent ELISA experiments.  
 
 
 
 
 
58 
 
Graph 3.4: Detection of dilution series of positive scrapie brain homogenate: (A) 
Dilution series of positive scrapie brain homogenate: 0.031 µl, 0.062 µl, 0.125 µl, 
0.25 µl, 0.5 µl, 1 µl positive brain homogenates spiked into healthy brain 
homogenates up to a total of 1 µl of brain homogenates per well. (B) & (C) Dilution 
series of Positive Scrapie Brain Homogenate: 0.031 µl, 0.062 µl, 0.125 µl, 0.25 µl, 
0.5 µl, 1 µl , 2 µl, 3 µl positive brain homogenates spiked into healthy brain 
homogenates (B) or PBS (C) up to a total of 5 µl of brain homogenates and/or PBS 
per well. The negative control samples were either healthy brain homogenate or PBS 
only .This experiment was performed based on the optimised ELISA procedures to 
determine the detection limit for PrPSc when present within brain. All samples were 
analysed in triplicate and the means of PrPSc were plotted. After calculating the R2 
(correlation coefficient) over several experiments, the limit of detection of PrPSc 
containing brain homogenate within the ELISA was 0.125 µl 10% positive brain 
homogenate (12.5 µg), with linear detection of PrPSc up to 3 µl (300 µg of positive 
brain material).  
LOD= 3* standard deviation of the mean of OD value for negative samples + mean 
of OD values for healthy brain homogenate (6 replicates) 
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3.2.6. Detection of ovine rPrP:  
Serially diluted samples containing 0 ± 40 ng VRQ rPrP were denatured and the 
optimised ELISA procedures were carried out. The linear range for the detection of 
VRQ ovine rPrP was between 0.5 - 5 ng per well (5 - 25 ng/ml) and the R2 value was 
equal to 0.992 (Graph 3.5: A & B).  
 
3.2.7. Comparison of PrP detection limits using high sensitivity 
Western blotting and the developed ELISA protocol:  
PrPSc detection by high sensitivity Western blot was carried out using the same 
samples analysed previously by ELISA (section 3.2.5). Two dilution series of 0.031 
µl, 0.062 µl, 0.125 µl, 0.25 µl, 0.5 µl, 1 µl, 2 µl, and 3 µl positive brain homogenates 
were spiked into healthy brain homogenates to a total volume of 5 µl of brain 
homogenates per well. The first spiked concentration series was digested with TH 
(100 µg/ml) at 70ºC for one hour, precipitated with NaPTA and re-suspended in the 
original sample volume. The second spiked concentration series was digested with 
PK (50 µg/ml) at 37ºC for one hour. Digested 10% (w/v) brain homogenate samples 
(5 µl each) were analysed by Western blot.  The detection limit of PrPSc by the 
developed ELISA assay showed similar PrPSc detection limits when compared to 
Western blot analysis; the latter detected the equivalent of 0.062 to 0.125 µl  of 
positive 10% (w/v) brain homogenate (Figure 3.1: A, B & C). It was noticeable that 
the control sample (healthy brain homogenate) was not fully digested with PK 
(Figure 3.1: A) whilst it was fully removed when treated with TH and precipitated 
with NaPTA (Figure 3.1 B & C). These data indicate that both TH digestion and the 
process of precipitation with N-lauryl-sarcosyl and NaPTA may aid in removing 
PrPC compared to PK digestion alone or that higher doses of PK are needed to 
remove PrPC from these samples. Furthermore, when using brain homogenate 
materials from healthy sheep (VRQ/VRQ, cerebellum) and scrapie infected sheep 
(VRQ/VRQ, brain stem), the developed ELISA showed  similar sensitivity for PrPSc 
detection as an established high-sensitivity Western blot technique, routinely applied 
for the detection of PrPSc. 
 
 
 
 
61 
 
Graph 3.5: Detection of dilution series of ovine VRQ rPrP: Dilution series of ovine 
VRQ rPrP ranging from 0 ng to 40 ng were loaded in triplicate into an ELISA plate 
coated with SAF34 (1: 8,000). Bound rPrP was detected with SHA31 (1: 8,000) and 
conjugated Alkaline Phosphates (AP)-Rabbit Anti-Mouse IgG1 (diluted 1: 2,000 in 
blocking buffer) (A). Determining the R2 value showed that the linear range for the 
detection of ovine VRQ rPrP ranged between 0.5 - 5 ng per well (5 - 25 ng/ml) (B). 
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Figure 3.1: PrP detection limits using Western blot after PK and TH digestion: 
Two dilution series of 0, 0.031 µl, 0.062 µl, 0.125 µl, 0.25 µl, 0.5 µl, 1 µl, 2.5 µl, 2 µl, 
and 3 µl 10% positive brain homogenate were spiked into healthy brain homogenates to 
a total volume of 5 µl (lanes 3-12). One dilution series was digested with PK (50 µg/ml) 
at 37ºC for one hour (A). The other two series were digested with TH (100 µg/ml) at 
70ºC for one hour, and then processed based on the optimised procedures for NaPTA 
precipitation of PrPSc and re-suspension of samples in the original volumes (B & C). 
Digested samples (5 µl each) were loaded per well. Molecular weight markers are shown 
(Lane 1) and PrP was visualised by probing with monoclonal antibodies SHA31 (PrP 
epitope: 145 ± 152) (A and B) or SAF34 (PrP epitope: 59 ± 89) (C) and detection with 
Western breeze kit.  
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3.2.8. Comparison between high sensitivity Western blotting and the 
developed ELISA protocol for detecting PMCA-PrPSc:  
The detection of PMCA-PrPSc samples (products of PMCA amplification of PrPSc seed) 
from a range of TSE affected sheep were analysed by the developed ELISA and an 
established Western blot protocol. Samples spiked into homozygous ARQ substrate 
were analysed (in triplicates) and detected by the developed ELISA before amplification 
(Time 0) and after one round of PMCA (Time 24).  The signals obtained were 
qualititatively assessed; i.e. samples were judged to be successfully amplified based on 
the difference in OD values before and after amplification (Graph 3.6).     
Some PMCA-PrPSc samples cannot be detected by ELISA whilst they can be detected by 
Western blotting using the same detection antibody SHA31 (Figure 3.2 and Table 3.3) 
In 0925/03 and SSBP1 isolates (Figure 3.2: panel B, lanes 2 and 10 respectively), 
Western blot analysis showed that PMCA-PrPSc is composed mainly of truncated C- 
terminal fragments, lacking the binding epitope of the capture antibody of the ELISA. 
Since the developed ELISA assay detects full length PrPSc through initial binding to a 
capture antibody to the N- terminal domain, these two isolates were not captured and 
could not be detected.   
However, a lack of full length PMCA-PrPSc does not fully explain the differences in 
detection between ELISA and Western blotting. For example, the sample ov BSE 0654 
and sample 0678 (Figure 3.2: panel D, lanes 2 and 4 and Table 3.3) gave high signal 
level of TH resistant full length PMCA-PrPSc in Western blot but were still not detected 
in the ELISA.  
In classical scrapie 1276/02 (VRQ/VRQ) (Figure 3.2: panel A, lanes 5 and 6), 0615/03 
(ARQ/VRQ) (Figure 3.2: panel B, lanes 7 and 8 respectively) and 0635/03 (ARQ/ARQ) 
(Figure 3.2: panel D, lanes 5 and 6) isolates, it seems that PMCA-PrPSc product 
contained conformers that are more sensitive to treatment with TH and more resistant to 
PK. This was demonstrated in the stronger signal intensity for PK PrPres than TH PrPres 
of the same samples.  Since these samples were classical scrapie of different genotypes, 
it seems unlikely strain or genotype dictates the observed variability towards proteases.  
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Graph 3.6: Detection of a PMCA-PrPSc by the developed ELISA: 1 µl 10% (w/v) 
cerebellum homogenate of different TSE samples were spiked into homozygous ARQ 
substrate to a final volume 100 µl in duplicate. First set of samples were kept at - 20ºC 
(Time 0). The second set was subjected to one round of PMCA reaction (Time 24).  5µl 
of each sample in both sets were digested with TH and analysed by the developed 
ELISA in triplicates (Chapter 2: Materials and methods; 2.7.8). OD value (absorbance 
read at 405 nm) for each sample was reported and analysed qualitatively. Samples were 
recorded as detected or not detected based on the difference of OD values before (Time 
0) and after amplification (Time 24) for each sample.  
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Figure 3.2: Comparison between the developed ELISA protocol and Western 
blotting to detect protease resistant PMCA- PrPSc: 1 µl cerebellum homogenate of 
different TSE samples were spiked into ARQ substrate to a final volume 100 µl. The 
mixture was subjected to 1 round of sPMCA reaction as described. After completing the 
reaction, 20 µl of each sonicated sample was digested with PK (50 µg/ml) for 1 hour at 
37ºC. Further 20 µl of each sonicated sample was digested for one hour with TH at 70ºC.  
5 µl of each digested sample was analyzed by Western blotting and probed with SHA31 
antibody. Each lane is marked with the type of protease used for digesting the sample. 
³&´ LV $54 VXEVWUDWH FRQWURO QRQ-spiked sample subjected to sonication). Sample 
details are given in table 3.3. Samples detected by Western blot that were not detected 
by ELISA are indicated by (*). Samples that showed PKres THsen conformers after 
amplification are indicated by (^)   
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Table 3.3: Comparison between Western blotting and the developed ELISA protocol for 
detecting PMCA- PrPSc: 
 
Lane No.  Strain Isolate ID Strain Genotype 
Protease 
used for 
digestion 
ELISA 
result     (D, 
ND)1 
Western Blotting 
signal evaluation    
(W, M, S)2 
Membrane A 
     
1 Classical Scrapie 0226/03 ARQ/VRQ PK  ND 
2 Classical Scrapie 0226/03 ARQ/VRQ TH ND ND 
3 Classical Scrapie 1563/02 VRQ/VRQ PK  S 
4 Classical Scrapie 1563/02 VRQ/VRQ TH D S 
5 Classical Scrapie 1276/02 VRQ/VRQ PK  M 
6 Classical Scrapie 1276/02 VRQ/VRQ TH D W/ND 
7 Classical Scrapie 1275/02 VRQ/VRQ PK  S 
8 Classical Scrapie 1275/02 VRQ/VRQ TH D S 
9 Classical Scrapie 0923/03 VRQ/VRQ PK  S 
10 Classical Scrapie 0923/03 VRQ/VRQ TH D M 
Membrane B 
     
1 Classical Scrapie 0925/03 VRQ/VRQ PK  M 
2 Classical Scrapie 0925/03 VRQ/VRQ TH ND S* 
3 Classical Scrapie 0455/03 ARQ/VRQ PK  ND 
4 Classical Scrapie 0455/03 ARQ/VRQ TH ND ND 
5 Classical Scrapie 0836/03 VRQ/VRQ PK  M 
6 Classical Scrapie 0836/03 VRQ/VRQ TH ND M* 
7 Classical Scrapie 0615/03 ARQ/VRQ PK  S 
8 Classical Scrapie 0615/03 ARQ/VRQ TH ND W/ND 
9 Classical Scrapie- SSBP1 SSBP1 VRQ/VRQ PK  M 
10 Classical Scrapie- SSBP1 SSBP1 VRQ/VRQ TH ND M* 
Membrane C 
     
 
CH1641 J2916 ARQ/AHQ PK 
 
M 
 
CH1641 J2916 ARQ/AHQ TH D ND 
 
CH1641 J2935 ARQ/AHQ PK 
 
M 
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CH1641 J2935 ARQ/AHQ TH D W/ND 
 
CH1641 J3011 AHQ/AHQ PK 
 
W 
 
CH1641 J3011 AHQ/AHQ TH D W/ND 
 
Ov BSE 0392/04 ARQ/ARQ PK 
 
S 
 
Ov BSE 0392/04 ARQ/ARQ TH D S/M 
 
Ov BSE 1693/03 ARQ/ARQ PK 
 
S 
 
Ov BSE 1693/03 ARQ/ARQ TH ND ND 
Membrane D 
     
1 Ov BSE 0654/04 ARQ/ARQ PK 
 
S 
2 Ov BSE 0654/04 ARQ/ARQ TH ND S* 
3 Classical Scrapie 0678/03 ARQ/ARQ PK  S 
4 Classical Scrapie 0678/03 ARQ/ARQ TH ND M* 
5 Classical Scrapie 0635/03 ARQ/ARQ PK  S 
6 Classical Scrapie 0635/03 ARQ/ARQ TH ND W 
7 CH1641 VLA-1 AHQ/AHQ PK 
 
W/ND 
8 CH1641 VLA-1 AHQ/AHQ TH ND W/ND 
 
Control (C; 
healthy brain 
homogenate) 
1035/05 ARQ/ARQ PK 
 
ND 
 
Control (C; 
healthy brain 
homogenate) 
1035/05 ARQ/ARQ TH ND ND 
1D: detected, ND: not detected 
2
 W: Weak signal, M: medium signal, S: strong signal 
*samples detected by Western blot and were not detected by ELISA.  
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3.3. Discussion:  
The development of high throughput immunoassays such as ELISAs to detect PrPSc, 
the surrogate marker for TSE diseases (Prusiner 1998), has received great efforts 
from many research groups and companies. Different approaches have been taken 
aiming at increasing the sensitivity and robustness of such assays either through 
concentrating PrPSc aggregates or increasing its concentration through in vitro 
amplification or both (Chang et al., 2007). Although many trials were successful the 
requirement for a highly specific, sensitive and very strict analytical diagnostic 
method for routine early diagnosis of prion diseases has not been fulfilled (Grassi et 
al., 2008). 
I developed an ELISA for quantifying PrPSc in prion infected brain tissue, as well as 
detecting PrPSc following in vitro prion amplification. The assay uses isotype 
specificity to recognise a detection antibody directed against the PrPSc core above a 
capture antibody directed towards an epitope in the N-terminal part of PrPSc. This 
was achieved through treating samples with the protease TH (Owen et al., 2007), 
thus digesting PrPC and revealing full length PrPSc, precipitating the resulting PrPSc 
with NaPTA (Cronier et al., 2008) to isolate this isoform away from PrPC fragments 
and  then detecting the PrPSc within the sandwich ELISA.  The sensitivity and 
similarity in LOD (12.5 µg of positive brain material) between dilution series of 
PrPSc spiked in PBS and healthy brain homogenate prove the high specificity of the 
developed ELISA to detect low level of PrPSc in brain samples.  
 
Although, the developed ELISA assay showed similar PrPSc detection limits in 
classical scrapie diseased brain homogenates when compared to Western blot 
analysis, I could not detect some PMCA-PrPSc in PMCA propagated samples using 
the same assay. This result could not be considered a limitation to the sensitivity of 
the assay. More likely it shows the biochemical difference of some PMCA-PrPSc 
compared to the original PrPSc seed. For example, Western blot analysis of classical 
scrapie affected cerebellum isolate (0635/03) did not show any difference between 
PK and TH resistant PrPSc (Chapter 4: Molecular differences of experimental and 
natural strains/isolates of ovine prion diseases, Figure 4.3, Panel C). On the contrary, 
PMCA amplified products from the same sample; 0635/03-PMCA-PrPSc showed 
more resistance to PK than TH. Therefore, the observed discrepancy between 
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Western blot and ELISA detection of the amount of resistant PMCA-PrPSc might 
reflect the variation of PMCA amplified isoforms which could be related to the 
conformers contained within the original sample and/or the effect of sonication on 
the propagation of distinct conformers. However, such observation needs to be 
further investigated.  
 
Detecting PrPSc by the developed ELISA technique has several advantages over 
Western blotting; first, considering the variation of PrPSc concentration in test 
samples, the methodology allows comparison to a rPrP standard curve within each 
assay, facilitating the quantitation of PrPSc (Maddison et al., 2010). Second, large 
numbers of experimental samples can be analyzed at one time. Third, since the 
developed ELISA detects only full length PrPSc, it can be used with other 
commercial ELISAs (e.g. Bio-Rad® TeSeE Sheep/Goat ELISA) to compare the 
proportion of N-terminally truncated to full length PrPSc in samples or the influence 
of other factors on the processing of PrPSc and the production of truncated PrPSc 
fragments (Maddison et al., 2012). Fourth, the use of the protease TH has the 
potential of detecting PK-sensitive PrPSc (Cronier et al., 2008) potentially making 
this assay more sensitive for some prion isolates. Fifth, it is shown in this study that 
PK, when used under standard conditions routinely applied for PrPSc detection (50 
µg/ml), might not fully digest all healthy PrP on every occasion (as shown in the 
result section, 3.2.7 and figure 3.1 A), an outcome reported previously (Hope, et al., 
1999 and TSE EU Community Reference Laboratory, 2007).  Therefore, digestion 
with TH can overcome this problem to differentiate between healthy and scrapie 
affected animals.  
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Chapter 4: Molecular Differences of Experimental 
and Natural Strains/Isolates of Ovine Prion Diseases 
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4.1. Introduction: 
According to the protein-only hypothesis, PrPSc is the main marker for prion diseases 
(Prusiner, 1998 & 1991) and specific prion diseases have been found to differentiate 
into multiple distinct strains. Scrapie in sheep has exhibited diverse heterogeneous 
prion strains with significant differences in the length of incubation periods and 
lesion profiles after transmission into transgenic mice or susceptible sheep (Bruce, 
1993).  
Mouse bioassay (either inbred wild-type mouse or transgenic mouse) is the definitive 
strain typing method. The length of incubation period, reproducible patterns of 
vacuolation and intensity of vacuolation in selected neuroanatomic locations are 
particular fearture of each strain/infected mouse line. These specific criteria allow 
successful discrimination between strains (Beck et al., 2010, Gavier-Widén, et al., 
2005).    
Histopathological changes and IHC analysis provides a tool to distinguish between 
distinct prion strains by detection of disease-related PrP species. Strains are defined 
through differences in neuropathological targeting and abundance of disease-related 
PrP in brain tissue (Jeffrey et al., 2006a, Gonzalez et al., 2002, van Keulen et al., 
1996) and vacuolation profiles (Begara-McGorum et al., 2002, Ligios et al., 2002). 
Furthermore, the IHC approach of PrPd (disease-specific prion protein) epitope 
mapping based on the intracellular cleavage of PrPd together with immunoreactivity 
of PrPd to a standard panel of PrP antibodies that recognise different epitopes 
allowed differentiation between SSBP/1 scrapie and CH1641 scrapie in sheep 
(Jeffrey and Gonzalez, 2007).   
In addition, differences in the biochemical characterization of different scrapie 
isolates by Western blotting through variability in glycoprofiles, antibody reactivity 
and the molecular weight profiles of PrPSc fragments after PK and TH digestion have 
added valuable rapid tests to discriminate between classical scrapie and experimental 
ovine BSE (Baron and Biacabe, 2007, Owen et al., 2007, Thuring et al., 2004, Stack 
et al., 2002). However, migration pattern differences of PrPres in Western blots 
showed that PK PrPres from sheep inoculated with CH1641 scrapie gave a molecular 
profile similar to that of sheep inoculated with BSE (Lezmi et al., 2004, Stack et al., 
2002, Hope et al., 1999). Although, both strains could be differentiated through the 
more protracted method of IHC PrPd profiling and peptide mapping (Jeffrey et al., 
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2006), the use of established rapid strain typing tests raises the possibility that field 
scrapie strains similar to CH1641 might be misclassified as ovine BSE.  
Strain discrimination is of keen interest for prion diagnostics and for public health. 
This study extends previous reports (Stack et al., 2006, Thuring et al., 2004) using 
Western blotting of cerebellum homogenates for the diagnosis and strain typing of a 
suspected case of TSE in sheep. These data also provide more information towards 
our understanding of the sensitivity and resistance of PrPSc towards proteases.  
 
4.2. Results:  
4.2.1. Molecular profiles of PrPres fragments:   
Representative results of Western blotting analysis of PrPres from the panel of 
different experimental TSE strains (Table 4.1) are shown from two experimental 
repeats. Samples were examined for the electrophoretic mobility and antibody 
binding between PK and TH resistant PrPres in experimental CH1641, SSBP1 and 
ovine BSE infected cerebellum tissue. Not all PK digested samples have shown the 
characteristic three glycoform banding patterns of PrPSc; diglycosylated, 
monoglycosylated and unglycosylated bands. There were also obvious variations in 
the levels of PrPres among individual isolates within each group of samples 
representing a particular strain, i.e. the samples from 4 x CH1641-experimentally 
infected sheep and 3 x BSE experimentally infected sheep (Figure 4.1).  
 
For samples probed with L42 (epitope 148-YEDRYY-153) and SAF84 antibodies 
(epitope 166-RPVDQY-172):  the 3 PrPres glycoforms of PK digested Ov BSE 
(0392/04) (Figure 4.1: panels A & C, lane 5, panels B & D, lane 19) and CH1641 
(J2935) (Figure 4.1: panels A & C, lane 9 and panels B and D lanes 13) showed a 
higher molecular weight for non glycosylated PrPres for the Ov BSE sample 
compared to CH1641. CH1641 (J3011) (Figure 4.1: panels B and D lane 15) gave 
consistent results for this strain.  
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Table 4.1:  Brain tissues from healthy, experimental BSE and scrapie infected 
sheep.  
 
Isolate Strain Breed Genotype Brain region 
1035 Healthy Dorset Horn ARQ/ARQ Cer 
 SSPB1 Cheviot VRQ/VRQ Cer 
J2916 CH1641 Cheviot ARQ/AHQ Cer 
J2935 CH1641 Cheviot ARQ/AHQ Cer 
J3011 CH1641 Cheviot AHQ/AHQ Cer 
VLA1 CH1641 Cheviot AHQ/AHQ Cer 
1693/03 Ovine BSE Romney ARQ/ARQ Cer 
0392/04 Ovine BSE Romney ARQ/ARQ Cer 
0654/04 Ovine BSE Romney ARQ/ARQ Cer 
0226/03 Scrapie Swaledale ARQ/VRQ Cer, CM and SC 
0678/03 Scrapie Suffolk cross ARQ/ARQ Cer and CM 
0284/97 Scrapie Finn Dorset AHQ/AHQ Cer, CM and SC 
1776/02 Scrapie Welsh Hill 
Speckled 
VRQ/VRQ CM 
0575/00 Scrapie Cambridge ARQ/ARQ CM 
0455/03 Scrapie Swaledale ARQ/VRQ Cer, CM and SC 
0635/03 Scrapie Charollais Cross ARQ/ARQ Cer 
0615/03 Scrapie Swaledale ARQ/VRQ Cer, CM and SC 
1275/02 Scrapie Welsh 
Mountain 
VRQ/VRQ Cer, CM and SC 
1276/02 Scrapie Welsh 
Mountain 
VRQ/VRQ Cer, CM and SC 
 
Brain tissues from healthy, experimental BSE and scrapie infected sheep were 
obtained from the Animal Health Veterinary Laboratories Agency TSE-Archive 
(AHVLA; Addlestone, Surrey, United Kingdom). CH1641 & SSBP1 were kindly 
supplied by N. Hunter (Institute for Animal Health, Neuropathogenesis Unit, 
Edinburgh, United Kingdom). SSBP1 was passaged at least 24 times through 
Cheviot and Cheviot crosses, including a final passage in VRQ/VRQ Cheviot sheep 
at the VLA. CH1641 (animals J2916, J2935 and J3011) were obtained from the 
Roslin Institute or passaged in AHQ/AHQ sheep at the AHVLA (animal VLA1). 
Samples were homogenised to 10% brain homogenates; Cerebellum (Cer), Caudal 
Medulla (CM) and Spinal Cord (SC) (according to the methodology of 2.1. Brain 
tissue homogenate preparation).  
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Figure 4.1: Western blot analysis of panels of ovine strains digested with either PK 
ȝJPOIRUKRXUDW&RU7+DWȝJPOIRUKRXUDW&DVLQGLFDWHG
+/-ȝORIHDFKZYFHUHEHOOXPKRPRJHQDWHVDPSOHZDVORDGHGSHUODQH
and molecular mass markers are indicated in kDa; Lanes 1 & 2: (SSBP1) VRQ/VRQ, 
Lane 3 & 4: Ov BSE (1693/03), Lanes 5, 6, 19 & 20: Ov BSE (0392/04), Lanes 7 & 
8: Ov BSE (0654/04), Lanes 9, 10, 13 & 14: CH1641 (J2935), Lanes 11 & 12: CH 
1641 (J2916), Lanes 15 & 16: CH1641 (J3011), Lanes 17 & 18: CH1641 (VLA1). 
Membranes A´$%´& B were probed with mAb L42, membranes C'´ & D were 
probed with mAb SAF84. Western blot exposures were taken at different time points; 
15, 30, 60 and 90 seconds.   
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Recently, using multiplex immunoblot approach (triplex-WB), for WB detection 
with L42 and  SAF84 antibodies,  CH1641 displayed a characteristic dominant 
diglycosylated PK PrPres band after binding with L42, and with SAF84 having 
roughly equal intensities between di- and monoglycosylated PrPres (Jacobs et al. 
2011). Therefore, we compared the different glycoprofiles obtained for PK PrPres of 
CH1641 and ovine BSE samples after binding with mAbs   L42 and SAF84 on the 
same blot at different exposure time. As a result, CH1641 (J3011) isolate revealed a 
PrPres with a glycoprofile of higher intensity for the diglycosylated band after 
SURELQJ ZLWK / 3DQHO %´ 	 % ODQHV  	  UHVSHFWLYHO\ In contrast, it was 
difficult to detect variation in the intensities between the di- and monoglycosylated 
bands with other CH1641 samples detected by both antibodies and whatever the 
condition of digestion. 
Samples probed with the mAb P4 (epitope 93-WGQGGSH-99): Generally, there 
was a clear variation in the amount of P4-binding-PrPres produced between individual 
samples for each strain. The SSBP1 sample and the BSE samples were distinguished 
by TH digestion as previously reported (Owen et al., 2007). Both TH digested 
SSBP1 (Figure 4.2: Panel A, lane 2) and CH1641 (J2935) (Figure 4.2: Panel A, lane 
10) isolates showed closely similar molecular profiles with apparent molecular mass 
of 36, 28, 23 kDa together with a lower band of ~ 15-17 kDa. This molecular profile 
was consistent in another Western blot analysis (Figure 4.2: Panel C, lanes 1 and 2).  
Two ovine BSE samples (0392/04) (Figure 4.2: lanes 6 & 20) and (0654/04) (Figure 
4.2: lane 8) had a different molecular weight to CH1641 (J2935); between 38 and 17 
kDa, and 38 and 23 kDa banding patterns for TH PrPres, respectively. Both Ov BSE 
(1693/03) (Figure 4.2: lanes 3 & 4) and CH1641 (J2916) (Figure 4.2: Panel B, lane 
11 & 12) hardly showed any detectable PrPres bands.  The other two CH1641 (J3011 
and VLA1), showed faint signals of approximately 26 kDa PK PrPres (Figure 4.2: 
lanes 15 & 17) and 38 and 27 kDa of TH PrPres (Figure 4.2: panels B, lanes 16 and 
18). Increasing the amount of brain homogenate analysed (either directly or 
following NaPTA precipitation) did not enhance the detection signals of ovine BSE 
(1693/03), CH1641 (J2916), CH1641 (J3011), and CH1641 (VLA1) (data not 
shown). Therefore, the observed low P4 reactivity generated by TH full length PrPres 
confirm the low level of full length PrPres in CH1641 (J3011) and (VLA1) samples as 
showed by L42 and SAF84 mAb detection producing much higher signals (Figure 
4.1). Overall, both experimental ovine BSE and CH1641 isolates demonstrated 
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significant heterogeneity in the levels of PrPres present in the cerebellum during 
clinical disease. In addition, for TH resistant/ P4 reactive PrPres fragments, BSE 
isolates gave consistent banding patterns whereas CH1641 isolates produced two 
distinct banding patterns with CH1641 (J2935) being distinct from the CH1641 
isolates (J3011) and (VLA1).  
 
 
 
 
 
Figure 4.2 (Panel A and B): Western blot analysis of panels of ovine strains 
GLJHVWHGZLWKHLWKHU3.ȝJPOIRUKRXUDW&RU7+DWȝJPOIRUKRXU
at 70ºC  (as indicated; +/-ȝORIHDFKZYFHUHEHOOXPKRPRJHQDWHVDPSOH
was loaded per lane and molecular mass markers are indicated in kDa; Lanes 1 & 2: 
(SSBP1), Lane 3 & 4: Ov BSE (1693/03), Lanes 5, 6, 19 & 20: Ov BSE (0392/04), 
Lanes 7 & 8: Ov BSE (0654/04), Lanes 9, 10, 13 & 14: CH1641 (J2935), Lanes 11 & 
12: CH 1641 (J2916), Lanes 15 & 16: CH1641 (J3011), Lanes 17 & 18: CH1641 
(VLA1). Membranes A & B were probed with mAb P4.  
 
 
 
 
Figure 4.2 (Panel C): Western blot analysis of CH1641 (J2935) and SSBP1ovine 
strains digested with TH DWȝJPOIRUKRXUDW&ȝORIHDFKZY
cerebellum homogenate sample was loaded per lane and molecular mass markers are 
indicated in kDa. Lane 1: CH1641 (J2935), Lane 2: SSBP1. The membrane was 
probed with mAb P4.  
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4.2.2. Detection of PrP fragment CTF14:  
Previous reports using Western blotting to discriminate between CH1641 and ovine 
BSE, showed that digesting "CH1641-like" scrapie with TH was characterized by the 
unique accumulation of a more C-terminally cleaved PrP fragment of 14 kDa, called 
(CTF14), when using SAF84 for PrPres detection (Nicot and Baron, 2010, Baron et 
al., 2008). This fragment was also detected in the absence of any protease digestion. 
Therefore, I applied the same reported method to my ovine samples in order to 
establish whether they could be differentiated through the detection of additional C-
terminal PrPres cleavage fragments (i.e. CTF14). Samples of SSBP1, ovine BSE 
(0654/04) & CH1641 (J2935) isolates were digested with 1 mg/ml TH for a total of 4 
hours and probed with SAF84. With my ovine samples, neither the undigested 
samples nor samples digested with TH for 4 hours (Figure 4.3) or PK for one hour 
(data not shown), have produced C-terminally cleaved unglycosylated PrP fragment 
of 14 kDa that are reported to characterise CH1641 and CH1641- like scrapie.  
 
 
 
 
Figure 4.3: Western blot analysis of 10% (w/v) TSE affected cerebellum isolates for 
the detection of CTF 14 fragments. Lanes 1-3 represent 5 µl of digested samples of 
SSBP1, ovine BSE (0654/04) & CH1641 (J2935) respectively. These samples were 
digested with 1 mg/ml TH for a total of 4 hours. Lanes 4-6 represent 5 µl of each 
original sample (diluted 1: 3 in PBS) without protease treatment. PrP was detected 
with mAb SAF84.   
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4.2.3. Differential protease susceptibility of ovine prion isolates:  
By qualitative comparing of signal intensities of PK PrPres and TH PrPres of TSE 
affected samples included in this study (Table 4.1), I was able to detect differences in 
the amount of PrPres produced as a result of digesting particular samples with either 
3.  ȝJPO IRU  KRXU DW & RU 7+ DW  ȝJPO IRU  KRXU DW & 7KHVH
amounts of proteases were optimised to the minimum amount required to remove all 
PrPC (data not shown). For SSBP1, Ov BSE (1693/03), Ov BSE (0654/04) and 
CH1641 (VLA1) isolates and detecting PrPres using core antibodies (Figure 4.1, 
Panel A to D, lanes 1 and 2, lane 3 and 4, lanes 7 and 8, and lanes 17 & 18), although 
each lane was loaded with 3.3 µl of digested materials, TH PrPres was at lower levels 
than PK PrPres. Approximately, similar levels of PK PrPres and TH PrPres were 
detected for other samples (Figure 4.1: Ov BSE 0392/04: lanes 5, 6, 19 & 20, 
CH1641 (J2935): lanes 9, 10, 13 & 14 and CH1641 (J3011) lanes 15 & 16). 
Equivalent results were produced with antibodies SAF84 and L42.   
I then looked for possible quantitative differences of protease-resistant PrPSc 
produced by a range of classical scrapie isolates and different regions of brain tissues 
from these scrapie affected animals (Figure 4.4). The relative levels of TH and PK 
resistant PrPSc for between scrapie affected animals was not consistent with some 
displaying very similar levels of TH PrPres and PK PrPres species (0678/03, 1776/02, 
0575, 0455/03, 0615/03 and 0635/03), whilst others displayed PrPSc with greater 
susceptibility to TH digestion than to PK (1275/02 and 1276/02). This was consistent 
when analysing protease-resistant PrPSc from different regions of the same brain for 
these animals. Furthermore, these experiments also revealed that in certain animals 
there was clear variation in differential protease susceptibility between different 
brain regions (0226/03 and 0284/97). In addition, certain samples produced 
additional C-terminal PrPres cleavage fragments. This was demonstrated in detecting 
faint PK PrPres fragments of ~ 15 kDa from three classical scrapie affected sheep: 
caudal medulla of animals 1776/02 and 0575/00 (Figure 4.4, panel B, lanes 7 & 9 
respectively), and cerebellum samples of 1275/02 and 1276/02 affected sheep 
(Figure 4.3, panel E and F, lanes 1 respectively).  Since these fragments were not 
detected from tissue treated with TH, these fragments seem to result from PK 
cleavage of full length PrPSc rather than endogenous proteolytic process.  
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Figure 4.4: Western blot analysis of panels of different brain regions from classical 
VFUDSLHDIIHFWHGVKHHSGLJHVWHGZLWKHLWKHU3.ȝJPOIor 1 hour at 37ºC or TH at 
 ȝJPO IRU  KRXU DW & DV LQGLFDWHG -). 3.3 µl of each 10% (w/v) brain 
region homogenate sample was loaded per lane; Cerebellum (Cer), Caudal Medulla 
(CM) and Spinal Cord (SC) samples were analysed. Membranes were probed with 
mAb SAF84. Molecular mass markers are indicated in kDa. C-terminal PrPres 
cleavage fragments are indicated by arrows.  
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4.3. Discussion:  
Multiple prion strains have been isolated from sheep after characterisation by their 
relative incubation periods and pattern of brain vacuolation in different inbred lines 
of mice (Bruce, 2003, Bruce and Fraser, 1991, Dickinson, 1976). In sheep, there are 
mainly four TSE types that have been recognized: classical scrapie, CH1641 scrapie, 
experimental BSE and atypical scrapie Nor98 (Benestad et al., 2003, Stack et al., 
2002, Hope et al., 1999). In addition, classical scrapie passaged in mouse bioassays 
revealed the description of approximately 20 distinct mouse-adapted ovine prion 
strains, based on patterns of brain vacuolation and length of incubation times (Bruce, 
2003, Bruce et al., 2002). Different typing methods have been used to differentiate 
between ovine TSE strains; including mouse bioassays, IHC or biochemical tests like 
Western blotting using PrP specific antibodies.  
With regard to rapid assays, using conventional Western blotting methods, atypical 
scrapie had multiple PK PrPres band patterns and a characteristic lower band of 
around 11 kDa which is different from the banding pattern of other animal prion 
diseases. Discrimination between PK PrPres in classical scrapie and ovine BSE can be 
achieved and is based on: (a) the high concentration of the diglycosylated fraction in 
ovine BSE compared to that in scrapie infected samples (Thuring et al., 2004, Stack 
et al., 2002). (b) The molecular mass of the nonglycosylated band which is ~1.6 kDa 
smaller in sheep BSE than in sheep scrapie. However, it had been noted that the use 
of glycoform ratios to distinguish ovine BSE and scrapie did not produce consistent 
findings and showed different observations between laboratories (Baron et al., 2000, 
Baron et al., 1999, Hill et al., 1998). The distinct molecular weight of the 
nonglycosylated PrPres has been further developed to describe the differential 
availability of antibody epitope binding sites after PK digestion; relative levels of 
binding of antibodies such as 66.94b4, 6H4, R521 in comparison to P4, with low 
reactivity of P4 with PrPres in sheep BSE. This discriminatory method was based on 
differences in the location of the N-terminal cleavage site for PK PrPres between BSE 
and scrapie and was considered a robust method for routine diagnosis of ovine BSE 
(Stack et al., 2006, Thuring et al., 2004).  
 
With all diagnostic methods mentioned for strain typing, there is still a need for a 
diagnostic method that could confirm the presence of BSE in small ruminants 
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particularly after the detection of BSE in two cases of goat in Europe (Spiropoulos et 
al., 2011, Jeffrey et al., 2006b, Eloit et al., 2005). Western blotting has been applied 
and recommended to diagnose BSE in mice and small ruminants (Spiropoulos et al., 
2011, Thuring et al., 2004, Stack et al., 2002). This method is cost effective and 
results can be obtained within short timescales which is suitable for massive 
surveillance.   
Although, BSE has not been isolated from ovine field cases, it might be present and 
there is more need to accurately differentiate BSE from strain(s) such as CH1641. 
The unusual CH1641 isolate has molecular similarities to experimental ovine BSE.  
Although it is a rare form of ovine TSE, CH1641 and CH1641-like isolates have 
been isolated from natural cases from a number of European countries, and 
propagated experimentally in both sheep and transgenic mice (Baron and Biacabe 
2007, Foster et al., 1988).  
In a previous study, using TH for digesting TSE affected brain tissue produced PrPres 
on Western blots that successfully distinguished ovine BSE from classical scrapie 
(Owen et al., 2007). Furthermore, TH produced a nonglycosylated PrP fragment of 
14 kDa in CH1641 and LQ³&+-OLNH´QDWXUDOVFUDSLH isolates (Nicot and Baron, 
2010). Therefore, I extended previous work to the identification of PrPres in the 
cerebellum of scrapie affected sheep using two proteases PK and TH and the analysis 
of the resulting fragments by Western blotting.   
When detecting protease-resistant fragments with the P4 antibody, my results 
demonstrate that one CH1641 (J2935, ARQ/AHQ), showed features of having 
banding patterns indistinguishable to that shown by a classical scrapie strain SSBP1.  
It is worth noting that CH1641 (J2935) showed molecular weights similar to classical 
scrapie in three analyses and this was different from other CH1641 isolates. In 
contrast, other CH1641 isolates (J3011 and VLA1) both have AHQ/AHQ Prnp 
genotypes and showed molecular profiles that were similar to Ov BSE (0654/04, 
ARQ/ARQ and 0392/04, ARQ/ARQ).  
Ov BSE (1693/03, ARQ/ARQ) and CH1641 (J2916, ARQ/AHQ) did not give a 
measurable level of PrPres clearly due to low levels of PrPres in both samples 
demonstrating that the level of PrPres in a defined brain region during clinical disease 
is highly variable for individual animals.  
Although CH1641 (J2935) together with CH1641 (J3011) and (VLA1) samples, 
showed readily detectable levels of PrPres when digested with PK & TH and probed 
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with mAbs L42 & SAF84, there were variations in the PrPres detected when probed 
with mAbs P4. mAb P4 had high level binding to CH1641 (J2935) but showed low 
binding to CH1641 (J3011), and (VLA1) samples. This reflects the reduced 
availability of P4 epitope in the latter two samples when digested with TH as a result 
of low levels of full length PrPres possibly resulting from the effect of endogenous 
proteases to the full length PrPSc contents in these samples or due to the in vitro 
cleavage by TH at unfavourable sites in the N-terminus of PrPSc. IHC investigation 
of brains of sheep infected experimentally with BSE or CH1641 support these 
findings, as data showed marked increase in the detection of  intraneuronal and 
intraglial labelling with anti C terminal antibody of the PrP molecule in comparison 
to detection with mAb P4 (Martin et al., 2005, Jeffrey et al., 2003, Jeffrey et al., 
2001). Furthermore, IHC studies revealed that CH1641 showed a distinctive PrPd 
profile and a cleavage site more towards the C terminus compared to PrPd from BSE 
experimentally infected sheep (Jeffrey et al., 2006b, Gonzalez et al., 2005). These 
variations in antibody labelling patterns might relate to variation in the truncation 
sites of different strains of PrPd as a result of variations in enzymatic activities or 
other lysosomal biochemical reactions (Martin et al. 2005).  However, the relatively 
high level of P4 binding to CH1641 (J2935) reported here, may indicate considerable 
variation in the endogenous protease cleavage of the total pool of PrPres in CH1641 
infected cerebellum samples.        
Although the relative binding of sheep scrapie to P4 in comparison to BSE was one 
of the main features in differentiation between typical scrapie and experimental ovine 
BSE (Stack et al., 2006), two of my ovine BSE samples (0392/04 and 0654/04) 
showed detectable level of PrPres after PK digestion and detection with P4, but this 
was less than the detection level with L42 and SAF84 and without clear banding 
patterns.    
 
A new technique using multiplexed-antibody detection and comparison of mAbs L42 
and SAF84 binding levels has been shown to distinguish BSE from CH1641. Both 
ovine experimental BSE and CH1641 demonstrated strong binding to both L42 and 
SAF84 mAb after PK digestion, but CH1641 produced diglycosylated PK PrPres that 
was the dominant band with L42 detection but gave equal intensities between di- and 
monoglycosylated bands with SAF84 detection (Jacobs et al., 2011). This was 
reported to form a strain typing assay. Within my samples, the glycoform ratios were 
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indistinguishable between L42 and SAF84 for other CH1641 and ovine BSE samples. 
However, given the low number of isolates examined, their descriptions need 
verifying with further samples.  
Variations in the conformational stability and solubility (CSSA) in GdnHCl between 
CH1641 and BSE have also been recorded (Pirisinu et al., 2011). This assay was 
based on the concentration of GdnHCl able to solubilise 50% of PrPSc (GdnHCl ½ 
values). This study reflected the higher resistance of ovine BSE PrPres to 
solubilisation with GdnHCl ½ values > 3.8 mol/L. In contrast, CH1641 and scrapie 
showed GdnHCl ½ values of 2.0 - 2.8 mol/L and 2.2 mol/L. These demonstrated 
conformational stabilities reflect the divergent physicochemical properties of PrPres 
between strains.   
 
Studies of the molecular traits of CH1641-like scrapie in transgenic mice have 
resulted in the description of C-terminal PrPres cleavage fragments (Baron et al., 
2008). Furthermore, this endogenous, more C-terminally cleaved, PrP fragment of 14 
kDa in its nonglycosylated form, was a feature LQ&+LQ³&+-OLNH´QDWXUDO
scrapie isolates and in the 87V scrapie strain and was absent from BSE samples 
(Nicot and Baron, 2010). Moreover, recent studies demonstrated the clear 
discrimination between CH1641-like natural isolates in sheep and goat from BSE 
based on the presence of C-terminally cleaved, PrP fragment of 14 kDa detected by 
SAF84 (Vulin et al., 2011). However, in the present study these PrP fragments of 
this molecular mass were not detected in CH1641 samples with SAF84. This might 
be due to my samples being obtained from experimentally infected sheep. The PrPSc 
inoculua have been passaged several times in mice or sheep which might affect the 
molecular features after treatment with proteases. Also, the results presented here 
were obtained after digesting samples with 100 µg/ml PK, which is different from 
the methodology of Baron et al., 2008. In my study, samples were also digested with 
1 mg/ml TH that is similar to the methodology of Nicot and Baron, 2010, therefore, 
it is not apparent that variations in the methodologies of analysis contribute to the 
differences in the results. Subtle methodological differences, geographical origins of 
samples, and sample preparations have been found to cause variations in the 
glycotypes and some diversity in the molecular masses of fragments (Gonzalez et al., 
2010, Sweeney et al., 2000).  
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Interestingly, a C-terminal PrPres cleavage fragment of ~ 15 kDa was detected with 
some classical scrapie affected field cases. This fragment was not seen in all animals 
and was not consistently seen across multiple brain regions within an individual 
sheep. This data suggests that PrPSc can have different physicochemical properties 
towards proteases and there are individual variations between animals and also PrPSc 
produced by different brain regions within the same animal. 
Since SSBP1, CH1641 and ovine BSE were all cerebellum tissues which is not the 
optimum recommended sample for detection of classical scrapie and BSE (OIE 
Terrestrial manual, 2009), it might explain why PrPres was not readily detected from 
certain samples (CH 1641, J2916) and (ovine BSE, 1693/03). Therefore, I examined 
the impact of the anatomical sources of brain tissue used on the detection of PrPres 
using both PK and TH from 10 different classical scrapie affected animals. 
Cerebellum regions of 1275/02 and 1276/02 scrapie affected sheep contained more 
PrPres than caudal medulla and spinal cord of each animal. However, it was 
hypothesised previously that different cell types process abnormal PrP in different 
ways (Gonzalez et al., 2003), this might explain how different brain tissues 
accumulate PrPSc to different extents. Furthermore, Dron et al., (2010) suggested that 
certain nerve cells might be more liable to endogenous proteolysis than others. Such 
tissue-specific differences may offer different environments for PrPSc selection 
within a single host and therefore result in dominant PrPSc conformers with different 
susceptibilities to exogenous proteases (Collinge and Clarke, 2007). This was 
confirmed by Stack et al, 2006, when they reported brain region specific differences 
in the molecular profile of ovine PrPres. Their study demonstrated by Western blot 
that PK PrPres from the same animal looked like experimental BSE in sheep after 
sampling of the whole brain stem, and gave the usual scrapie profile when caudal 
medulla was sampled. However, on the basis of the discriminatory IHC results, the 
sample gave a scrapie pattern. Therefore, biochemical typing results should be 
interpreted with caution until other tests such as IHC and bioassay data confirm the 
results.  A further report concluded that endogenous proteolytic digestion that might 
occur before the in vitro analysis of samples may affect trimming of full length PrPSc 
and in turn the interpretation of the molecular profiles of such strains (Dron et al., 
2010).  
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In my assay conditions, all samples were represented by 3.3 µl of protease treated 
brain tissue, and it was noted that there was variation in the PrPres signal intensity 
produced for individual samples, dictated by treatment with either PK or TH. The 
present data showed that some samples contained more PK PrPres than TH PrPres 
whilst other contained similar levels of these two resistant isoforms. One molecular 
trait was observed consistently with some animals across neuroanatomical regions 
whilst other animals displayed both traits. The level of differential protease 
resistance did not appear to be influenced by genotype or PrPSc strain. Therefore, 
these findings suggest that protease-resistant PrP isoforms vary between individual 
animals/ brain regions which might be related to unidentified host factors. 
The availability of PK-sensitive isoforms of PrPSc has been well documented for 
rodent scrapie models and in human CJD (Pastrana et al., 2006, Tzaban et al., 2002, 
Safar et al., 1998). My result demonstrates that for ovine prion strains TH-sensitive 
PrP isoforms exist for numerous isolates and their presence varies between individual 
sheep and brain regions.  
 
Therefore, in view of my analysis of classical scrapie, ovine BSE and CH1641 
isolates, I conclude that differences in the protease resistant PrPSc molecular profiles 
revealed with multiple antibodies can be apparent between individual isolates of the 
same TSE strains and reflect the biological diversity of PrPres. Protease-resistant PrP 
for individual isolates for CH1641, ovine BSE and classical scrapie had divergent 
physicochemical properties towards proteases, and this was independent of Prnp 
genotype and TSE strain in this study. However, the genotype variability among my 
samples was low and the analysis of further samples could be required to fully define 
any effect of the genotype or breed on the results.  
Previous reports suggested that biochemical methods for scrapie strain discrimination 
did not show clear evidence supporting the effect of genotype on the molecular 
profile of scrapie strains (Nonno et al., 2003, Sweeney et al., 2000). In addition, a 
recent publication showed that Prnp polymorphisms did not account for PrPd profile 
variation and pathological phenotype diversity (Gonzalez et al., 2010).  In contrast, a 
strong association was seen between differences in PrPSc patterns and vacuolation 
profiles of natural scrapie cases and PrP genotype using IHC methodology 
(Spiropoulos et al., 2007).  It is possible that Prnp genotypes can select for certain 
strains under field conditions and the strains dictate pathological features. This could 
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account for the different conclusions across these studies. However, my presented 
data clearly shows that for defined strains under experimental conditions that the 
PrPSc accumulation and molecular phenotype of a particular TSE strain can vary 
between individuals. This conclusion was also demonstrated in a previous 
experimental study (Yokoyama et al., 2010), where two sheep of identical genotype, 
but different breeds, responded differently to inoculation with a single scrapie strain. 
These differences were observed in the incubation period of disease, molecular 
phenotype of propagated PrPSc conformers by Western blot analysis, and 
pathological lesions in transgenic mice. This in turn indicates that prion propagation 
could be affected by other factors and there is selection for certain PrPres conformers 
by individuals during intra- and interspecies transmission (Ushiki-kaku et al., 2010, 
Yokoyama et al., 2010). 
 
In conclusion, my study highlights the availability of TH-sensitive, PK PrPres 
isoforms in sheep scrapie and the biological diversity of PrPres of different prion 
strains. Significantly I have shown that the detection of particular isoforms of PrPres, 
which depend on the stability of PrPSc conformers towards exogenous proteases to 
yield distinct protein fragments, is variable even between individual sheep 
experimentally infected with the same strain, and between distinct brain regions for 
naturally infected animals. This was highlighted for CH1641 where 2 distinct 
molecular phenotypes were noted, further studies of field cases of CH1641-like 
samples are needed to define these molecular profiles further.  
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Chapter 5. In Vitro Amplification of Ovine Prion 
Strains in Substrates of Different Prnp Genotypes  
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5.1. Introduction:  
6LQFHWKHSURSRVLWLRQRIWKH³SURWHLQ only K\SRWKHVLV´ (Prusiner 1998 & 1982), major 
research efforts have investigated the epidemiology, pathogenesis, diagnosis and 
therapeutic treatment or vaccination against prion diseases. The development of in 
vitro prion propagation systems to help understand the molecular mechanisms of 
such diseases, have been difficult subjects to tackle in the neuroscience research field 
(Ryou and Mays, 2008). The past decade has seen significant developments in the 
molecular diagnostic techniques of prion diseases, but as yet, we are still limited to 
post-mortem examination (Ryou and Mays, 2008). However, continuous 
advancements in the in vitro conversion assays offers a way to understand the 
mechanism of PrPSc propagation and a method to improve early non- invasive 
diagnosis of TSE diseases particularly in pre-clinical cases. The developments of 
PMCA and QUIC technologies have shown great potential for the development of an 
ultra- sensitive diagnostic test through amplification of prion in vitro. The present 
study looks to further apply PMCA to the diagnosis of sheep prion diseases.  
The PMCA technique was developed by Soto and colleagues (Saborio et al. 2001), 
and has been further modified to a technique called sPMCA (Castilla et al., 2005a). 
sPMCA has enabled high level amplification and sensitive detection of PrPSc in 
different biological materials from scrapie infected rodents in the clinical and 
preclinical stages of disease (Gonzalez-Romero et al., 2008, Maluquer de Motes et 
al., 2008, Murayama et al., 2007, Saa et al., 2006, Castilla et al., 2005, Soto et al., 
2005). It has also been applied to detect ovine scrapie PrPSc in blood (Thorne and 
Terry, 2008), milk (Gough et al., 2009, Maddison et al., 2009), as well as saliva 
(Gough et al., 2012, Maddison et al., 2010) and faeces (Terry et al., 2011), and 
within environmental samples (Gough and Maddison 2010, Maddison et al., 2010 a 
& b). In addition, the technique also demonstrated successful amplification of PrPSc 
from a range of mammalian species including CWD in deer (Angers et al., 2009, 
Haley et al., 2009, Kurt et al., 2007), BSE in cattle (Soto et al., 2005) and vCJD in 
humans (Jones et al., 2009 & 2007). In some of these studies, experimental animal 
infection together with the PMCA technique were applied to improve the 
understanding of PrPSc dissemination and routes of disease transmission. Other 
studies have looked at the ability of PMCA to model the genetic susceptibility of 
sheep to scrapie (Bucalossi et al., 2011). In addition, PMCA has been used in 
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comparative studies to define the specific infectivity generated in PMCA compared 
to that of brain derived in vivo infectivity (Klingeborn et al., 2011).    
 
In this report, I investigated the potential sPMCA amplification of different ovine 
prion strains within distinct ruminant substrates: ovine substrates of distinct Prnp 
genotypes as well as bovine substrate. Statistical analysis was also performed with 
binomial logistic regression test using SPSS software for statistical computing. The 
aim was to use sPMCA to investigate the complex interaction of in vitro specific 
naturally occurring ruminant PrP sequences and prion strain types during prion 
propagation.    
 
5.2. Results:  
5.2.1. Determining the sensitivity of sPMCA for the detection of 
PrPSc: 
To assess the sensitivity of the PMCA technique for the detection of animal TSE 
diseases, different dilution series of 10% infected brain tissues for bovine BSE, ovine 
BSE, scrapie of Prnp genotype VRQ/VRQ and ARQ/ARQ were spiked into prion-
free ruminant brain substrates (Table 5.1). Four PMCA rounds were performed for 
each sample; a total of 192 cycles over 4 days. Further samples were prepared and 
amplified in exactly the same way but were non-spiked controls; no controls yielded 
any protease-resistant PrPSc. Samples were digested with PK and analysed by 
Western blot using antibody SHA31.   
Data show the high efficiency amplification of bovine BSE PrPSc in healthy bovine 
brain substrate. The de novo formed PrPSc were detected following amplification of 
100 ng of the BSE brain spike (Table 5.1 and Figure 5.1: A). Similarly, high 
amplification efficiency was achieved with bovine BSE infected brain tissue spiked 
into healthy homozygous ARQ ovine substrate, detecting just 10 ng of brain (Table 
5.1; Figure 5.1: B). Both healthy bovine substrate and homozygous ARQ Ovine 
substrate supported amplification of homozygous ARQ ovine BSE infected brain 
tissue, PrPSc from 1 and 0.1 ng of brain being detected respectively (Table 5.1; 
Figure 5.1: C & D). Furthermore, SSBP1 strain (VRQ/VRQ) showed only low levels 
of PrPSc being amplified but this was detected from just 0.1 ng of brain (Table 5.1; 
Figure 5.1: E). This amplification was only seen in VRQ/VRQ substrate. No 
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amplification was seen in ARQ, ARR or bovine substrate. Homozygous ARQ PrPSc 
spike demonstrated very low levels of PrPSc amplification, but again PrPSc could be 
detected after very high dilutions of the brain spike (100 ng of brain spike was 
detected) (Table 5.1; Figure 5.1: F). None of the spiked bovine and ovine PrPSc brain 
homogenates were amplified in homozygous ARR substrate (data not shown). In 
addition, neither ovine nor bovine BSE could be amplified in VRQ substrate. None 
of the spiked non sonicated samples (amplification efficiency control samples) were 
detected on Western blots (data not shown). No detectable spontaneous protease-
resistant PrP formation was observed in all control brain homogenate substrates 
samples that were subjected to sPMCA (data not shown).  
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Table 5.1: Dilution series of bovine BSE, ovine BSE, scrapie SSBP1 (VRQ/VRQ), 
and scrapie (ARQ/ARQ) infected brain tissue spiked into different brain 
homogenate substrate. 
 
PrPSc 
Sample 
Genotype and 
ID of spike 
Dilution series 
analysed         (ng TSE 
brain) 
sPMCA 
Substrate 
Limit of detection 
(ng TSE brain) 
Bovine 
BSE 03/0572 
10,000 ± 100 
 
 
VRQ/VRQ 
 
No amplification 
(>10,000) 
Bovine 
BSE 03/0572 
1000 ± 0.1 
 
 
Bovine 
 
100 
Bovine 
BSE 03/0572 
10,000 ± 10 
 
 
ARQ/ARQ 
 
10 
Bovine 
BSE 03/0572 
10,000± 10 
 
 
ARR/ARR 
 
No amplification 
(>10,000) 
 
Ovine 
BSE 
 
ARQ/ARQ 
1693/2036 
1000 ± 10 
 
VRQ/VRQ 
 
No amplification  
(>1,000) 
 
Ovine 
BSE 
 
ARQ/ARQ 
1693/2036 
10 ± 0.01 
 
Bovine 
 
1 
 
Ovine 
BSE 
 
ARQ/ARQ 
1693/2036 
10 ± 0.01 
 
 
ARQ/ARQ 
 
0.1 
 
Ovine 
BSE 
 
ARQ/ARQ 
1693/2036 
10,000 ± 0.1 
 
 
ARR/ARR 
 
No amplification 
(>10,000) 
 
Scrapie 
 
SSBP1 
VRQ/VRQ 
10 ± 0.01 
 
 
VRQ/VRQ 
 
0.1 
 
Scrapie 
 
SSBP1 
VRQ/VRQ 
10,000 -1,000 
 
 
Bovine 
 
No amplification 
(>10,000) 
 
Scrapie 
 
SSBP1 
VRQ/VRQ 
10,000 ± 10 
 
 
ARQ/ARQ 
 
No amplification 
(>10,000) 
 
Scrapie 
 
SSBP1 
VRQ/VRQ 
10,000 ± 1,000 
 
 
ARR/ARR 
 
No amplification 
(>10,000) 
 
Scrapie 
 
ARQ/ARQ 
0678/2129 
10,000 ± 0.1 
 
ARQ/ARQ 100 
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Figure 5.1: Serial PMCA analysis of ruminant prions: 10-fold dilution series (DS) 
of brain homogenate from clinically affected sheep with either scrapie or BSE, or 
cattle with clinical BSE were seeded into sPMCA reactions (lanes 2 to 8 represent 
10000 to 0.01 ng of brain homogenate seed respectively). Each sample underwent 
four rounds of sPMCA and products were digested with PK before analysis of 5 ȝORI
each sample on Western blots. PrP was detected with monoclonal antibodies SHA31 
and P4 and molecular weight markers of 30 and 20 kDa are indicated. Control 
VDPSOHV &´were brain homogenates from TSE-free bovine or ovine sources. All 
sPMCA reactions were carried out as described by Castilla et al., 2005. Bovine BSE 
was amplified and detected from 100 ng of brain homogenate seed spiked into 
healthy bovine (A), and 10 ng spiked into healthy ARQ/ARQ substrate (B). Ovine 
BSE was amplified and detected from 1 ng when spiked into bovine healthy substrate 
(C), and 0.1 ng spiked into ARQ/ARQ healthy substrate (D). Similarly, SSBP1 
(VRQ/VRQ) was amplified and detected from 0.1 ng spiked into VRQ/VRQ healthy 
substrate (E). Homozygous ARQ PrPSc demonstrated very low amplification signals 
when spiked into ARQ/ARQ healthy substrate (F). (*) is the cut off point determined 
by Western blot for the highest dilution of brain homogenate seed from sheep with 
either scrapie or BSE, or cattle with clinical BSE amplified by PMCA.   
 
 
 
(A)                            (B)                            (C)
(D)                              (E)                             (F)
4*   5    6   7 &´ 1    2   3    4   &´ &´
5  6   7*  8   &´ 1      5     6   &´ 1    C´ 2      3      4
kDa
30 
20
kDa
30 
20 20 20
30 30 
30 
20 20 
30 
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5.2.2. Application of sPMCA to the amplification of sheep TSEs: 
To assess the ability of the PMCA technique to amplify sheep scrapie, 50 or 100 µg 
of brain seed from a range of scrapie affected animals were amplified within PMCA 
brain homogenate substrates of Prnp genotypes; VRQ/VRQ, ARQ/ARQ and 
AHQ/AHQ . Up to five PMCA rounds for samples spiked with 50 µg TSE positive 
brain seed were carried out, and 10 rounds were performed for samples spiked with 
100 µg of TSE positive brain homogenate. All sampOHVZHUHGLJHVWHGZLWKȝJPO
PK and analysed by Western blotting detecting PrPSc with SHA31 mAb (Table 5.3).  
 
5.2.3. Amplification of PrPSc spikes in VRQ/VRQ Substrate:  
The VRQ/VRQ substrate supported amplification of the highest number of isolates. 
The detected PrPSc showed successful amplification over 10 rounds of classical 
scrapie from sheep with Prnp genotypes that have at least one VRQ allele using 
either 50 or 100 µg spike. Unexpectedly, after 5 rounds of amplification, two 
VRQ/VRQ spikes (0836/03 and SSBP1) were not detected in VRQ/VRQ substrate 
using 100 µg of spike although they were detected after 10 rounds, and after 5 rounds 
when using 50 µg spike. These variations in detection of such amplified PrPSc 
samples, after increasing the spike volume, might reflect variation in the efficiency 
of amplification between two different experiments. None of the PrPSc classical 
scrapie from the two homozygous ARQ animals (0678/03 and 0635/03) was 
amplified in VRQ/VRQ substrate, whatever the volume of spike. Similarly, CH1641 
PrPSc (4 samples) was not amplified at round 5 or even during prolonged sPMCA 
over 10 rounds and increasing the volume of spike to 100 µg. In contrast, ovine BSE 
spikes demonstrated successful amplification at all rounds analysed except one 
isolate (1693/03) that was not detected at round one.      
 
5.2.4. Amplification of PrPSc spikes in ARQ/ARQ Substrate:  
Seeded ARQ/ARQ substrate reactions had different amplification efficiencies 
compared to VRQ/VRQ substrate. None of the classical scrapie or CH1641 samples 
amplified in ARQ/ARQ substrate using 50 µg spike after 5 rounds of sonication. 
However, after increasing the spike volume to 100 µg, 7 out of the 12 classical 
scrapie isolates were amplified to some extent. The two ARQ/ARQ classical PrPSc 
scrapie samples were detected either after 5 and 10 rounds (0678/03) or after 10
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Table 5.3: PMCA Amplification of different PrPSc strains/isolates with distinct genotypes: 
Strain Isolate ID Strain genotype 
TSE-free substrate VRQ ARQ AHQ 
spike  (µg of brain) 50 100 50 100 50 100 
No. of  rounds 5 1 5 10 5 1 5 10 5 1 5 10 
Classical scrapie 1563/02 VRQ/VRQ 
             
Classical scrapie 1276/02 VRQ/VRQ 
             
Classical scrapie 1275/02 VRQ/VRQ 
             
Classical scrapie 0923/03 VRQ/VRQ 
             
Classical scrapie 0925/03 VRQ/VRQ 
             
Classical scrapie 0836/03 VRQ/VRQ 
             
Classical scrapie ± SSBP1 SSBP1 VRQ/VRQ 
             
Classical scrapie 0226/03 ARQ/VRQ 
             
Classical scrapie 0455/03 ARQ/VRQ 
             
Classical scrapie 0615/03 ARQ/VRQ 
             
Classical scrapie 0678/03 ARQ/ARQ 
             
Classical scrapie 0635/03 ARQ/ARQ 
             
CH1641 J2916 ARQ/AHQ 
             
CH1641 J2935 ARQ/AHQ 
             
CH1641 J3011 AHQ/AHQ 
             
CH1641 VLA1 AHQ/AHQ 
             
Ovine BSE 1693/03 ARQ/ARQ 
             
Ovine BSE 0654/04 ARQ/ARQ 
             
Ovine BSE 0392/04 ARQ/ARQ 
             
 
x Positive = yellow and negative = blue  
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rounds of sonication (0635/03) when using 100 µg of seed. Furthermore, classical 
PrPSc spike 0455/03 (ARQ/VRQ), SSBP1 (VRQ/VRQ) and CH1641 (VLA1- 
AHQ/AHQ) were detected after 10 rounds of PMCA reaction. Interestingly, the three 
ovine BSE spikes showed successful amplification independent of the volume of 
spike or number of PMCA rounds. Classical scrapie 0923/03 (VRQ/VRQ), 0925/03 
(VRQ/VRQ) and 0615/03 (ARQ/VRQ), and CH1641 J3011 (AHQ/AHQ) were 
detected transiently at round 1 and/or round 5 and then not seen in later rounds. 
CH1641 J2935 (ARQ/AHQ) was detected at all rounds analysed, but with a decrease 
in signal intensity between rounds 5 and 10 (Figure 5.2). The kinetics of PrPres 
propagation after each round of sonication was analysed for 0923/03 (VRQ/VRQ) 
and CH1641 J2935 (ARQ/AHQ). The detected PrPres on each round showed an 
increase in PMCA-PrPSc amplification up to round 3 for 0923/03 and round 4/5 for 
CH1641 J2935, after which the PrPres levels decreased (Figure 5.2). 
 
5.2.5. Amplification of PrPSc spikes in AHQ/AHQ Substrate:  
None of the classical scrapie PrPSc spikes or CH1641 scrapie samples were detected 
after 5 rounds of amplification in AHQ/AHQ substrate seeded with either 50 µg or 
100 µg of brain seed. After 10 rounds of sonication, and seeding the reaction with 
100 µg spike, amplified PrPSc of SSBP1 (VRQ/VRQ) and CH1641 (3 out of four 
samples, J2935 ARQ/AHQ, J3001 AHQ/AHQ and VLA1 AHQ/ AHQ) were 
detected. Again, seeding PMCA reactions with 50 or 100 µg of each ovine BSE 
spike demonstrated successful amplification of the three isolates independent of the 
number of PMCA rounds.  
 
Statistical analysis of the result of amplification (binomial data; positive or negative) 
and the influence of other elements (strain, PrPSc genotype, substrate genotype, 
amount of seed, number of rounds) included in PMCA reactions showed significant 
association to the effect of strain (degree of freedom (df) = 2, P < 0.001), seed 
genotype (df = 1, P < 0.01), substrate genotype (df = 1, P < 0.001), and number of 
rounds (df = 2, P < 0.01). Furthermore, within the model including all variables, 
comparison of amplification between different strains showed that ovine BSE 
amplification were highly significant (df = 1, P < 0.001) while CH1641 (df = 1, P= 
0.088) was less significant in comparison to classical scrapie.  However, there was 
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no statistical difference between CH1641 and ovine BSE amplification which seems 
to be due to the lack of other genotypes rather than ARQ/ARQ for Ov BSE.   
Further trial using Chi-Square test showed a significant difference in amplification 
between the three strains (P < 0.0001). At odds to the observed results within the 
model, there was a significant difference in amplification between ovine BSE and 
CH1641 (P < 0.0001) 
 
 
 
 
 
 
Figure 5.2: In vitro amplification of (A) classical scrapie VRQ/VRQ (0923/03) 
and (B) experimental ovine CH1641 ARQ/AHQ (J2935) over 10 rounds of 
sonication: 100 µg cerebellum homogenate of each strain was spiked into ARQ 
substrate to a final volume 100 µl. The mixture was subjected to 10 rounds of 
sPMCA reaction as described. After completing the reaction, 20 µl of each sonicated 
sample on each round was digested for 1 hour at 37ºC with PK (50 µg/ml). Typically, 
5 µl of each digested sample was analyzed by Western blotting and probed with 
SHA31 antibody. Each lane is marked in the top with the number of rounds of 
DPSOLILFDWLRQ  LV VSLNHG $54 VXEVWUDWH ZKLFK ZDV QRW VRQLFDWHG ³&´ LV $54
substrate (control non-spiked sample subjected to sonication).   
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5.3. Discussion:  
One of the main objectives of using the PMCA technique is to facilitate the rapid 
detection of PrPSc where the levels of PrPSc are undetectable by the current diagnostic 
methods (Thorne and Terry, 2008). Within the present study, different strains of 
ruminant prions were successfully amplified in vitro using sPMCA. Bovine BSE 
showed high conversion efficacy in both bovine brain homogenate substrate and 
ovine ARQ/ARQ brain homogenate substrate, and from a dilution of 100 ng and 10 
ng brain seed. Also, SSBP1 classical scrapie strain demonstrated amplification in 
VRQ/VRQ substrate from a dilution equal to 0.1 ng scrapie positive brain material. 
Ovine BSE was also amplified in bovine or ovine ARQ substrate from as little as 0.1 
ng of brain spike.  
At present PMCA has only applied to a limited number of ovine TSE strains/ isolates. 
Here, PMCA reactions of 19 PrPSc isolates with different genotypes were examined 
to ascertain the possibility of prion amplification for the different combinations of 
prion seeds and Prnp genotypes substrates. This was illustrated in the successful 
amplification of 10 classical scrapie spikes (7 VRQ/VRQ and 3 VRQ/ARQ) out of 
12 isolates in VRQ substrate with only ARQ/ARQ samples being refractory to 
amplification. AHQ substrate did not support such high efficiency amplifications 
with only a single classical scrapie sample amplified over 10 rounds. Ovine BSE was 
readily propagated in all substrates independent of the substrate genotypes while 
CH1641 was refractory to amplification in VRQ and AHQ substrates after 10 and 5 
rounds respectively.   
 
A preliminary trial (Priem et al., 2008) demonstrated the potential amplification of 
different bovine and ovine PrPSc isolates in distinct ovine and bovine PrPC substrates. 
At the same time, previous studies showed that the success of PMCA and efficiency 
of amplification was influenced by prion strains and ovine PrPC substrate genotype 
(Thorne and Terry, 2008), as well as by cross species compatibility between the 
PrPSc seed and PrPC substrate (Soto et al., 2005). This is in agreement with my 
results where classical scrapie samples from sheep with Prnp genotype that have at 
least one VRQ allele were amplified successfully in VRQ/VRQ substrate.  
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In the present study, low levels or absence of amplification was seen when some 
classical VRQ/VRQ or VRQ/ARQ PrPSc were seeded into ARQ/ARQ substrate and 
when CH1641 was seeded into VRQ/VRQ substrate. These data highlight the impact 
of genotype on a template-substrate interaction for classical scrapie amplification in 
vitro (Panza et al., 2008, Kupfer et al., 2007, Bossers et al., 2000, Bossers et al., 
1997). The efficiency of replication is clearly influenced by high homology between 
the amino acid sequences of a fibrillar template and a precursor substrate (Makarava 
et al., 2009). Therefore, mismatch between a template and a substrate might act as a 
barrier for amplification in vitro, and host susceptibility to TSE agent in vivo 
(Cancellotti et al., 2007). They concluded that as well as primary amino acid 
sequence homology between substrate and seed, the conformational similarity 
between the two components affect replication efficiency. For rodent scrapie strains, 
Atarashi et al., 2006, showed that two prion strains with the same PrP sequence but 
different conformations have differing abilities to convert the same mutated PrPC in a 
cell culture. This conclusion is in agreement with the sPMCA data where seeding 
ARQ/ARQ healthy substrate with homozygous scrapie ARQ PrPSc required higher 
levels of spike or further rounds of sPMCA to amplify successfully compared to 
seeding with the three ARQ ovine BSE spikes.    
 
In addition, low efficacy amplification might also be related to low levels of PrPSc 
molecules in the spiked dose and duration of amplification which was clearly 
demonstrated by using 50 or 100 µg of seed and detection of amplified products at 
different rounds of sonication for classical scrapie and CH1641 samples seeded into 
both homozygous ARQ and AHQ substrates. 
 
Interestingly and contrary to classical scrapie and CH1641, the three homozygous 
ARQ Ovine BSE samples were successfully amplified and detected in all 
amplification experiments independent of the Prnp substrate genotype or the volume 
of spike seeded into the PMCA reaction or the number of PMCA rounds. It seems 
that ovine BSE conformers are compatible with multiple conformations assumed by 
the different substrate genotypes, and are readily able to amplify and produce similar 
stable conformers that support further substrate conversion. In contrast, classical 
scrapie and CH1641 strains are not capable of forming some of these stable 
conformers and their amplification is much more dependent on other variables 
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affecting amplification in vitro. In vivo studies showed that BSE and CH1641 can 
infect homozygous VRQ, ARQ and AHQ sheep (Hunter, 2003, Goldmann et al., 
1994). Furthermore, since the first isolation of CH1641 isolate in 1970, it is 
maintained in vivo through sub-passage in sheep of different Prnp genotypes. 
Therefore, why ovine BSE and not CH1641 prions would be efficiently amplified in 
this study is not clear. These phenomena of prion strain propagation in sheep indicate 
that the in vitro replication for BSE and CH1641 strains may be distinct from in vivo 
propagation. The presented data would suggest that BSE is much more likely to 
efficiently replicate in sheep with a range of genotypes compared to classical scrapie 
or CH1641. Yet to date, no BSE infections have been detected in the European sheep 
population despite extensive surveillance (Stack et al., 2006, Lezmi et al., 2004). 
This indicates that there are other factors controlling the spread of infection of these 
distinct strains in the field amongst sheep populations one or more of which has 
prevented efficient transmission of the BSE agent.  
 
Despite the similar structure between ovine BSE and CH1641 PrPSc, CH1641 had 
very distinct amplification properties. CH1641 was refractory to amplification in 
VRQ substrate whatever the volume of PrPSc spike or PMCA rounds. This distinct 
pattern of amplification compared to ovine BSE is not due to the level of protease 
resistant PrPSc within the seed. For example, ovine BSE (1693/03) and CH1641 
(J2916) contained low levels of PrPSc, whereas CH1641 (J2935, J3011 and VLA-1) 
samples, together with ovine BSE (0654/04 and 0392/04) contained relatively high 
levels of PrPSc (Chapter 4, Figure 4.1)  
When matching template-substrate interaction for Prnp genotype, neither of the two 
homozygous AHQ CH1641 samples nor the two ARQ/AHQ CH1641 samples 
amplified in AHQ substrate after 5 rounds of PMCA reaction. However ovine BSE 
(ARQ/ARQ isolates) were readily amplified in the AHQ substrate even after 1 round 
of sPMCA. These data strongly indicate that the success of amplification seen for 
ovine BSE and CH1641 are due to prion strain and not to Prnp genotype effects.  
The distinct amplification patterns for BSE and CH1641 isolates in VRQ and AHQ 
substrates over 5 rounds of PMCA reactions have now been validated in independent 
experiments and could form the basis for a rapid strain typing assay.  
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My results demonstrate that PrPres can be formed following spiking ARQ substrate 
and performing PMCA reaction. However, the pattern of PrPres production was 
variable in the amount of PrPres produced from some seeded spikes at different 
rounds. PrPres production peaked at 3 - 5 rounds of amplification and subsequent 
rounds contained less PrPres and PrPres was not detectable at later rounds for some 
experiments. Previous studies of prion propagation in a cell culture model showed 
fluctuation in PrPres level that was dependent on composition of the medium and the 
differentiation state of cells, cells density and direct cell to cell contact (Nakamitsu et 
al., 2010, Ghaemmaghami et al., 2007, Bate et al., 2004, Rubenstein et al., 1990). 
Furthermore, the acute formation and persistence of PrPres in cell lines might depend 
upon the scrapie strains ability to persistently infect the cellular compartment and in 
turn the sustainable formation of PrPres (Vorberg et al., 2004).  Therefore, using 
PMCA as a cell free conversion assay with ARQ substrate, whilst 10 out of 16 
scrapie isolates were amplified, the products were often only seen after high numbers 
of rounds or were produced transiently with low levels or absence of PrPres at later 
rounds. I speculate that for the latter isolates the PrPres formation and propagation 
was driven mainly by the PrPSc present in the spike and that whilst PrPSc conformers 
within each spike were readily able to amplify rapidly, the PrPres products of 
amplification could not support further efficient recruitment of PrPC substrate and 
formation of PrPres. Similar results were found using cell culture, where acute 
formation of PrPres was not indicative of a persistent scrapie infection (Vorberg et al., 
2004). In addition, if replication of prions was relatively inefficient, it might be that 
the methodology of diluting amplified products 1: 3 into fresh PrPC substrate 
between each round reduced the quantity of in vitro produced PrPSc available to act 
as template for further conversion events. Alternatively, there is potential that 
amplification with ARQ substrate produced PrPSc conformers that were more 
sensitive to protease digestion which therefore could not be detected after PK 
digestion. These scenarios may well result in apparently transient or low efficiency 
production of PrPSc during sPMCA. This distinct pattern of scrapie amplification 
within ARQ substrate appears to be very much dependent on the individual spike and 
not the scrapie strain.  
 
Collectively, although not all strains have been amplified in this study due to the 
complex nature of ovine prion diseases, PMCA is still a promising diagnostic 
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methodology of high sensitivity. It is also a useful technique for studying prion 
propagation. The data obtained in these preliminary in vitro amplification 
experiments might correlate with my knowledge and understanding to 
genotype/species barriers phenomena in classical scrapie transmission in vivo, where 
VRQ sheep are the most susceptible genotype to infection in comparison to ARQ and 
AHQ sheep.  Based on various animal experimental studies, the species barrier or 
genotype barrier is thought to be a combination of different factors that include 
differences in primary amino acid sequence between the donor and host, in the 
glycoform patterns, and in PrP three dimensional structures which can result in 
inefficient interaction between donor PrPSc and host PrPC (Moore et al., 2005, Hill et 
al., 2000). Moreover, the effect of a variety of different prion strains has been found 
(Jeffrey et al., 2006a, Telling, 2004, Bruce, 2003, Houston et al., 2002).  
A major new finding in my study is the potential of using sPMCA as a strain typing 
method for differentiating between two prion strains with similar molecular profiles, 
such as CH1641 and ovine BSE. Further investigation looking at repeat analysis of 
CH1641 and BSE samples as well as using panels of CH1641-like field isolates will 
be of high importance in validating this strain typing methodology. 
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Chapter 6. In Vitro Amplification of Different PrPSc 
Strains in rPrP Substrates. 
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6.1. Introduction:  
The initial success of sPMCA to detect extremely low levels of PrPSc in brain 
homogenates, secreta and excreta of scrapie infected animals indicates the potential 
for this method in prion disease diagnosis and research. However, a major limitation 
is imposed by the use of crude brain homogenate as a substrate. This method requires 
a consistent supply of brain tissue from scrapie free sheep that imposes both a 
financial burden and technical difficulties. In addition, variations within brain 
homogenate substrate of the same Prnp genotypes have been demonstrated to affect 
amplification efficiency (B. Maddison, personal communication). These 
disadvantages have created the need to circumvent the use of brain homogenates as 
substrate. In addition, as demonstrated in the previous chapter the PrPSc genotype and 
prion strain can affect amplification efficiencies. Therefore, a single substrate that 
would support PMCA amplification with little or no influence of prion strain or 
genotype is still a requirement if PMCA is to be applied for diagnosis of prion 
diseases in small ruminant. One possibility to overcome the limitation of PMCA is 
by using rPrP expressed in bacteria as a substrate, known as rPrP- PMCA.   
 
rPrP expressed in Escherichia coli has been used as a substrate for conversion into 
distinct conformers with some properties of PrPSc. This model has been used to 
understand different aspects of prion conversion including the self-replicating 
properties and species-specificity of in vitro fibrillization reactions; particularly using 
human, hamster and mouse models (Baskakov, 2009, Makarava et al., 2009, Moore 
et al., 2009, Lee et al., 2007, Surewicz et al., 2006, Bocharova et al., 2005, Baskakov, 
2004, Baskakov et al., 2002). Furthermore, in vitro studies have looked at the 
physico-chemical properties of rPrP allelic variants of sheep (Rezaei et al., 2000), 
particularly with respect to prion strain specific effects on PrP conversion (Kupfer et 
al., 2007, Eiden et al., 2006), to gain further insight into the sequence linked basis of 
scrapie susceptibility and resistance (Morel et al., 2007). Moreover, the conversion 
mechanism of recombinant bovine PrP to amyloid fibrils using BSE-prion as seeds 
and producing PrPSc-seeded fibrils has been shown to be a model of in vivo BSE 
infection, adding to the understanding of a significant veterinary disease (Panza et al., 
2008). Additionally, recombinant ovine and murine PrP were used to simulate intra- 
and interspecies transmission in vitro (Panza et al., 2010).  
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Recent studies have illustrated the use of bacterially expressed rPrP as a substrate in 
cell-free conversion assays (Peden et al., 2012, Orrú et al., 2011, Wang et al., 2011, 
Kim et al., 2010, Wang et al., 2010,  Wilham et al., 2010, Orru et al., 2009, Atarashi 
et al., 2008, Atarashi et al., 2007). These studies have shown that the sPMCA 
procedure can be adapted to convert bacterially expressed recombinant full length 
Syrian hamster prion protein (rSha PrP) to PK rPrPres, with a 16-17 kDa PK PrPres 
fragment being generated. Overall, these studies have been limited to a few isolates 
of rodents, ovine and human TSEs, but the results of these studies have shown 
promising diagnostic and screening methodologies. They have demonstrated a 
greater sensitivity, relative simplicity and more rapid detection of minute amounts of 
PrPSc in biological samples, including from pre-clinical cases, compared to the use of 
brain homogenate substrate. However, one challenge with the use of rPrP as the 
substrate for in vitro replication of sheep scrapie is the existence of multiple strains 
within different genotypes.  
Therefore, the aim in this chapter was to assess the use of rSha PrP and ovine VRQ 
rPrP as substrates in PrPSc seeded sPMCA reactions with a range of sheep prion 
seeds to generate PK rPrPres fragments. The future aim being that this in vitro 
replication format will further be validated for the potential application of this system 
for the development of a pre-clinical prion diagnostic test.   
 
6.2. Results: 
6.2.1. Expression and purification of full length rPrP: 
Ovine PrP (PrP23-231), containing VRQ polymorphism, was expressed within E. 
coli resulting in the production of rPrP within insoluble cytoplasmic inclusion bodies. 
These inclusion bodies containing highly purified rPrP had shown approximately 
equal quantities of both full length and truncated PrP fragments (Figure 6.1). In order 
to separate full length rPrP from other truncated PrP fragments, a purification 
strategy was employed to take advantage of the metal chelating capacity of the 
octapeptide repeat region (Viles et al., 1999) through direct binding to Cu ions. 
FPLC affinity purification included denaturation of the protein, binding to Cu-
containing resin, refolding of the full length rPrP through a wash step using a 
decreasing urea gradient, and elution with imidazole. The pooled protein fractions 
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corresponding to a peak elution on the A280 chart recorder showed a band of single 
species with an estimated molecular mass of approximately 24 kDa when analysed 
by Coomassie staining of SDS-PAGE gels of the eluted fraction (Figure 6.1). This 
represents full length PrP with no PrP fragment contamination. Quantification of 
rPrP using a Bradford assay against a BSA standard curve indicated that the 
concentration of rPrP was 0.5 mg/ml in a total volume of 13 ml (data not shown). 
The total quantity of rPrP recovered was therefore 6.5 mg. This represented the 
purification from 500 ml of the original expression culture; therefore, the yield of 
pure, soluble rPrP obtainable per litre of bacterial culture would be approximately 13 
mg. The same procedures were applied to expression and purification of full length 
rSha PrP.    
 
6.2.2. Optimization of rPrP substrate concentration and number of 
sPMCA rounds:   
rPrP substrate concentration was optimised through sPMCA reactions seeded with 
50µg of caudal medulla brain homogenate from VRQ/VRQ classical scrapie affected 
sheep (1563/02) using two concentrations of monomeric rSha PrP and VRQ rPrP 
substrates; 0.2 mg/ml and 0.1 mg/ml of each. Upon completion of the reaction 
(mainly 3 ± 6 rounds), the sonicated products were digested with PK and analysed by 
gel electrophoresis and Western blotting. The concentration of PK used was 10 
µg/ml based on the results of optimising PK concentration for digestion previously 
described (Chapter 2: Materials and methods and Figure 6.2).  
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Figure 6.1: Production of pure rPrP: PrP was expressed in E. coli and washed 
inclusion bodies resolubilised in urea were analysed.  The SDS-PAGE and 
Coomassie Brilliant Blue staining of the solubilised inclusion bodies containing rPrP 
showed both full length (approximately 24 kDa) and truncated PrP fragments 
(approximately 11 kDa) (A: lane 2). After FPLC purification that involved rPrP 
being purified on an immobilised metal affinity column, full length rPrP 
(approximately 24 kDa) was obtained with no PrP fragment contamination (B: lane 
2).    
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Primarily, when samples were probed with SAF84, no signals of PK rPrPres 
fragments were produced from spiked samples in 0.1 mg/ml substrate (both rSha PrP 
and VRQ rPrP) following 2 rounds of amplification. After 3 rounds, signals were 
produced with a band of approximately 7 - 8 kDa. After 6 rounds of amplification, 
the signal produced had increased in intensity and further band of approximately 16 
kDa (together with bands of ~ 7 - 10 kDa) were detected (Figure 6.3).  
The analysis of sPMCA products from spiked samples in 0.2 mg/ml substrate 
showed no detectable PK rPrPres fragments after the first round of PMCA reaction 
using both rSha PrP and VRQ rPrP substrates (data not shown). After the second 
round, there were amplified products from scrapie spiked samples in VRQ rPrP 
substrate with clear PK rPrPres fragments of 7-8 kDa and 16 kDa, while no fragments 
were detected from samples spiked in rSha PrP (data not shown). Analysing samples 
from the 3rd round showed clear bands of PK rPrPres fragments produced from spiked 
samples in both substrates. Further rPrP-PMCA reaction using both rSha PrP and 
VRQ rPrP substrate spiked with multiple classical scrapie affected caudal medulla 
samples (VRQ/VRQ 1563/02, VRQ/VRQ 1275/02, VRQ/VRQ 1276/02) and 
VRQ/VRQ (1699/05) healthy cerebellum as a control, showed efficient amplification 
of all scrapie spikes (Figure 6.4). Given the apparent increase in sPMCA efficiency 
when using 0.2 mg/ml VRQ PrP substrate, a concentration of 0.2 mg/ml substrate 
was selected for further analysis for the generation of PK rPrPres fragments using 
rSha PrP and VRQ rPrP substrates. 
 
6.2.3. Optimization of anti-PrP antibodies for the discrimination of 
PrPSc and PrPC spiked samples following PMCA amplification: 
To detect PK-resistant fragments rPrPres (Sc) (resulting from seeding reactions with 
either 50 µg brain homogenate scrapie affected medulla (1563/02), or 50 µg healthy 
cerebellum homogenate (1699/05), and to specifically differentiate between scrapie 
and healthy spiked samples, PK resistant rPrP fragments were probed with panels of 
antibodies.  
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Figure 6.2: Western blot of the optimization of PK concentration for the 
digestion of rPrPsen and detection rPrPres-Sc: Panels A and B: 10 µl of 0.1 mg/ml 
rSha PrPsen (two batches on panel A lanes 1- 4 and 5 - 8) and VRQ rPrPsen (two 
batches on panel B lanes lanes 1- 4 and 5 - 8) were treated with 0, 1, 10, or 20 µg/ml 
PK as indicated for 1 h at 37°C. 5 µl of each digestion were loaded per lane. Panels C 
and D: following 3 rounds of sonication, using 0.2 mg/ml rSha PrPsen substrate (one 
batch) spiked with either healthy (lane 1) or scrapie brain homogenate (lane 2) were 
digested with 10 µg/ml PK (panel C) or 20 µg/ml PK (panel D). All Digested 
samples were analysed by gel electrophoresis and immunoblotting with SAF84 
antibody (1: 40,000).  
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Figure 6.3: Western blot of the optimization of rPrP substrate concentration 
and number of sPMCA rounds: 50 µg spike of classical scrapie affected brain 
homogenate (VRQ/VRQ, 1563/02) was seeded into 85 µl of 0.1 mg/ml rPrP 
substrates; rSha PrP (A & B) and VRQ rPrP (C & D). Both seeded substrates were 
subjected to 3 rounds (A & C) and 6 rounds (B & D) of sPMCA reaction. Sonicated 
samples were digested for 1 hour at 37ºC with 10 µg/ml PK and 5 µl of each digested 
sample was analysed by Western blot. PK rPrPres fragments were detected with mAb 
SAF84 (1: 40,000). Lane 1: ovine classical scrapie (VRQ/VRQ, 1563/02) spiked 
sample without sonication, Lane 2: ovine classical scrapie (VRQ/VRQ, 1563/02) 
spiked sample after sonication. Molecular weight markers are shown (kDa).  
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Figure 6.4: Western blot of the optimization of rPrP substrate concentration 
(0.2 mg/ml) and number of sPMCA rounds: 50 µg spike of VRQ/VRQ classical 
scrapie affected caudal medulla homogenates from 3 different animals (Lane 1 & 2: 
1563/02, lane 3&4: 1275/02, lane 5 & 6: 1276/02), together with 50 µg spike of 
healthy caudal medulla homogenate (lane 7: 1699/05) were seeded into 85 µl of 0.2 
mg/ml rPrP substrates; rSha PrP (A) and VRQ rPrP (B) in duplicate. Both seeded 
substrates were subjected to two treatments; one set of seeded samples was frozen 
immediately after spiking and called round 0. The second set of same seeded samples 
were subjected to 3 rounds of sPMCA reaction and called round 3.  Both round 0 and 
round 3 sonicated samples were digested for 1 hour at 37ºC with 10 µg/ml PK and 10 
µl of each digested sample were analysed by Western blot. PK rPrPres fragments 
were detected with mAb SAF84 (1: 40,000). Molecular weight markers are shown 
(kDa).  
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These antibodies recognise different epitopes directed towards either the N- or C-
terminal of PrP; AG4, SAF32, P4, 8G8, SAF70, SHA31, SAF84 and 8H4. These 
monoclonal antibodies were diluted and used to probe Western blots (Chapter 2, 
Materials and methods, Table 2.1). 
No PK rPrPres products were detected when SAF32, P4, 8G8 and 8H4 antibodies 
were used. When samples were probed with AG4 (diluted 1: 2,000), a single or 
double band with a molecular mass of ~ 7 - 9 kDa was the marker for the presence of 
PK-resistant fragments produced from PrPSc spiked rSha PrP substrate (Figure 6.5: 
A). Using either SAF70 or SAF84 (both were diluted 1: 40,000), a PK-resistant 
fragment with a molecular mass of approximately 7 kDa was detected from PrPSc 
seeded reactions. However, a relatively weak band of ~ 7 kDa was also seen in some 
PrPC seeded reactions (Figure 6.5: B). This weak band also occurred with non-seeded 
sonicated control samples (data not shown). In addition, a further band of PK-
resistant fragments of approximately 17-19 kDa was produced specifically from 
PrPSc seeded reactions (Figure 6.5: B and C). However, when the same PK-resistant 
fragments were subjected to immunoblotting with anti-PrP antibody SHA31 (diluted 
1: 80,000) a set of PK-resistant fragments with molecular mass of ~10, 12, and ~15 
kDa were detected in PrPSc seeded reaction. No samples seeded with healthy brain 
homogenates or non-spiked control substrate samples subjected to sPMCA generated 
any PK-resistant, SHA31 reactive fragments (Figure 6.5: D). Therefore, to further 
examine the specificity of mAbs to differentiate between scrapie and healthy spiked 
samples, further PMCA reactions seeded with range of classical scrapie, CH1641 
scrapie and ovine BSE samples were carried out, and PK-resistant fragments were 
detected using SAF70 or SHA31.    
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Figure 6.5: Western blot of the comparison of antibodies to detect PMCA 
products following amplification of PrPSc and PrPC spiked samples: 50 µg spike 
of healthy brain homogenate (Lane 1: VRQ/VRQ, 1699/05) or classical scrapie 
affected brain homogenate (Lane 2: VRQ/VRQ, 1563/02) were seeded into 85 µl 
rSha PrP and subjected to 3 rounds of sPMCA. Sonicated samples were digested for 
1 hour at 37ºC with 10 µg/ml PK and 10 µl of each digested sample was analysed by 
Western blot. PK rPrP fragments were detected with monoclonal antibodies: (A) 
AG4 (1: 2,000), (B) SAF70 (1: 40,000), (C) SAF84 (1: 40,000) and (D) SHA31 (1: 
80,000). Molecular weight markers are shown (kDa).  
 
 
 
 
(A)
28
19
14
7
28
19
14
7
28
19
14
7
28
19
14
7
(B) (D)(C)
1     2 1     2 1     21     2kDa kDa kDa kDa
113 
 
6.2.4. The application of rPrP-PMCA to detect different strains of 
prion diseases in sheep:  
Reactions were seeded with 50 µg of infected cerebellum homogenate for classical 
scrapie, CH1641 scrapie and ovine BSE, or with 50 µg of healthy ovine cerebellum 
homogenate. Isolates analysed were from sheep with a range of homozygous and 
heterozygous Prnp genotypes (Table 6.1). Amplifications were carried out in both 
rSha PrP and VRQ rPrP [0.2 mg/ml rPrP in conversion buffer] substrates. The 
reactions were carried out according to the sPMCA protocol described previously 
(Chapter 2: Materials and Methods). Three to four sPMCA rounds were performed 
for each sample. Further samples were prepared and analysed in exactly the same 
way as for the sPMCA samples, but were to act as controls without being subjected 
to amplification. 
The initial analysis of the products of amplifications of a range of classical scrapie, 
ovine BSE and CH1641 isolates (n = 19) along with healthy control (n = 4) and non-
seeded sonicated control sample (1) with mAb SAF70, showed a PK-resistant 
fragment with a molecular mass of ~ 7 kDa that was detected from PrPSc seeded 
reactions, as well as healthy seeded and non-seeded control samples. Moreover, a 
further band of PK-resistant fragments of approximately 17-19 kDa was produced 
from some but not all PrPSc seeded reactions (10 out of 19 reactions in duplicates) 
(data not shown). Further analysis of the same products of amplification with mAb 
SHA31 revealed PK-resistant fragments with molecular mass of either ~10, or ~ 12, 
or ~15 kDa for PrPSc seeded reactions. Some PrPSc seeded reactions showed the 
formation of all 3 of rPrPres(Sc)  bands. Neither samples seeded with healthy brain 
homogenates nor non-spiked sonicated control substrate samples subjected to 
sPMCA generated any PK-resistant fragments. Based on the results of SAF70 in 
detecting PK-resistant fragments, it seems that there are spontanous generation of 
PK- resistant fragments of 7 kDa from all seeded and non-seeded samples as a result 
of sonication.  
Therefore, in all future applications it was decided to detect all rPrP-PMCA products 
with SHA31and if any single band of one of the 3 rPrPres(Sc) specific bands was 
detected, the sample would be considered successfully amplified.  
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Table 6.1: Amplification of ovine cerebellum brain homogenate of different 
Prnp genotypes by sPMCA using recombinant substrate.   
 
Isolate 
ID genotype strain 
rSha PrPa VRQ rPrPa 
R3b R4 b R3 b R4 b 
1563/02 VRQ/VRQ Classical Scrapie  2 - c 2 2 
1276/02 VRQ/VRQ Classical Scrapie  2 - 2 2 
1275/02 VRQ/VRQ Classical Scrapie  2 - 2 2 
0923/03 VRQ/VRQ Classical Scrapie  2 - 2 2 
0925/03 VRQ/VRQ Classical Scrapie  2 - 2 2 
0836/03 VRQ/VRQ Classical Scrapie  2 - 2 2 
SSBP1 VRQ/VRQ Classical Scrapie  2 - 2 2 
0226/03 ARQ/VRQ Classical Scrapie  2 - 2 2 
0455/03 ARQ/VRQ Classical Scrapie  2 - 2 2 
0615/03 ARQ/VRQ Classical Scrapie  2 - 2 2 
0678/03 ARQ/ARQ Classical Scrapie  2 - 2 2 
0635/03 ARQ/ARQ Classical Scrapie  2 - 2 2 
J2916 ARQ/AHQ CH1641 2 - 2 2 
J2935 ARQ/AHQ CH1641 2 - 2 2 
J3011 AHQ/AHQ CH1641 2 - 2 2 
VLA1 AHQ/AHQ CH1641 0 2 2 2 
1693/03 ARQ/ARQ Ovine BSE  0 0 1 2 
0654/04 ARQ/ARQ Ovine BSE  2 - 2 2 
0392/04 ARQ/ARQ Ovine BSE  0 1 0 2 
0877/03 ARQ/ARQ Healthy ovine 0 0 0 2 
1035/03 ARQ/ARQ Healthy ovine 0 1 0 0 
1037/03 ARQ/ARQ Healthy ovine 0 0 0 0 
1699/05 VRQ/VRQ Healthy ovine 0 0 0 0 
C rPrP 
substrate 
substrate only  
(no spike) 0 0 0 0 
a
 PMCA substrate, both at 0.2 mg/ml.  
b
 round of amplification, each sample was amplified in duplicate and the numbers of positive reaction 
are indicated (as detected with SHA31). 
C
 -; not done.  
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6.2.4.1. Amplification of ovine prions seeded into VRQ rPrP-PMCA reactions:   
After 3 rounds of amplification, VRQ rPrP (0.2 mg/ml) reactions seeded with PrPSc 
showed successful amplification, with the detection of PK rPrPres(Sc) bands of 
approximately 10 and 12 kDa, and on occasion, further bands of 15 kDa when 
immunoblotted with the SHA31 antibody. PK rPrPres(Sc) were detected in 35 out of 38 
reaction. The samples that were not successfully amplified were one of the duplicate 
samples of ovine BSE (ARQ/ARQ, 1693/03) and both duplicate samples of ovine 
BSE (ARQ/ARQ, 0392/04). There was no PK-resistant product generated from the 
reactions seeded with brain homogenate spikes from 4 healthy sheep, or non-seeded 
rPrP substrate (10 samples) (Table 6.1 and Figure 6.6).  
To enhance the detection and production of rPrPres(Sc), samples which gave no PK-
resistant product after 3 rounds of amplification were subjected to a further round of 
sPMCA sonication. This resulted in all TSE-spiked samples generating PK-resistant 
fragments. However, this also resulted in the generation of PK-resistant bands from 
one healthy brain homogenate spike (ARQ/ARQ, 0877/03). These PK-resistant 
fragments produced from reactions seeded with brain homogenates from healthy 
sheep, or in non-seeded rPrP substrate were considered to be spontaneous PK-
resistant fragments, called rPrPres(spon).  
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Figure 6.6: Western blot molecular characterization of VRQ rPrP PMCA seeded reactions: 50 µg of each classical scrapie, CH1641 and 
ovine BSE (19 spikes in duplicates) together with 8 samples each seeded with 50 µg healthy brain homogenates from 4 sheep were subjected to 
sPMCA reaction (Table 6.1). Each seeded reaction was within 85 µl VRQ rPrP (at 0.2 mg/ml) and was for 3 rounds. Sonicated samples were 
digested with PK (10 µg/ml) and analysed by Western blotting. Bound PK rPrPres were probed with SHA31 anti-PrP antibody (1: 80,000) and 
goat anti-mouse HRP conjugate diluted (1: 40,000) and visualised after exposure of the membranes on Fuji X- ray film. A and B: Lane 1: 
ARQ/VRQ (0226/03), Lane 2: VRQ/VRQ (1563/02), Lane 3: VRQ/VRQ (1276/02), Lane 4: VRQ/VRQ (1275/02), Lane 5: VRQ/VRQ 
(0923/03), Lane 6: VRQ/VRQ (0925/03), Lane 7: ARQ/VRQ (0455/03), Lane 8: VRQ/VRQ (0836/03), Lane 9: Healthy BH (0877/03),  Lane 10: 
(A): unamplified VRQ/VRQ (SSBP1) (round 0), (B): unamplified ARQ/ARQ (0678/03) (round 0), Lane 11: digested VRQ rPrP substrate. C and 
D: Lane 1: ARQ/VRQ (0615/03), Lane 2: VRQ/VRQ (SSBP1), Lane 3: ARQ/AHQ (CH1641, J2916), Lane 4: ARQ/AHQ (CH1641, J2935), 
Lane 5: AHQ/AHQ (CH1641, J3011), Lane 6: AHQ/AHQ (CH1641), Lane 7: ovine BSE, ARQ/ARQ (1693/03), Lane 8: ovine BSE, ARQ/ARQ 
(0654/04), Lane 9: Healthy BH (1035/03), Lane 10: (A): unamplified ARQ/AHQ (CH1641, J2935), (round 0), (B): unamplified ARQ/ARQ 
(0392/04), (round 0), Lane 11: VRQ rPrP substrate. E and F: Lane 1: ARQ/ARQ (0678/03), Lane 2: ARQ/ARQ (0635/03), Lane 3: ovine BSE 
ARQ/ARQ (0392/04), Lane 4:  Healthy BH (1037/03), Lane 5:  Healthy BH (1699/05), Lane 6: control sample (non-seeded sonicated rPrP 
substrate only).   
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6.2.4.2. Determining the sensitivity and specificity of sPMCA for the detection of 
PrPSc using VRQ rPrP substrate with two different concentrations:  
The level of sensitivity of VRQ rPrP PMCA reaction for the detection of PrPSc was 
carried out through eight 10x times dilution series of VRQ/VRQ classical scrapie 
affected brain homogenate (0836/03) starting with 50 µg of brain in duplicate. In 
addition, to test specificity, 20 negative control reactions, each seeded with 0.5 µg 
brain homogenate from 8 healthy sheep with different Prnp genotypes were also 
analysed. The level of sensitivity of VRQ rPrP PMCA reaction was carried out using 
different VRQ rPrP substrate preparations in two different independent experiments.  
When different batches of VRQ rPrP substrate were used (final concentration 0.2 
mg/ml), rPrPres(Sc) was detected in all duplicate samples seeded with PrPSc from as 
little as 0.5 ng of brain. Whilst no PK rPrPres was observed in 7 negative control 
samples seeded with healthy brain homogenate representing 3 healthy animals 
(ARQ/ARQ, 1037/03, VRQ/VRQ, 1699/05, AHQ/AHQ, 1102/05), rPrPres(spon) was 
detected from other negative spiked samples from healthy animals either in both 
duplicate samples (ARQ/ARQ, 0877/03) or one of two samples (ARQ/ARQ, 
1035/03, VRQ/VRQ, 1100/05 and AHQ/AHQ, 1101/05) or two of the triplicate 
samples (VRQ/VRQ, 1111/05). Furthermore, PK rPrPres(spon) was also detected in one 
of the duplicate non-seeded rPrP substrate samples (Figure 6.7).  
Using the same VRQ rPrP batch, but at a decreased concentration of 0.1 mg/ml, PK 
rPrPres(Sc) was detected in all duplicate samples seeded with PrPSc from as little as 50 
ng of brain and no PK rPrPres(spon) from the reaction seeded with healthy brain 
homogenates or non-seeded rPrP substrate were observed by Western blot (22 
amplifications, Figure 6.8, Table 6.2).  
 
118 
 
 
 
Figure 6.7:  Sensitivity and specificity of sPMCA for the detection of PrPSc using VRQ rPrP substrate (batch 2 at concentration of 0.2 
mg/ml): 50 µg of each eight 10x dilution series of VRQ classical scrapie (0836/03), together with 20 samples each seeded with 50 µg of healthy 
brain homogenates from 8 sheep with different Prnp genotypes were spiked into 85 µl VRQ rPrP (0.2 mg/ml) and subjected to 3 rounds of 
sPMCA reaction. Sonicated samples were digested with PK (10 µg/ml) and analysed by Western blotting. PK rPrPres were probed with SHA31 
anti-PrP antibody (1: 80,000) and goat anti-mouse HRP conjugate diluted (1: 40,000) and visualised by using an ICCD225 camera .   A, B and C: 
Lanes 1 - 9 show amplifications containing no PrPSc. A: Lane 1 & 2: ARQ/ARQ (0877/03), Lane 3 & 4: ARQ/ARQ (1035/03), Lane 5 & 6: 
ARQ/ARQ (1037/03), Lane 7 & 8: VRQ/VRQ (1699/05). B: Lane 1, 2 & 3: VRQ/VRQ (1100/05), Lane 4, 5 & 6: AHQ/AHQ (1101/05), Lane 7, 
8 & 9: AHQ/AHQ (1102/05). C: Lane 1, 2 & 3: VRQ/VRQ (1111/05), Lane 5 & 6: VRQ rPrP substrate only. D and E show amplifications of the 
dilution series of a scrapie affected ovine brain in duplicates.  D: Amplifications containing 10x dilution series of 50,000 to 50 ng of brain is 
shown in lanes 1 & 2, 3 & 4, 5 & 6, 7 & 8 respectively. E: Amplifications containing 10x dilution series of 5 to 0.005 ng of brain is shown in 
lanes 1 & 2, 3 & 4, 5 & 6, 7 & 8 respectively. For panels A, B, D and E, lane 10 contains 3 µl undigested VRQ rPrP substrate. Molecular weight 
markers are shown (kDa).  
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Figure 6.8: Sensitivity and specificity of sPMCA for the detection of PrPSc using VRQ rPrP substrate (batch 2 at concentration of 0.1 
mg/ml): 50 µg of each eight 10x dilution series of VRQ classical scrapie (0836/03), together with 20 samples each seeded with 50 µg of healthy 
brain homogenates from 8 sheep with different Prnp genotypes were spiked into 85 µl VRQ rPrP (0.1 mg/ml) and subjected to 3 rounds of 
sPMCA reaction. Sonicated samples were digested with PK (10 µg/ml) and analysed by Western blotting. PK rPrPres were probed with SHA31 
anti-PrP antibody (1: 80,000) and goat anti-mouse HRP conjugate diluted (1: 40,000) and visualised by using an ICCD225 camera (Photek Ltd., 
East Sussex, United Kingdom).  A, B and C: lanes 1 - 9 show amplifications containing no PrPSc. A: Lane 1 & 2: ARQ/ARQ (0877/03), Lane 3 
& 4: ARQ/ARQ (1035/03), Lane 5 & 6: ARQ/ARQ (1037/03), Lane 7 & 8: VRQ/VRQ (1699/05). B: Lane 1, 2 & 3: VRQ/VRQ (1100/05), Lane 
4, 5 & 6: AHQ/AHQ (1101/05), Lane 7, 8 & 9: AHQ/AHQ (1102/05). C: Lane 1, 2 & 3: VRQ/VRQ (1111/05), Lane 5 & 6: VRQ rPrP substrate 
only. D and E are replicate analysis of amplifications of the dilution series of a scrapie affected ovine brain.  Amplifications containing 50,000 to 
0.005 ng of brain are shown in lanes 1 - 8 respectively. For panels A, B, C, D and E, lane 10 contains a 3 µl undigested VRQ rPrP substrate. 
Molecular weight markers are shown (kDa).  
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Table 6.2: Variations of specificity and limit of detection of different rSha PrP 
and VRQ rPrP substrate batches.    
Substrate Batch No. 
Substrate 
concentration 
rPrPres(spon) /total, after three 
rounds of sonication Limit of Detection   
(ng) brain 1
st
 
experiment a 
2nd 
experiment b 
rSha PrP one 0.2 mg/ml 0/10 0/22 5 ng 
rSha PrP two 0.2 mg/ml - 0/22 5 ng 
VRQ rPrP one 0.2 mg/ml 0/10 - - 
VRQ rPrP two 0.2 mg/ml - 8/22 0.5 ng 
VRQ rPrP two 0.1 mg/ml - 0/22 50 ng 
 
a
 1st experiment: 19 PrPSc and 4 PrPC spiked isolates (as detailed in table 6.1) 
together with non-seeded substrate sample (all in duplicates) were subjected to 
sPMCA reaction.  
b
 2nd experiment: 8 times dilution series of PrPSc (in duplicate) together with 20 PrPC 
spiked samples (representing 8 healthy animals with different genotype) together 
with two non-seeded substrate samples were analysed.  
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6.4.2.3. Amplification of ovine prions seeded into rSha PrP-PMCA reactions:   
After 3 rounds of amplification, rSha PrP (0.2 mg/ml) seeded reactions supported 
amplification of 50 µg TSE affected brain homogenate seed in 32 out of a total of 38 
PrPSc spiked reactions (Table 6.1). The samples that were not successfully amplified 
were CH1641 (AHQ/AHQ, VLA1) and dublicate samples of both ovine BSE 
(ARQ/ARQ, 1693/03) and (ARQ/ARQ, 0392/04).  
Detection of PK rPrPres(Sc) when immunoblotted with SHA31 antibody showed 
analogous banding patterns similar to VRQ PK rPrPres(Sc) bands. There was no 
rPrPres(spon) fragments from any of the 8 samples spiked with 50 µg brain homogenate 
from 4 healthy sheep or non-seeded rPrP substrate (two samples).   
After 4 rounds of sPMCA reaction, rPrPres(Sc) was observed in one of the duplicate 
reactions seeded with ovine BSE spike (0392/04, ARQ/ARQ) and both replicate 
amplification for CH1641 (AHQ/AHQ, VLA1). However, there was also generation 
of PK rPrPres(spon) bands resulting from one healthy brain homogenate spike (1035/03, 
ARQ/ARQ).  
 
6.4.2.4. Determining the sensitivity and specificity of sPMCA for the detection of 
PrPSc using rSha PrP substrate:  
Similarly to VRQ rPrP, the level of sensitivity of rSha PrP-PMCA reactions was 
confirmed through seeded reaction of eight 10x dilution series of a VRQ classical 
scrapie affected brain homogenate (1275/02) starting with 50 µg of brain in 
duplicate. Again, to test specificity, 20 negative control reactions each seeded with 
50 µg healthy brain homogenates from 8 sheep with different Prnp genotypes were 
also subjected to the same conditions of amplification. These amplification reactions 
were done twice using two different rSha PrP substrate batches to test the effects of 
rPrP production on amplification efficiency. After 3 rounds of amplification, PK 
rPrPres(Sc) was detected in all duplicate samples seeded with PrPSc from as little as 
5ng of brain. In addition, no PK rPrPres(spon) products were observed from the 
reactions seeded with healthy brain homogenates or non-seeded rSha PrP substrate 
(Figure 6.9). These results were the same in two independent experiments with the 
two batches of rSha PrP (Table 6.2).  
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Figure 6.9: Sensitivity and specificity of sPMCA for the detection of PrPSc using rSha PrP substrate: 50 µg of each eight 10x dilution series 
of VRQ classical scrapie (1275/03), together with 20 samples each seeded with 50 µg of healthy brain homogenates from 8 sheep with different 
Prnp genotypes were spiked into 85 µl Sha rPrP (0.2 mg/ml) and subjected to sPMCA reaction for 3 rounds. Sonicated samples were digested 
with PK (10 µg/ml) and analysed by Western blotting. PK rPrPres were probed with SHA31 anti-PrP antibody (1: 80,000) and goat anti-mouse 
HRP conjugate diluted (1: 40,000) and visualised by using an ICCD225 camera.  A, B and C: lanes 1 - 9 show amplifications containing no PrPSc. 
A: Lane 1 & 2: ARQ/ARQ (0877/03), Lane 3 & 4: ARQ/ARQ (1035/03), Lane 5 & 6: ARQ/ARQ (1037/03), Lane 7 & 8: VRQ/VRQ (1699/05). 
B: Lane 1, 2 & 3: VRQ/VRQ (1100/05), Lane 4, 5 & 6: AHQ/AHQ (1101/05), Lane 7, 8 & 9: AHQ/AHQ (1102/05). C: Lane 1, 2 & 3: 
VRQ/VRQ (1111/05), Lane 4 & 5: rSha PrP substrate only. D and E show replicate amplifications of the dilution series of a scrapie-affected 
ovine brain.  Amplifications containing 50,000 to 0.005 ng of brain are shown in lanes 1 - 8 respectively. For panels A, B and E, lane 10 contains 
a positive scrapie brain control (digested with 50 µg/ml). Molecular weight markers are shown (kDa). 
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6.3. Discussion:  
One of the major challenges in the TSE field is the development of sensitive, fast and 
accurate assays for PrPres detection in the pre-clinical diagnosis of TSEs and the 
identification of potential sources of infection. Therefore, since the advent of the 
sPMCA method, many reports have shown sensitive detection of PrPSc at low level 
in biological and environmental samples. In the present study, to achieve optimal 
sensitivity and to overcome the limitation of using brain PrPC as an amplification 
substrate, different trials were conducted using bacterially expressed rPrP protein as 
a definable and readily available substrate.    
The data generated from Western blot analysis of PrPSc seeded rPrP-PMCA reactions 
confirm that rPrPres can be generated by sPMCA from highly purified rPrP. Although 
the rPrP differs from PrPC in the absence of N-linked glycans and GPI moiety, it 
explains that these cofactors and the post-translational modifications are not essential 
requirement for prion replication in vitro. On the other hand, previous studies also 
suggested that these cofactors might enhance the production of PrPres in vitro as well 
as in vivo (Kim et al., 2010 & 2009, Tuzi et al., 2008, Chesebro et al., 2005). At the 
same time, rPrP-PMCA generated PK-resistant products are distinct from PrPSc 
conformers isolated from scrapie infected brain or PK-resistant PMCA products 
derived from healthy brain homogenates. This was clearly demonstrated through the 
lack of glycosylation, differences in molecular weight of rPrPSc and lower PK 
resistant PrPres (Smirnovas et al., 2009). They are also distinct from amyloid fibres 
produced during polymerization of rPrP. As visualised by electron microscopy, 
rPrPSc are small spherical aggregates rather than elongated fibres (Piro et al., 2011).  
 
Orru et al., 2009, found that rSha PrPsen was a more effective substrate than ovine 
rPrP in amplifying ovine classical scrapie using the QuIC reaction conditions. By 
comparison, I found rSha PrPsen has better specificity than VRQ rPrP at 3 rounds of 
rPrP-PMCA amplifications, and the specificity of VRQ rPrP varied between batches. 
Indeed, to achieve high specificity, VRQ needed to be used at a lower concentration 
than Sha rPrP. The Sha rPrPsen could detect just 5 ng of infected scrapie brain with 
high specificity. In comparison, VRQ rPrP could detect 50 ng of infected brain with 
similar specificity. Both substrates demonstrated the same amplification efficiency 
towards a range of classical scrapie isolates independent of the host Prnp genotype. 
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In contrast, VRQ rPrP (0.2 mg/ml, as demonstrated using batch one) was more 
efficient preliminary than rSha PrP in amplifying other strains than classical scrapie 
such as CH1641 and ovine BSE. But, after repeating the sensitivity and specificity 
test, there was doubt as to the specificity of VRQ rPrP when used at 0.2 mg/ml. 
These differences in the efficiency of amplification might be related to differences in 
the amino acid sequence between rSha PrP and VRQ rPrP that might have influence 
on seed/substrate interaction. It might also be related to other co- factors included in 
PrPSc seed contents of these strains.  
Under the assay conditions, I could not distinguish between PK rPrPres(Sc) and 
potentially produced PK rPrPres(spon) from VRQ rPrP (0.2 mg/ml) substrate through 
the sensitivity towards PK digestion and molecular weight of the resulting PK 
resistant fragments. They also could not be distinguished by detection with a range of 
anti-PrP mAbs binding to distinct epitopes (data not shown). This result is in contrast 
to previous published research work (Smirnovas et al., 2009, Atarashi et al., 2007). 
These previous reports demonstrated that a 17 kDa PK-resistant fragment was the 
most characteristic band for rPrPres(Sc), while rPrPres(spon) had only the smaller 10-11 
and 12 kDa when analysed by immunoblotting and probed by R20 hamster PrP 
reactive anti-sera (directed towards C-terminal residues 219-232), or 12 kDa in the 
case of polyclonal antibody R 18 (directed towards residue 142-154) (Atarashi et al., 
2007). Here, using anti-prion rabbit polyclonal antibody with an epitope situated in a 
very similar region of PrP to that of R20 (raised against a peptide corresponding to 
residues 217-229 of bovine PrP), I detected a 10 kDa PK-resistant fragment from 
some but not all healthy-spiked samples as well as from PrPSc spiked rPrP samples. 
With monoclonal antibodies SHA31 (directed towards the C-terminal ovine PrP 
residues 145±152) which binds to a similar region to R18, the molecular weight of 
PK rPrPres(spon) was indistinguishable to those of PrPSc seeded sPMCA reactions.  
The differences in banding pattern between SHA31 and SAF70 were also difficult to 
explain. The epitope of SAF70 (directed towards the C-terminal ovine PrP residues 
145 - 162) should include the epitope of SHA31. Therefore, a band of 17 kDa PK-
resistant fragment was expected to be seen with SHA31, but it was not visulaised in 
my assay. My result suggest that there is some kind of epitope masking occurring 
due to conformational changes to the immobilised prion fragments preventing 
SHA31 antibody from binding and showing similar binding patterns to SAF70.  
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Previous research has also shown that producing a 17 kDa PK-resistant fragment was 
dictated by the conditions of digestion, i.e. the presence of specific detergents (0.1% 
SDS, 0.1% Triton X-100) in the rPrPsen buffer , which could  occlude PK cleavage 
sites resulting in an apparent resistance to proteolytic digestion by fragments of 
certain molecular weight (Smirnovas et al., 2009). Since all rPrP-PMCA reactions 
were treated with the same buffer (that included 0.05% (wt/vol) SDS and 0.05% 
Triton X-100) and exposed to the same conditions of reaction, it is unlikely that 
buffer conditions contributed to the detection of PK rPrPres(Sc) or rPrPres(spon) within 
some replicates of the same seed. My data also argues against the possibility of 
contamination that might be the cause of producing these PK-resistant fragments. 
However, differences in tube positions have been found to influence intensity of 
amplification (Atarashi et al., 2007) although it is unlikely to explain the production 
of rPrPres(spon) in my study. Interestingly, decreasing the concentration of VRQ rPrP 
substrate to 0.1 mg/ml produced higher specificity as I did not detect any PK 
rPrPres(spon) from healthy seeded or non-seeded control samples. Therefore, under the 
rPrP-PMCA condition that I tested, my results suggest that the generation of both PK 
rPrPres(Sc) and PK rPrPres-spon depends on rPrPsen substrate sequence and concentration, 
variations between batches, together with the number of sPMCA rounds within each 
experiment. In addition, the variability observed between some replicate reactions 
using both substrates, suggest the importance of analyzing multiple replicates for 
accurate detection of PK rPrPres(Sc). Previous investigations into the variations within 
different batches of purified recombinant protein, found that despite a robust protocol 
for purification, batch to batch variation affected the morphology of amyloid fibril 
production (Ostapchenko et al., 2008). So, this observation might also explain the 
variation of amplification fidelity between different batches of the VRQ rPrP 
produced in my study. Furthermore, the amount of pure PrPSc in each seed and other 
co-factors contained within each PrPSc strain may influence the efficiency of 
amplification. Therefore, all these factors should be considered in order to establish a 
sensitive diagnostic assay with high accuracy.  
Collectively, the present findings have important methodological implications. Since, 
the pattern of PK digestion has been used as a marker for the generation of PK-
resistant fragments that confirm efficient amplification, more experimental 
optimisations coupled with mass spectrometry analysis are needed to differentiate 
between PK rPrPres(Sc) and PK rPrPres(spon), particularly when using VRQ rPrP 
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substrate. VRQ rPrP substrates have shown batch to batch variation that highlights 
the need to define each batch of substrate in terms of specificity before use. From my 
data, rSha PrP was a better substrate with improved specificity and sensitivity, as 
well as efficient amplification of all classical scrapie PrPSc seeded sPMCA reactions 
analysed. rSha PrP did not show batch to batch variation indicating that it is a more 
robust substrate for PrPSc amplification.  rPrP has the advantage of being easily 
generated in high purity and in large amounts that could overcome the limitations of 
conventional sPMCA and facilitate the practicality of the technique as a diagnostic 
assay. Furthermore, comparing efficiency of amplification using brain homogenate 
as substrate (chapter: 5: In Vitro Amplification of Different PrPSc Strains in 
Substrates of Different Genotypes) with consideration to the differences in biological 
(brain tissue components) and chemical factors (detergents and proteases) included 
in each reaction, rPrP-PMCA was significantly more rapid than standard sPMCA.  
Importantly, the use of rSha PrP as a substrate for PMCA allows the detection of all 
classical scrapie isolates analysed irrespective of Prnp genotype. It also detected 3 
out of 4 CH1641 samples. This represents a significant step forward in allowing the 
use of PMCA for the development of high sensitivity tests for scrapie in sheep.   
Although, I intended to apply this assay to detect PrPSc in buccal swabs of infected 
sheep in the pre-clinical phase of the disease and compare the efficacy of this rPrP-
PMCA assay with what has been described previously using brain homogenate as a 
substrate (Gough et al., 2012, Maddison et al., 2010), I was limited by the duration 
of this project. Further application of these assays to such biological samples is 
required to establish the use of rPrP-PMCA assay in the development of a live 
animal diagnostic for prion diseases in sheep.    
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Chapter 7: Conclusion and Future Work 
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This thesis presents new findings to add to our understanding of the biological 
properties of disease-related PrP and to assist in the development of new diagnostic 
techniques. Firstly, divergent physicochemical properties of PrPSc towards proteases 
and the existence of thermolysin-sensitive / PK-resistant PrPSc. Secondly, the novel 
use of sPMCA to distinguish experimental BSE from CH1641 in ovine samples and 
thirdly, efficient and accurate amplification of classical scrapie PrPSc using rSha PrP 
substrate.  
 
The present study demonstrates an ELISA for PrPSc detection that utilises the 
protease TH. Others have reported that TH preserves disease-related PrP in a full 
length form and has the potential of detecting PK-sensitive PrPSc in rodents passaged 
scrapie samples. Through the developed ELISA, the isolation of full length PrPSc and 
clearing PrPC with TH has overcome the problem of not fully digesting all healthy 
PrP using the standard 50 µg/ml PK. In addition, the developed ELISA is a helpful 
tool for quantifying the amount of full length PrPSc in samples in comparison to all 
PrPSc species including N-terminally truncated fragments (for example using Bio-
Rad® TeSeE Sheep/Goat ELISA).  
 
The study also describes TH-sensitive PK-resistant PrPSc that was detected from 
different ovine scrapie isolates. The presence of these isoforms varied between 
different brain regions of classical scrapie affected sheep and between individual 
sheep with the same prion infection. Previous studies hypothesised that different cell 
types process abnormal PrP in different ways and certain nerve cells might be more 
liable to endogenous proteolysis than others (Dron et al., 2010, Gonzalez et al., 
2003). In turn, these tissue-specific differences may offer different environments for 
PrPSc selection within a single host and therefore result in dominant PrPSc conformers 
with different susceptibilities to exogenous proteases (Collinge and Clarke, 2007). 
Therefore, my finding also confirms the divergent physicochemical properties of 
PrPSc isoforms towards proteases and also reflects differences in the pathological 
process by different tissues and cell types for propagating PrPSc and producing 
heterogeneous populations of disease related PrP.  
Other studies have reported TH-resistant / PK-sensitive PrPSc isoforms in rodents 
(Cronier et al., 2008) and existence of the PK-sensitive PrPSc isoform in sheep with 
scrapie (Thackray et al., 2007). Since PrPSc is the only marker for prion diseases 
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through its resistance to proteases, further work is recommended to examine the 
availability of PrPSc that displays differential protease susceptibility in different 
tissues, secreta and excreta of different species, together with using other proteases 
such as Pronase E. Moreover, analysing samples by CDI may enable the quantitation 
of the percentage of protease sensitive PrPSc in comparison of total PrPSc in an 
infected sample. This proposed study may improve diagnostic tests as proteases with 
improved diagnostic sensitivity for PrPSc might exist and recognise a large proportion 
of the PrPSc population.  
 
The characteristaion of isolates of ovine BSE and CH1641 with the protease TH and 
PK also offered preliminary evidence that these strains may be distinguished by TH 
digestion followed by detection with the mAb P4.  Experimental CH1641 presented 
PrPSc with two very distinct molecular phenotypes indicating divergent PrPSc 
conformer replication pathways in individuals infected with same prion strain. These 
data clearly indicate the complex nature of in vivo prion replication and the 
difficulties in defining prion strains at the molecular level.  
 
Based on the protein hypothesis, generation of PrPSc in vivo occurs following direct 
interaction of PrPC with the pathogenic protein, which acts as a template to drive the 
conformational change to PrPSc, and subsequently further conversion of the normal 
PrPC molecule into PrPSc. This conversion process can be achieved in vitro using 
PMCA. Serial PMCA was initially tested on scrapie samples of susceptible genotype 
mainly homozygous VRQ PrPSc seeded homozygous VRQ substrate.  Using diverse 
strains of ruminant prions and Prnp genotypes substrates in this study had 
considerable success for detecting minute amounts of PrPSc which is in agreement 
with the protein hypothesis. As the molecular weight of amplified products did not 
change from the molecular characteristics of the original seed upon in vitro 
amplification, it shows that conversion of PrPC in PMCA reactions could reflect 
conversion of host PrPC in vivo particularly in experimental passage of particular 
strain into different generations of particular species. It also demonstrated the 
complex nature of prion strains propagation. The data supports the influence of 
substrate and seed Prnp genotypes as well as scrapie strain on in vitro conversion 
efficiency. This further coincides with the role of the Prnp genetic code in 
determining susceptibility and resistance to prion diseases in vivo.  
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A novel result in my study is the successful application of sPMCA to the 
differentiation of ovine BSE and CH1641 prion strains based on their distinct in vitro 
replication properties. This initial success has since been validated in repeated 
experiments and in the diagnosis of CH1641-like field isolates (Thorne et al., 
unpublished data). Given the high sensitivity of sPMCA, these data also suggest the 
possibility of a promising diagnostic test to detect ovine BSE during preclinical or 
subclinical infections. At the same time, although CH1641 was refractory to 
amplification upon 5 rounds of PMCA reaction, the addition of poly(A) RNA to the 
PMCA reactions yielded positive amplification of this strain (Thorne et al., 
unpublished data). This indicates that cellular factors other than PrPC might be 
required to stimulate efficient PrPSc production and host RNA molecules may have a 
role in the pathogenesis of prion diseases.  
Taken all factors together, in order to use PMCA to screen for a wide range of field 
scrapie isolates, the use of multiple Prnp genotypes, as well as non-PrP factors may 
be required to achieve optimal amplification efficiency.  
 
Using rPrP as a substrate for sPMCA has overcome most of the limitations of using 
brain homogenate as substrate in the standard sPMCA. The main advantages are a 
continuous supply of rPrP and rapid detection of PrPSc with accurate specificity of 
classical scrapie regardless of strain or host genotype.  
Comparing the sensitivity of sPMCA and rPrP-PMCA, both rSha PrP and VRQ rPrP 
supported amplification of all classical scrapie and CH1641 isolates, independent of 
seed Prnp genotype. These amplification efficiencies were not obtained using 
different ovine Prnp brain homogenate substrates. Furthermore, variable 
amplification results were obtained in rPrP-PMCA reaction for ovine BSE samples. 
It seems that using brain homogenate as a source of PrPC could be more sensitive 
than using rPrP for particular strains like ovine BSE and SSBP1. This might be 
related to the contents of proteins, lipids, glycosylphosphatidylinsitol (GPI) anchor 
and nucleic acids within brain homogenate substrate that support replication of these 
particular strains and sustained conversion of PrPC.  On the other hand, although the 
specificity of rPrP VRQ varied between batches, efficiency of amplification was 
found between ovine brain homogenates of similar genotypes (B. Maddison, 
personal communication). In addition, recent study of comparing amplification 
efficiency for particular human prion diseases like vCJD and sCJD using rPrP as a 
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substrate showed that there are mechanistic differences between amplification 
techniques like PMCA and QuIC that could affect accumulation of PrPSc in vitro 
(Peden et al., 2012).  
Therefore, my study suggest that in vitro amplification efficiencies of TSEs in sheep 
could be driven by the nature of the seeds, substrates and the biochemical condition 
of PMCA reaction. Moreover, rPrP-PMCA may provide convenient and robust assay 
for ovine scrapie strains amplification (i.e. classical scrapie and CH1641 strains) but 
not for ovine BSE. Further applications and comparison of both sPMCA and rPrP-
PMCA to detect PrPSc in secreta and excreta of infected sheep in the pre-clinical 
phase of the disease is of high importance to validate the practicality of the PMCA 
technique as a future diagnostic assay to field cases of a wide range of strains and 
genotypes. Moreover, further experiments are required to examine the difference of 
DPSOLILFDWLRQWHFKQLTXHV¶PHFKDQLVPDQGFRPSDULVRQEHWZHHQ30&$DQG4X,& in 
relation to amplification of sheep TSE strains in vitro.  
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